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Abstract 
 
Katie Beth Paul 
 
Triclosan Disrupts Thyroid Hormones: Mode-of-Action, Developmental Susceptibility, and 
Determination of Human Relevance 
 
(Under the direction of Kevin M. Crofton, Ph.D.) 
 
Preliminary study demonstrated that triclosan (TCS), a bacteriostat in myriad 
consumer products, decreases serum thyroxine (T4) in rats.  Adverse neurodevelopmental 
consequences result from thyroid hormone (TH) disruption; therefore determination of 
whether TCS disrupts THs during development, its mode-of-action (MOA), and the human 
relevance is critical.  This research tested the hypothesis that TCS disrupts THs via activation 
of pregnane X and constitutive androstane receptors (PXR, CAR), mediating Phase I-II 
enzyme and hepatic transporter expression and protein changes, thereby increasing 
catabolism and elimination of THs, resulting in decreased TH concentrations.  For Aim One, 
the hypothesized MOA was assessed using weanling female Long-Evans rats orally exposed 
to TCS (0-1000 mg/kg/day) for four days.   Serum T4 decreased 35% at 300 mg/kg/day.  
Activity and expression of markers of Phase I (Cyp2b, Cyp3a1) and Phase II (Ugt1a1, 
Sult1c1) metabolism were moderately induced, consistent with PXR and/or CAR activation 
and increased hepatic catabolism.  Susceptibility of dams and developing rats to TCS-
induced hypothyroxinemia was determined for Aim Two.  Long-Evans dams received TCS 
(0-300 mg/kg/day) orally from gestational day (GD) 6 to postnatal day (PND) 21; tissues 
were collected from fetuses (GD20), pups (PND4, 14, 21), and dams (GD20, PND22).  
iv 
 
Serum T4 decreased 30% in GD20 dams and fetuses, PND4 pups, and PND22 dams 
(300 mg/kg/day).  Minor increases in activity and expression of markers of hepatic Phase I 
(Cyp2b, Cyp3a) and Phase II (T4-glucuronidation in PND22 dams) metabolism were 
consistent with PXR/CAR activation and concomitant minor decreases in T4.  For Aim 
Three, cell-based rat and human PXR and CAR reporter assays were employed to evaluate 
the human relevance of the putative MOA.  TCS (10-30 µM) demonstrated human receptor 
reporter activities: inverse agonism of CAR1 and agonism of CAR2 CAR3, and PXR.  TCS 
was an inverse agonist of rat CAR, similar to compounds that increase Phase I-II metabolism 
downstream.  Although the data indicate potential species differences in the initiating key 
event, downstream effects on hepatic catabolism may be similar due to overlapping 
transcriptional regulatory functions of PXR and CAR.  These data establish a plausible MOA 
for TCS-induced hypothyroxinemia in rats and demonstrate initiation of the MOA in human 
models. 
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1.  Overview 
 Triclosan (2,4,4’-trichloro-2’-hydroxyphenylether) (TCS) is a chlorinated phenolic 
bacteriostat found as an active ingredient in many personal care products, including items 
such as shower gels, soaps,deodorants, and toothpastes(Bhargava et al., 1996; DeSalva et al., 
1989), and in a majority of liquid hand soaps sold in the US (Perencevich et al., 2001).   
Availability of environmental TCS concentrations and ecotoxicity data initiated important 
questions about the potential non-target toxicity of TCS.  Measurements confirming parts per 
trillion (ng/L) to low parts per billion (µg/L) TCS concentrations in surface waters and 
wastewater treatment plant effluents in the United States and other countries (Kanda et al., 
2003; Kolpin et al., 2002; Lopez-Avila, 1980; Paxeus, 1996; Singer et al., 2002) coincided 
with reports of systemic toxicity to microorganisms, daphnids, fish, and algae (Orvos et al., 
2002; Singer et al., 2002).  Aquatic reproductive toxicity studies suggested TCS acted as a 
weak androgen (Foran et al., 2000) or estrogen in medaka (Oryzias latipes) (Ishibashi et al., 
2004), or anti-estrogen in male South African clawed frogs (Xenopus laevis) (Ishibashi et al., 
2004; Matsumura et al., 2005; Tatarazako et al., 2004).  Particularly interesting was a report 
that TCS exposure resulted in advanced thyroid-hormone dependent metamorphosis and 
altered gene expression of thyroid receptor β (TRβ) in triiodothyronine (T3)-stimulated frogs 
(Veldhoen et al., 2006).  These endocrine-related effects suggested an impact on thyroid 
hormone homoestasis in frogs, but the effects of TCS on thyroid hormone homeostasis in 
mammals remained to be elucidated. 
 Initial study of TCS exposure using a 4-day short-term assay paradigm, used 
previously to identify thyroid hormone disruptors such as polyaromatic hydrocarbons and 
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polychlorinated biphenyls (Craft et al., 2002; Crofton et al., 2005a; Zhou et al., 2001) 
produced dose-dependent decreases in thyroxine (T4) in weanling female Long Evans rats 
(Crofton et al., 2007).  These authors suggested that TCS might increase hepatic catabolism 
and elimination of T4, resulting in the observed serum T4 concentration decreases (Crofton 
et al., 2007).  Disruption of thyroid hormones during development adversely affects 
neurodevelopment in both rats (Berbel et al., 2010; Lavado-Autric et al., 2003; Zoeller et al., 
2000; Zoeller et al., 2007a) and humans (Haddow et al., 1999; Kooistra et al., 2006; Pop et 
al., 2003; Pop et al., 1999).  Therefore it is critical to determine whether TCS disrupts 
thyroid hormones during development, to characterize its mode-of-action, and to discern the 
human relevance of this mode-of-action using comparative in vitro models.  This research 
tests the global hypothesis that TCS induces thyroid hormone disruption via activation 
of hepatic nuclear receptors, mediating downstream Phase I- Phase III xenobiotic 
metabolizing enzyme expression and protein changes, resulting in decreased circulating 
thyroid hormone concentrations in rats.   
This research was comprised of three Specific Aims.  For Specific Aim 1, the effects 
of TCS on hepatic catabolism and transport in rats following a short-term exposure were 
determined in vivo using hepatic microsomal activity and mRNA expression, and in vitro 
using functional activity assays in sandwich-cultured rat hepatocytes.  Sensitivity of the 
developing organism to TCS-induced thyroid hormone disruption via maternal TCS 
exposure, and the plausibility of the hypothesized MOA from Specific Aim 1, was evaluated 
in Specific Aim 2.  The potential human relevance of the hypothesized MOA was determined 
in Specific Aim 3 by assessing activation of the constitutive androstane receptor and 
pregnane X receptor by TCS in both rat and human receptor-reporter assays. 
 These data provide the first report of
doses of TCS necessary to elicit effects across multiple developmental life
Importantly, this work evaluates a p
key events across species.  Further, this work contributes to a growing understanding of 
species-specific nuclear receptor
2.  Triclosan applications
Figure 1.1.  TCS is a chlorinated biphenyl 
 
TCS is a chlorinated biphenyl ether (Figure 1) with antimicrobial and antifungal 
properties that have made it a useful additive for myriad personal care and medical products
for approximately forty years 
2006).  The biphasic action of 
application concentration, with higher concentrations of 
bacteria and fungi via disruption of cellular membranes 
al., 2006).  The bacteriostatic activity of 
4 
 TCS-induced thyroid hormone changes
-stages.
otential MOA in rats that can be used to 
-regulated hepatic metabolic mechanisms.  
 in personal care and pharmaceutical products
ether structurally similar to iodothyronines.
(Bhargava et al., 1996; Fang et al., 2010; Waltman
TCS as a bacteriostat and bacteriocide depends upon the 
TCS eliciting lethal effects on 
(Guillen et al., 2004; 
TCS results from inhibition of the FabI
 and the 
  
identify shared 
 
 
 
 
 et al., 
Yazdankhah et 
-associated 
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enoyl-acyl carrier protein reductase, preventing bacterial fatty acid elongation in susceptible 
bacteria and fungi species (Heath et al., 2000; Levy et al., 1999; McMurry et al., 1998a).  
The resultant efficacy of adding TCS to soaps in household and hospital settings is a matter 
of debate (Aiello et al., 2007; Gordin et al., 2005; Haas et al., 2005; Sickbert-Bennett et al., 
2005), in particular with respect to the risk of promoting antibiotic-resistance via modulation 
of several modes of antibiotic resistance (McMurry et al., 1998b; Saleh et al., 2011; 
Yazdankhah et al., 2006). 
TCS is present in the majority of liquid hand soaps sold in the U.S. (Perencevich et al., 
2001).  The U.S. Department of Health and Human Services Household Product Database 
lists common personal care products containing TCS at 0.0015 to 1% of the product 
formulation, including deodorants, hand soaps, pet shampoos, dish soap, Colgate Total ® 
toothpaste, and liquid lipstick (http://householdproducts.nlm.nih.gov).  In addition to 
personal care products, TCS is incorporated into dentrifices and other dental applications, 
impregnated into plastic products, clothing, and toys, and included in many surfaces under 
the commercial name, Microban® (Bhargava et al., 1996; Rodricks et al., 2010).   
3.  Environmental occurrence 
The use of TCS as a broad spectrum antibacterial agent (Heath et al., 2000) in many 
commercial and household products has resulted in widespread contamination of 
anthropogenic and natural environments (Kolpin et al., 2002).  By some estimates, 96% of 
the consumer products containing TCS are washed down residential drains (Reiss et al., 
2002).  Although wastewater treatment plant (WWTP) processes remove 70-98% of the TCS 
load (Bock et al., 2010), this incomplete removal constitutes the primary route for TCS 
entrance into surface waters and the environment.  TCS surface water concentrations in the 
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ng/L range (parts per trillion) have been confirmed across the U.S. (Chalew et al., 2009; 
Loraine et al., 2006; McAvoy et al., 2002; Waltman et al., 2006) and abroad (Nakada et al., 
2006; Nishi et al., 2008; Singer et al., 2002).  In a nationwide study of impacted surface 
water sites from 1999-2000, TCS was one of the most often detected pollutants measured; 
TCS was detected at nearly 60% of tested sites, with an average concentration estimated at 
50 ng/L for TCS when it was detected (Kolpin et al., 2002).  The high octanol to water 
coefficient of both the ionized and protonated forms of TCS (pKa estimates = 7.9 - 8.14) 
suggests high sediment sorption and low mobility (Orvos et al., 2002; Singer et al., 2002).  
Land-applied biosolids may also redistribute a minute amount of TCS back to the aquatic 
environment, due to high average concentrations of 4280 µg/kg sediment in biosolids derived 
from WWTP processes (Langdon et al., 2010; Singer et al., 2002).  Another small 
contributor to environmental occurrence may be bioaccumulation; limited bioaccumulation is 
indicated by the relatively low bioaccumulation factors estimated for algae (900-2700) 
(Coogan et al., 2007) and fish (2500-4157) (Orvos et al., 2002) when compared to known 
bioaccumulative toxicants like Aroclor and chlordane, which have bioaccumulation factors in 
fish that are 1 to 2 orders of magnitude higher (30,000 – 274,000) (Orvos et al., 2002).  The 
TCS metabolite methyl-TCS may have more bioaccumulative potential; bioaccumulation 
factors for methyl-TCS were estimated to be 100,000-260,000, suggesting a higher 
bioaccumulative potential (Balmer et al., 2004).  Clearly the environmental occurrence of 
TCS at parts per trillion concentrations stems from anthropogenic use of consumer products, 
but characterization of the distribution in the aquatic, and in particular terrestrial, 
environment is the subject of ongoing research. 
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4. Measured exposures to TCS 
4a. Wildlife exposure 
Several studies of aquatic species have demonstrated wildlife exposure to TCS in surface 
waters downstream of WWTPs or otherwise impacted waterways, demonstrating that TCS is 
present in the environment and environmental exposures may contribute to overall human 
exposure.  TCS exposure of fish has been confirmed by measurements of TCS in fish bile, 
ranging from 0.24 to 25 ng/g, depending on species and distance from a WWTP (Adolfsson-
Erici et al. 2002).  An analysis of lean fish fillet tissue collected in Texas demonstrated a 
similar range of TCS concentrations, 17-31 ng/g (Mottaleb et al., 2009); TCS was detected in 
fish fillet and liver collected from five other U.S. sites, but at concentrations below the 
detection limit of 38 ng/g (Ramirez et al., 2009).   In Swedish lakes, the metabolite methyl-
TCS was detected at 35 ng/g in fish (Balmer et al., 2004).   
4b.  Human exposure 
Measurements of TCS in human serum (Allmyr et al., 2008; Allmyr et al., 2006b; Allmyr 
et al., 2009; Hovander et al., 2002), breast milk (Adolfsson-Erici et al., 2002; Allmyr et al., 
2006a; Dayan, 2007),  and TCS metabolites in urine (Calafat et al., 2008; Wolff et al., 2007) 
demonstrate that humans are exposed.  Concentrations of TCS in human serum have ranged 
from 0.4 to 296 µg/kg wet weight in studies of the Swedish and Australian populations 
(Allmyr et al., 2006a; Allmyr et al., 2008; Allmyr et al., 2009).  A survey of Australian 
volunteers demonstrated slightly higher average serum values (4.1-19 µg/kg)  than in Sweden 
where there are general advisories against TCS use (Allmyr et al., 2008).  The results from 
this study of the Australian population suggest relatively homogeneous exposure throughout 
territory, age group, and gender, with only slightly higher serum TCS concentrations 
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correlated with males aged 31-45 (Allmyr et al., 2008).  A study of Swedish nursing mothers 
revealed that TCS concentrations in the serum of these mothers was 0.010 to 38 µg/kg fresh 
weight (Allmyr et al., 2006a).  Of particular interest is that the TCS partitioned into serum at 
a much greater rate than into breast milk of these volunteers (Allmyr et al., 2006a).  For these 
mothers, TCS was detected in the women who had been exposed to personal care products 
containing TCS at much higher concentrations than mothers who had not been exposed to 
these types of products (Allmyr et al., 2006a).  However, since TCS was present in all 
mothers regardless of intentional personal care product exposure, this indicates that 
potentially unaccounted sources of exposure contribute to the total TCS exposure of the 
human population.  The range of TCS detected in the breast milk of the mothers in this study, 
both control and exposed, was 0.018 µg/kg-lipid to 0.95 µg/kg-lipid (Allmyr et al., 2006a).  
In another study of five breast milk samples from Sweden, TCS concentrations ranged from 
less than 20 µg/kg-lipid to 300 µg/kg-lipid (Adolfsson-Erici et al., 2002).    A study of 62 
breast milk samples from milk donation banks in California and Texas demonstrated a range 
of TCS concentrations from below the limit of detection to 2100 µg/kg-lipid, with the 
majority of samples containing 200 µg/kg-lipid or less (Dayan, 2007).  Based on these 
findings, and the standard volume of milk consumed by infants (Butte et al., 1984; Butte et 
al., 2002; EPA, 1997), Dayan (2007) used a conservative, high estimate of breast milk TCS 
concentration (1742 µg/kg-lipid) to estimate the maximum infant exposure to TCS as 
approximately 7.4 µg/kg/d.  These findings underscore the potential for human 
developmental exposure via breast milk, when the potential impact of thyroid hormone 
disruption may be most deleterious (Miller et al., 2009). 
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Urinary markers of TCS exposure further demonstrate widespread TCS exposure.  A 
2004-2005 study of girls from three U.S. metropolitan areas found mean urinary TCS 
concentrations of 17.1 µg/g-creatinine (10.0 µg/L when not corrected for creatinine) (Wolff 
et al., 2007).  A broader National Health and Nutrition Examination Survey (NHANES) 
study of the U.S. population detected TCS above the LOD in approximately 75% of samples, 
and reported the mean and 95th percentile as 13.0 µg/L (12.7 µg/g-creatinine) and 459 µg/L 
(363.8 µg/g-creatinine), respectively (Calafat et al., 2008).  Significant correlations between 
urinary TCS concentrations and age and socioeconomic status suggested that concentrations 
peaked for individuals in their thirties of greater economic means (Calafat et al., 2008).  A 
comparison of the magnitude of these spot test urinary TCS concentrations with the known 
rate of cumulative urinary excretion, 44-57% at 48 hr after exposure (DeSalva et al., 1989; 
Sandborgh-Englund et al., 2006), would suggest that the order of magnitude for daily human 
exposure is in the ng /kg/day range.   This is consistent with U.S. EPA conservative estimates 
of potential oral exposure from water sources (USEPA, 2008).  TCS was detected in drinking 
water sources in Southern California at 49 ng/L (Loraine et al., 2006); assuming that this is 
the concentration of tap water for human consumption, this would be roughly equal to 98 
ng/day (2L of water per day), or 1.4 ng/kg/day (average person of 70 kg)   (USEPA, 2008).   
5.  Absorption, distribution, metabolism, and excretion (ADME) of TCS 
5a. Routes of exposure and absorption 
TCS is readily absorbed from the gastrointestinal tract and oral mucosa (Bagley et al., 
2000; Lin, 2000), and oral exposure is considered to be the predominant route of exposure 
(Sandborgh-Englund et al., 2006).  Dermal exposure may supplement oral exposure to TCS.  
The chlorinated phenolic structure (Figure 1) and high octanol/water partition coefficient at 
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neutral pH (log Kow = 4.76), and a pKa = 7.9 (Allmyr et al., 2006b) suggests a potential for 
dermal absorption.  Topical application results in TCS binding to the stratum corneum and 
continued bacteriostatic action against native and transient skin bacteria (Bhargava et al., 
1996).  Evidence for dermal absorption in the rat over 24 hours was 23% of the applied dose, 
while human absorption was 6.3%, suggesting that like other chemicals, dermal absorption in 
rats is higher than in humans (Moss et al., 2000).  The leading source of oral human exposure  
is likely the use of personal care products (Allmyr et al., 2006a), but surface water and food 
source contamination may contribute to this exposure . 
5b.  Distribution, metabolism, and excretion 
Limited available kinetic studies support rapid elimination of TCS from mice and rats, 
and enterohepatic circulation and biliary elimination of TCS (Rodricks et al., 2010).  There 
may be a species-specific distribution profile for TCS, as mice appear to accumulate TCS in 
the liver whereas rats do not (Rodricks et al., 2010).  Alhough TCS tissue distribution into 
multiple compartments has not been reported in humans, serum concentrations of TCS 
following extended human exposures further supports a lack of accumulation of TCS 
following exposure (Bagley et al., 2000; Rodricks et al., 2010). 
Glucuronidation and sulfation comprise the two major modes of mammalian TCS 
metabolism.  The predominant pathway for metabolism of TCS in guinea pigs and rats is 
glucuronidation (Black et al., 1975; Calafat et al., 2008; Moss et al., 2000), although TCS 
may also be hydroxylated at any of the chlorinated sites on the molecule (Tulp et al., 1979).  
Metabolism of TCS to the glucuronide and sulfate conjugates occurs locally in skin, with 
TCS-glucuronide diffusing well into the skin of rats and humans within several hours (Black 
et al., 1975).  Human TCS metabolism proceeds through glucuronidation and sulfation 
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(Calafat et al., 2008; Sandborgh-Englund et al., 2006) , though sulfation may be the primary 
pathway (DeSalva et al., 1989).  Conjugation of TCS also occurs in skin following dermal 
application (Black et al., 1975; Moss et al., 2000).  
The human half-life of TCS is 21 hours as determined by a study comprised of ten 
volunteers who received one oral 4 mg dose, with a rapid absorption phase of 1-3 hours, and 
primarily urinary excretion of TCS and glucuronide and sulfate metabolites (Sandborgh-
Englund et al., 2006).  In contrast to previous studies where serum TCS appeared to be 
completely conjugated (DeSalva et al., 1989), Sandborgh-Englund et al.  found that 30-35% 
of the total TCS was unconjugated in serum (DeSalva et al., 1989; Sandborgh-Englund et al., 
2006); this difference may have been due to differences in exposure duration and sampling 
time or dose used.  The half-life of TCS in rats is fairly comparable at 10-18 hrs, depending 
on exposure route and study cited (Black et al., 1975; Rodricks et al., 2010; Siddiqui et al., 
1979). 
6. Brief examination of toxicity in mammals 
Overall TCS demonstrates low toxicity by traditional metrics of adverse effects.  TCS has 
a high acute LD50 dose in mammals, and does not produce any measurable overt toxicity in 
the population following routine use, and has a low potential for inducing dermal irritation.  
An earlier review of industry studies of human exposure to TCS through dental hygiene 
products demonstrated no adverse effects following routine and prolonged exposures to 
products containing 0.01 to 0.6% TCS (DeSalva et al., 1989).  Further review of safety 
studies of TCS-containing dental hygiene products suggest that TCS has no systemic toxicity 
when exposures increase up to 30 mg/kg/day or when TCS-containing dentrifices are used 
for periods of years (Rodricks et al., 2010).   
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6a.  Dermal toxicity 
Numerous studies performed by Ciba-Geigy, Inc. of single-dermal application exposures 
to TCS preparations in rats and humans did not reveal any acute toxicity or sensitization 
when TCS comprised less than or equal to 1.5% of the formulation (Barbolt, 2002; Bhargava 
et al., 1996; Lyman et al., 1969).  Typically consumer products contain 0.01 to 0.3% TCS 
(Bhargava et al., 1996).   
However, repeated topical application of preparations with greater than 1.5%  in rats and 
mice resulted in dermal irritation (Lyman et al., 1969; Rodricks et al., 2010) and in rabbits 
with preparations containing 3% TCS (Moss et al., 2000).  Only limited sporadic instances of 
dermal irritation have been reported following human use (Bhargava et al., 1996). 
6b.  Oral toxicity 
TCS demonstrates extremely low acute oral toxicity in rats, rabbits, dogs, or humans, 
with demonstrated safety for use in dental products in humans (DeSalva et al., 1989).  The 
oral LD50 in rats for TCS is 3750-5000 mg/kg, and by subcutaneous injection route the LD50 
climbs to greater than 14,700 mg/kg; chemicals with LD50 values greater than 2000 mg/kg 
are considered acutely nontoxic (Barbolt, 2002; Lyman et al., 1969).  The no observable 
effect level for clinical toxicity in a subchronic 90-day oral exposure in rats was 50 
mg/kg/day, and 30 mg/kg/d for baboons (Barbolt, 2002; DeSalva et al., 1989).   
Increasing exposure to subacute, subchronic, and chronic durations in murine models 
suggests that TCS increased liver weight and produced adaptive hepatic responses such as 
centrilobular hypertrophy, consistent with induction of Phase I cytochrome P450 enzymes 
and Phase II metabolic enzyme, with no other substantial effects noted in reviews of many 
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studies (Bhargava et al., 1996; Rodricks et al., 2010), with the exception of the production of 
liver tumors in mice only (Rodricks et al., 2010). 
6c. Carcinogenicity 
A preponderance of data confirm that TCS is nonmutagenic and nongenotoxic.  Negative 
results in the Ames test, in vitro mammalian point mutation assay, in vivo chromosomal 
aberration assay, and unscheduled DNA synthesis assay in rat hepatocytes (Barbolt, 2002; 
Rodricks et al., 2010) provide consistent evidence that TCS does not cause genotoxic effects.  
However, the results of carcinogenicity studies in animals are stratified by species, with mice 
demonstrating differential susceptibility to induction of liver tumors via activation of the 
peroxisome proliferator-activated receptor alpha (PPARα), a tumor pathway not thought to 
be relevant for the development of human liver tumors (Gonzalez et al., 2008; Klaunig et al., 
2003; Rodricks et al., 2010).   In an eighteen-month carcinogenicity assay, an increased 
incidence of hepatocellular adenoma and/or carcinoma was observed in  male and female 
CD-1 mice, with a no adverse effect level (NOAEL) of 10 mg/kg/d (Rodricks et al., 2010) 
(See, 1996) (Barbolt, 2002; Dayan, 2007).  In contrast, TCS was not carcinogenic in a dietary 
two-year chronic toxicology and carcinogenesis assay in rats. Non-neoplastic lesions 
reported from the two-year bioassay included a dose-dependent increase in centrilobular 
hypertrophy particularly in male rats (Source: Goodman DG Pathology Working Group, 
Ciba) (Rodricks et al., 2010), suggesting induction of cytochrome P450s in the centrilobular 
(zone 3) region of the liver. No thyroid-related endpoints, including histology or hormone 
concentrations, were reported for this study, though other chronic exposure studies that 
examined thyroid histology in multiple species have reported no effects of TCS exposure on 
thyroid weights or histology (Rodricks et al., 2010). 
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6d.  Reproductive and teratological toxicity 
Two generation reproductive studies demonstrated  no adverse effects observed in rats or 
rabbits for reproductive performance, teratology, or postnatal development (Barbolt, 2002; 
Dayan, 2007); however, the endpoints included in the reproductive toxicology report did not 
include endocrine or neurological measurements.  Thus the NOAEL obtained for rat 
reproductive toxicology analysis, 50 mg/kg/d for mothers, and a developmental NOAEL for 
pups as 150-300 mg/kg/d (Bhargava et al., 1996; DeSalva et al., 1989), does not reflect 
possible developmental thyroid or neuroendocrine effects. 
7.  Evidence for TCS-induced endocrine disruption and potential mechanisms  
Over the last decade a growing body of evidence has emerged to suggest that TCS is an 
endocrine disruptor in laboratory animals.  This includes evidence for anti-androgenic, 
estrogenic, and anti-thyroid effects.  The current work is specifically directed at improving 
the understanding of thyroid disruption in mammals due to limited suggestive evidence in 
aquatic models. 
7a.  Evidence for TCS-induced sex hormone disruption 
In vitro receptor-reporter assays suggest that TCS may be weakly anti-estrogenic and 
possibly weakly anti-androgenic.  When TCS was co-applied with 1 nM estradiol in estrogen 
receptor (ER) reporter assays (CALUX assays), TCS acted as an antagonist, with an IC50 of 1 
µM TCS (Ahn et al., 2008); however, TCS alone produced no agonist or antagonist effects in 
this assay (Ahn et al., 2008). Another study using radioligand binding assays demonstrated 
that large molar excesses of TCS inhibit estradiol binding to ERα, and to a lesser extent ERβ 
(Gee et al., 2008).  Anti-estrogenic effects also were observed in human breast cancer cell 
lines (MCF-1 and SkBr-3), which suggested that TCS may be an ER antagonist of low 
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potency (Gee et al., 2008).  Yet, in another ER assay using stably transfected T47D human 
breast cancer cells, TCS was reported as a very weak ER agonist (Houtman et al., 2004).   
Potential effects of TCS as an anti-androgen have been reported; TCS inhibited AR-
mediated testosterone activity by 92% at 10 µM and by 39% at 1 µM (Chen et al., 2007).  In 
competitive binding assays in mouse mammary and human breast cancer cell lines, TCS 
antagonized the AR, and inhibited testosterone induction of reporter gene activity (Gee et al., 
2008).  This web of in vitro receptor-reporter data suggests perhaps mixed and weak activity 
of TCS as a moderate estrogenic and anti-androgenic compound. 
Aquatic models of sex hormone disruption further demonstrate a mixed picture of the 
estrogenic and anti-androgenic action of TCS.  A two-week aquatic exposure to developing 
medaka (Oryzias latipes) failed to demonstrate estrogenic effects on the development of 
phenotypic sex; instead, small changes in fin morphology and non-significant changes to the 
sex ratio suggested slight androgenic effects (Foran et al., 2000).  Strangely a different 21-
day study of TCS exposure to medaka demonstrated induction of hepatic vitellogenin in male 
medaka, suggestive of a weak estrogenic effect, possibly due to a TCS metabolite (Ishibashi 
et al., 2004).  Additionally, anti-estrogenic activity of TCS was observed in aquatic 
exposures to male South African Clawed frogs (Xenopus laevis) (Matsumura et al., 2005). 
Recent studies of mammalian in vivo sex hormone effects have demonstrated estrogenic 
effects in rats.  In a rat uterotrophic assay, TCS potentially enhanced estrogenic activity; 
when co-administered with ethinyl estradiol to prepubescent rats, TCS increased uterine 
weight and histological markers of estrogenic response, compared to TCS exposure alone, 
which had no effect (Stoker et al., 2010).  Zorrilla et al. (2009) reported evidence for weak 
androgenic activity in a study that included evaluation of the histological, morphological, and 
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hormonal effects of TCS exposure on prepubescent male rats (Zorrilla et al., 2009); a 
significant decrease in serum testosterone concentration was observed at 200 mg/kg/day, but 
this was not observed at higher doses and was not dose-dependent (Zorrilla et al., 2009).  The 
current array of in vitro and in vivo studies on TCS-induced sex hormone disruption appear 
to support the perspective that TCS may have mild, and potentially mixed, effects on sex 
hormone status. 
7b.  Evidence for TCS-induced thyroid hormone disruption 
Initial concern for TCS-induced thyroid disruption first arose due to increases in TRβ 
mRNA expression in Xenopus laevis XTC-2 cells following coapplication of TCS and T3 
(Veldhoen et al., 2006). In addition, TCS accelerated hind limb formation and decreased 
weight gain in developing Rana catesbeina following T3 treatment-induced metamorphosis 
(Veldhoen et al., 2006).  These results prompted questions regarding the potential for TCS to 
induce thyroid-related changes in other species.  Initial work in our laboratory demonstrated 
that TCS exposure results in dose-dependent decreases in T4 in weanling female Long-Evans 
rats in a 4-day exposure model (Crofton et al., 2007).  Following this work, other groups 
have corroborated our finding that TCS exposure decreased T4 in several different rat models 
(Zorrilla et. al, 2009, Stoker et al 2010, Rodriguez et al 2010). 
Further suspicion of potential TCS-induced thyroid hormone disruption stems from in 
vitro evidence for TCS interaction with xenobiotic nuclear receptors.  Interaction with the 
constitutive androstane receptor (CAR) and/or the pregnane X receptor (PXR) is suggestive 
of potential effects on thyroid hormone homeostasis (Kretschmer et al., 2005; Omiecinski et 
al., 2011), as CAR and PXR regulate the hepatic enzymes that function in thyroid hormone 
turnover.  Activation of PXR results in transcriptional induction of CYP3A isoforms (Jones 
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et al., 2000), as well as other Phase I and II hepatic biotransformation enzymes, i.e. 
glucuronyltransferases and sulfotransferases that catabolize thyroid hormones as part of 
thyroid hormone homeostasis (Capen, 1994; DeVito et al., 1999; Schuur et al., 1997; Wang 
et al., 2006).  Activation of PXR also transcriptionally regulates Phase III transporters, 
including organic anion transporting peptides and multidrug resistance proteins (Kretschmer 
et al., 2005), which are known to mediate hepatic uptake and secretion of thyroid hormones 
(Jansen et al., 2005).  Similary, activation of CAR results in transcriptional up-regulation of 
CYP2B isoforms, and a set of Phase II and Phase III hepatic enzymes that overlaps with the 
functional transcriptional activity of PXR (Kretschmer et al., 2005).  Thus, activation of CAR 
and PXR by xenobiotics may lead to increased hepatic catabolic enzyme expression and 
activity and a subsequent dysregulation of thyroid hormone homeostasis. 
A luciferase-based human PXR reporter assay in human hepatoma (HuH7) cells 
demonstrated moderate in vitro activation of PXR by TCS; 10 µM TCS produced 
approximately 46% of the response of the prototypical inducer rifampicin (Jacobs et al., 
2005).  Assessment of in vitro exposures of rat hepatocytes further support hepatic nuclear 
receptor activation via demonstrated increases in Cyp2b and Cyp3a1 protein content and 
enzymatic activity increases in markers of CYP activity including pentoxyresorufin-O-
depentylase (PROD), benzyloxyresorufin-O-debentylase (BROD), and ethoxyresorufin-O-
deethylase (EROD) (Jinno et al., 1997).  In vivo TCS exposure also induced hepatic 
microsomal Cyp2b, Cyp3a, and Cyp4a protein content, as well as PROD and BROD activity 
in rats (Hanioka et al., 1997).  Further, TCS inhibited Cyp1a and Cyp2b induction by 3-
methylcholanthrene (3MC) and phenobarbital (PB) treatment, indicating some competitive 
and/or noncompetitive interaction with the aryl hydrocarbon receptor (AhR)  and CAR, 
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respectively (Hanioka et al., 1996).  Evidence of Phase I induction in vitro and in vivo, in 
addition to in vitro PXR activation by TCS, suggest interactions with xenobiotic nuclear 
receptors, in particular CAR and/or PXR, as indicated by inductive effects on Cyp2b and 
Cyp3a  respectively.  Increased Cyp4a protein (Hanioka et al., 1997) suggests that TCS may 
also interact with peroxisome proliferator-activated receptor alpha (PPARα) (Johnson et al., 
2002c; Johnson et al., 1996; Xu et al., 2005), which is further supported by the induction of 
PPARα-related liver tumors in mice (Rodricks et al., 2010).  As a whole these effects on 
hepatic xenobiotic nuclear receptors and metabolic enzymes support the findings of TCS-
induced changes in THs in rats via activation of nuclear receptors and increased hepatic 
catabolism. 
Discriminating between the potential roles of CAR versus PXR activation by TCS 
may be difficult due to the promiscuity of these receptors with respect to DNA binding.  Both 
CAR and PXR regulate Cyp3a1 expression in rats by interacting with the DR3 site in the 
pregnane X response element of CYP3A1 (Smirlis et al., 2001).  Similarly, both PXR and 
CAR regulate Cyp2b, by binding to the DR site within the phenobarbital response element of 
Cyp2b (Smirlis et al., 2001).  Studies in rodents have demonstrated CAR and PXR functional 
overlap; PXR is capable of binding the phenobarbital responsive enhancer module (PBREM), 
commonly denoted as the CAR binding site for induction of CYP2B subfamily proteins, and 
CAR is capable of binding the xenobiotic responsive enhancer module (XREM) commonly 
denoted as the PXR binding site (Wei et al., 2002).  PXR, and CAR to a lesser extent, both 
have flexible ligand-binding pockets that can accommodate a diverse, species-dependent set 
of activating compounds (Kretschmer et al., 2005; Omiecinski et al., 2011; Timsit et al., 
2007).  Understanding whether TCS activates CAR and/or PXR activation may highlight key 
19 
 
events in a potential MOA for TCS-induced hypothyroxinemia that can be tested in vitro 
across species to determine the relevance of data collected in rat models (see Chapter 5). 
8.  Thyroid hormones regulate physiology 
Thyroid hormones modulate a variety of processes in adult and developing organisms in 
target tissues including brain, pituitary, heart, fat, liver, and bone, from maintenance of 
metabolic and cardiac output rate to neurodevelopment (Williams, 2008; Yen, 2001; Zoeller 
et al., 2007a).  An important distinction is that disruption of thyroid hormones during 
neurodevelopment results in permanent alterations, whereas the effects during adulthood are 
generally reversible with a return to euthyroid levels, naturally or by pharmacological 
intervention (Miller et al., 2009).  The regulation of the thyroid system, the effects of 
disruption in adults and developing organisms, and potential mechanisms of thyroid 
disruption are briefly considered below. 
8a.  Overview of regulation of the thyroid hormone system  
Euthyroid status in most vertebrates requires multiple organs and complex regulation 
maintained by critical negative feedback signals.  Regulation begins with the brain: tripeptide 
thyrotropin-releasing hormone (TRH) is synthesized by paraventricular neurons in the 
hypothalamus, and transported via vasculature to the anterior pituitary (Zoeller et al., 2007a).  
This prompts a localized increase in pituitary transcription of thyroid-stimulating hormone 
(TSH) and post-translational glycosylation to activate this glycoprotein for secretion into the 
systemic circulation (Yen, 2001; Zoeller et al., 2007a).  Upon release of TSH from the 
pituitary, it binds to surface receptors on the follicular cells of the thyroid gland, initiating a 
series of events to increase iodothyronine production in the colloid of the follicular cells; 
bound TSH increases adenylate cyclase, increasing cyclic AMP production, resulting in 
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increased iodide uptake via the sodium-iodide symporter (NIS), increased thyroglobulin 
synthesis and iodination, and consequently increased T4 and T3 production and release from 
the gland (Yen, 2001; Zoeller et al., 2007a). TRH and TSH secretion are under the regulatory 
negative feedback control of thyroid hormones in circulation (Yen, 2001).  Further, 
hypothalamic concentrations of dopamine and somatostatin may negatively regulate TSH 
secretion (Yen, 2001), demonstrating layers of negative feedback control at the level of 
stimulation of iiodothyronine production. 
In most vertebrate species, T4 production greatly exceeds T3 production; both 
iodothyronines are systemically transported to their target tissue sites, but T4 is considered 
the “prohormone” as T3 mediates the majority of the physiological action of the thyroid via 
its agonist interaction with the thyroid receptor (TR) (Williams, 2008).  T4 is typically bound 
to serum binding proteins in the circulatory compartment; the ratios and kinetics of these 
binding proteins is a key difference between thyroid hormone homeostasis between humans 
and rodent models.  Approximately 75% of T4 is bound to thyroxine binding globulin (TBG) 
in humans (Schussler, 2000); this serum binding protein has high affinity for T4 and a long 
half-life of 5 days, thereby maintaining the plasma half-life of T4 as 5-9 days in humans 
(Zoeller et al., 2007a).  The remaining T4 pool is bound to transthyretin (TTR) (15%) and 
albumin (10%) in humans (Schussler, 2000).  Both T4 and T3 are actively transported into 
target tissues (Friesema et al., 1999; Friesema et al., 2005), and T4 is converted to T3 in the 
periphery by outer ring deiodinases to provide localized increases in availability, providing 
up to 80% of the T3 in the human body (Chopra et al., 1996; Kohrle, 2002).  Thyroid 
hormones are eliminated from circulation by hepatic catabolism, i.e. by glucuronidation or 
sulfation (Findlay et al., 2000; Visser et al., 1988; Visser et al., 1990; Yamanaka et al., 2007) 
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and  excreted via the bile. Assays using human jejunum microsomes demonstrated that 
UGT1A8, UGT1A10, and UGT1A1 catalyze high-affinity glucuronidation of T4 and may 
result in a lowered absorption rate of T4 from the intestine and increase the excretion of the 
stable T4 glucuronide via the urine (Yamanaka et al., 2007).  Many uncertainties regarding 
human metabolic clearance and elimination of thyroid hormones from circulation remain due 
to the absence of comprehensive studies especially in humans. 
After reaching target tissues, and conversion of the prohormone T4 to T3, T3 exerts 
genomic action via interaction with thyroid hormone receptors.  TRs are nuclear receptors 
that act as transcription factors (TFs) with ligand-modulated activity, as the receptor is bound 
to DNA even in the absence of T3 ligand; this aporeceptor recruits corepressors to inhibit 
target gene transcription, while T3-activated receptor recruits coactivators through a 
conformational change, enabling up-regulation of target gene expression (Bernal, 2007; 
Williams, 2008).  Thus, there is a bidirectional regulatory potential, whereby the absence of 
T3 can repress gene expression and the presence of greater T3 concentrations can result in 
increased transcription of target genes (Kapoor et al., 2010; Morreale de Escobar et al., 
2004).  Local cellular availability of T3 to interact with TRs is determined primarily by the 
outer ring deiodinase 2 (D2) (Gereben et al., 2008). Two subtypes of thyroid receptors (TRs), 
TRα and TRβ, are expressed on a tissue- and cell-specific basis to regulate localized TH 
action (Zoeller et al., 2007b); alternative splicing of the transcripts from the genes that 
encode these subtypes produces three functional receptor isoforms: TRα1, TRβ1, and TRβ2 
(Williams, 2008; Yen, 2001).  TRβ1 is most highly expressed in liver but present in many 
tissues, and TRβ2 is most highly expressed in the anterior pituitary (Yen, 2001) and is 
thought to be a primary determinant of hypothalamic-pituitary-thyroid axis regulation 
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(Williams, 2008). TRα1 is expressed in neurons (Wallis et al., 2010; Yen, 2001),  with levels 
that are particularly high during fetal development, but expression levels decrease in the 
weeks following birth to coincide with dramatic increases in TRβ1, suggesting that a 
developmental pattern of TR isoform expression is related to receptor-specific regulation of 
genes for neurodevelopment (Yen, 2001).  The gene targets of the transcriptional action of 
TRs in target tissues continue to be elucidated, with lists of TR-regulated genes growing for 
the brain, heart, and liver (Grijota-Martinez et al., 2011). 
In addition to the TR-mediated effects of thyroid hormones, there may be nongenomic 
actions of thyroid hormones. Thyroid hormone action on angiogenesis and cell proliferation 
may be mediated by interaction of T3 or T4 with cell surface integrin receptors that initiate 
signaling through the mitogen-activated protein kinase (MAPK) pathway, resulting in 
molecular actions including phosphorylation of TRs such that they can autoregulate gene 
targets (Axelband et al., 2011; Davis et al., 2005; Davis et al., 2008).  There is some 
suggestion that in addition to activation of cellular kinase and calmodulin pathways, T4 alone 
could affect calcium signaling and transport to modulate cytoskeleton modeling in the cortex 
of rats (Yen, 2001; Zamoner et al., 2008; Zoeller et al., 2007a).  Relatively little is known 
about the nongenomic action of thyroid hormones in in vivo models, but the developing 
evidence suggests that there may be important TR-independent roles for the “prohormone” 
T4 in addition to T3. 
8b.  Physiological action of thyroid hormones in adult organisms 
The function of thyroid hormones in adult organisms is quite different from the function 
of thyroid hormones in the developing neonate.  In adults, thyroid hormones modulate 
cardiac output, metabolism, nervous system control of mental and physical ability, including 
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muscle tone, calcium-phosphate balance for bone density, pituitary and adrenocortical 
function, respiration, and reproductive function (Yen, 2001).  There is further evidence that 
TRs and TR mutations may be involved in the development of human cancers in myriad 
tissues (Cheng, 2003; Gonzalez-Sancho et al., 2003).  Autoimmune diseases of the thyroid 
are the largest cause of dysregulation of thyroid hormone function in adult humans. Grave’s 
disease and Hashimoto’s thyroiditis demonstrate a prevalence of 5-10% in the population, 
and result in hyperthyroidism and loss of thyroid function, respectively (Michels et al., 
2010).  Fortunately the clear health risks exerted by dysregulation of TH concentrations are 
reversible with T4 supplementation, or treatment with antithyroid drugs, radioablation of the 
thyroid, or surgical removal of the thyroid followed by T4 supplementation (Arbelle et al., 
1999).   
8c.  Thyroid hormones during development  
In contrast to adult humans, thyroid dysregulation during development has deleterious 
and permanent adverse consequences on the developing organism.  Severe thyroid hormone 
deficiencies during the first trimester of pregnancy result in neurological cretinism, including 
motor skill deficits and mental retardation, and if deficiency is continued through the second 
trimester, the cerebral cortex, basal ganglia, and cochlea are susceptible to irreversible injury 
(Berbel et al., 2007; Bernal, 2002; Williams, 2008).  Generally, there are three phases of the 
thyroid hormone environment during neurodevelopment: the first trimester period during 
which maternal thyroid hormones are the only source of thyroid hormones; at 16-20 weeks 
post-conception in humans and embryonic day 17.5-18 in rats, fetal thyroid function begins 
to complement maternal supplies of thyroid hormone; and, finally, the early postnatal period 
during which neonatal thyroid hormones alone modulate remaining neurodevelopment 
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(Morreale de Escobar et al., 2000; Williams, 2008).  Available T3 in the developing brain 
activates TRs to transcriptionally regulate required gene expression for a host of 
neurodevelopmental processes including myelination, neuronal and glial cell differentiation 
and migration during and pregnancy and the early postnatal period (Bernal, 2007).  Prior to 
the onset of fetal thyroid function, neurogenesis and neuronal migration are regulated by 
maternal T4 (Auso et al., 2004; Cuevas et al., 2005; Lavado-Autric et al., 2003).  Following 
the onset fetal thyroid function, maternal thyroid hormones still supplement fetal thyroid 
hormone production to regulate neurogenesis, neuronal migration, axonal outgrowth, 
dendritic branching, synaptogenesis, glial cell development, and the beginnings of 
myelination;  these susceptible ongoing, thyroid hormone-modulated processes can be 
adversely impacted by disruption of maternal T4 supply (de Escobar et al., 2008; Morreale 
de Escobar et al., 2000; Morreale de Escobar et al., 2004).  Postnatally, neuronal cell 
migration in the hippocampus and cerebellum continue along with glial cell development and 
myelination, requiring normal neonatal thyroid function (Porterfield et al., 1993; Williams, 
2008).  All of these processes are subject to permanent alteration in the event that thyroid 
hormone signaling is disrupted. 
The correlation between maternal hypothyroxinemia and irreversible neonatal cognitive 
and brain abnormalities is well established (Barone et al., 2000; Berbel et al., 2009; Cuevas 
et al., 2005; Howdeshell, 2002; Morreale de Escobar et al., 2000; Rice et al., 2000; Zoeller et 
al., 2000).  Even relatively small changes in maternal T4 during pregnancy affect the IQ of 
human children (Haddow et al., 1999) and other measures of cognition, socialization, and 
motor function (Berbel et al., 2009; Kooistra et al., 2006; Li et al., 2010; Pop et al., 2003; 
Pop et al., 1999). The lasting effects of decreased in utero T4 may be explained by rodent 
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models which demonstrate correlations between decreased maternal T4 and alterations in 
cytoarchitecture (Auso et al., 2004; Cuevas et al., 2005; Lavado-Autric et al., 2003; Sharlin et 
al., 2008), decreased expression of proteins involved in calcium regulation at the synapse and 
myelination (Ibarrola et al., 1997; Iniguez et al., 1996), and/or changes in the expression of 
genes associated with calcium homeostasis at the synapse, transcriptional regulation, synapse 
transmission, myelination and developmental cell adhesion (de Escobar et al., 2008; 
Morreale de Escobar et al., 2000; Morreale de Escobar et al., 2004; Royland et al., 2008).  
Maternal production of both T4 and T3 increase during normal pregnancy, with a sharp spike 
in serum T4 concentrations during the first trimester (Glinoer, 1997), corresponding to 
increased disposition of maternal T4 to the fetal compartment (Morreale de Escobar et al., 
2004). In the fetal compartment during early gestation, T4 is found predominantly as fT4, 
and is dependent upon the T4 and fT4 in the systemic circulation of the mother; thus, 
subclinical maternal hypothyroxinemia may affect the thyroid status of the developing 
progeny (de Escobar et al., 2008).  Disruption of maternal T4, even in the absence of overt 
hypothyroidism, classically defined as decreased T4 and increased TSH, may result in 
adverse effects on fetal neurodevelopment.    
8d.  Mechanisms of thyroid hormone disruption 
Thyroid-disrupting chemicals include xenobiotics that alter structure or function of the 
thyroid gland itself, interfere with regulatory enzymatic mechanisms responsible for thyroid 
hormone homeostasis, or change systemic or tissue thyroid hormone concentrations (Capen, 
1994; Crofton et al., 2005a; DeVito et al., 1999).  Thyroid disruptors act via multiple targets, 
including: inhibition of thyroid hormone synthesis by disruption of iodide uptake or 
thyroperoxidase; binding to thyroid hormone transport proteins; interference with TRs 
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systemically; inhibition of iodothyronine deiodinases at sites of thyroid action; and increased 
rates of clearance of THs (Boas et al., 2006; Capen, 1994; Crofton, 2008).   
Prevention of iodothyronine production at the level of the thyroid gland has been 
demonstrated by toxicants that inhibit iodide uptake via the sodium-iodide symporter (NIS) 
or catalysis of iodide to iodine for conjugation to tyrosine residues on thyroglobulin by 
thyroperoxidase (TPO) (Crofton, 2008).  Perchlorate (Wolff, 1998), nitrate, and thiocyanate 
(De Groef et al., 2006) are known environmental contaminants that inhibit NIS function.  
The antithyroid drugs propylthiouracil (PTU) and methimazole (MMI) inhibit TPO (Cooper, 
2005), as well as the ultraviolet filter benzophenone-2 (Schmutzler et al., 2007) and 
isoflavones (Chang et al., 2000) among others (Crofton, 2008).   
Many thyroid disrupting chemicals act extrathyroidally via: agonism or antagonism of 
TRs; displacement of thyroid hormones from serum binding proteins; and, disruption of 
normal rats of thyroid hormone metabolism.  Few xenobiotics have been reported to interact 
with TRs; the environmental contaminant bisphenol-A is an antagonist in vitro (Moriyama et 
al., 2002; Zoeller et al., 2005), and Aroclor 1254, a mixture of polychlorinated biphenyls 
(PCBs), appeared to exert agonist action against TR in vivo (Gauger et al., 2007; Gauger et 
al., 2004), although the neuroendocrine response to Aroclor 1254 was not fully attributable to 
unidirectional agonism (Bansal et al., 2008).  Xenobiotic competition for transthyretin 
(TTR), a minor thyroid hormone binding protein in humans, has been suggested as an 
alternate mode of thyroid hormone disruption by toxicants like PCBs (Lans et al., 1994; van 
den Berg, 1990).  However, this MOA has been disputed for PCBs by in vivo studies in rats 
that indicated that the timing of peak serum concentrations of PCBs did not result in 
increased fT4 in serum (Hedge et al., 2009).   
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A widely accepted MOA for thyroid hormone disruption is up-regulation of thyroid 
hormone metabolism, either by inhibition of peripheral deiodination of T4 to T3 (Kohrle, 
2002; Kohrle, 1996) or up-regulation of hepatic catabolism and transport of thyroid 
hormones (Barter et al., 1994; Capen, 1994; Hood et al., 2003; Johnson et al., 2002b; 
Klaassen et al., 2005; Lecureux et al., 2009; Vansell et al., 2001).  Xenobiotics including 
PCBs (Morse et al., 1993), PTU (Visser et al., 1979), and FD&C Red No. 3 dye (Capen, 
1998) have been implicated in inhibition of peripheral deiodination.  Many thyroid disrupting 
chemicals have been proposed to activate xenobiotic nuclear receptors including the aryl 
hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), and pregnane X 
receptor (PXR) to increase metabolism and elimination of thyroid hormones.  AhR, CAR, 
and PXR transcriptionally regulate gene expression of glucuronyltransferase, 
sulfotransferase, and hepatic transporter isoforms necessary for catabolism and elimination of 
thyroid hormones at a normal rate to maintain euthyroid status (Craft et al., 2002; Crofton et 
al., 2005a; Kohn, 2000; Kretschmer et al., 2005; Timsit et al., 2007).  Activation of these 
receptors by xenobiotics has resulted in up-regulation of glucuronidation, sulfation, and 
export of thyroid hormones leading to thyroid hormone decreases by a variety of compounds, 
including examples such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 3-
methycholanthrene (3-MC), Aroclor 1254, PCBs, phenobarbital (PB), pregnenolone-
16alpha-carbonitrile (PCN), DMP-904, and oltipraz that have largely been described in 
rodent and in vitro human models as microsomal enzyme inducers (Barter et al., 1994; 
Buckley et al., 2009; Cheng et al., 2005; Guo et al., 2002; Johnson et al., 2002b; Kohn, 2000; 
Lecureux et al., 2009; Schuur et al., 1997; Vansell et al., 2002; Vansell et al., 2001; Visser et 
al., 1993; Wong et al., 2005).  The basic hypothesis is that these microsomal enzyme 
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inducers cause a systemic thyroid hormone concentration decrease because more thyroid 
hormone exits the system following increased metabolic clearance and/or transport.  Recently 
the importance of increased T4 glucuronidation by the Ugt1a subfamily in mediating serum 
T4 decreases has been questioned by studies in the rat, which demonstrated that T4 decreases 
were possible in Ugt1a-deficient Gunn rats following microsomal enzyme induction with 
Aroclor 1254, 3-MC, and PCN (Richardson et al., 2010).  Previously a poor correlation 
between T4-glucuronidation and T4 decreases and TSH increases has been observed (Craft et 
al., 2002; Hood et al., 2000; Vansell et al., 2001), and the decrease in serum T4 observed 
with PB treatment in Gunn rats also demonstrated a lack of dependence on Ugt1a-mediated 
glucuronidation of T4 (Kato et al., 2005).  These data do not negate the potential contribution 
of T4-glucuronidation to observed systemic decreases in T4, but rather suggest that other 
mechanisms, identified or yet to be identified, contribute to decreased thyroid hormone 
concentrations.  One possibility is the contribution of thyroid hormone sulfation.  Another 
speculation might be that increased clearance of thyroid hormones may rely on increased 
export of parent T4, as observed with DMP-904 in rats (Wong et al., 2005).  Hepatic 
catabolic modulation of thyroid hormone homeostasis and characterization of the associated 
MOA require further clarification. 
9.  Rat as a model of TH-disruption 
Particularly for environmental toxicants, it is difficult to obtain human data; in vivo 
human data for thyroid hormone disruptors is limited and centers on pharmacological agents 
with off-target thyroid toxicity or epidemiological studies burdened by weak exposure 
metrics.  Fortunately, rats appropriately model the neurological effects of developmental 
thyroid hormone insufficiency (Zoeller et al., 2004).  The general mechanisms of thyroid 
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hormone homeostasis are conserved, but key differences in the specific gene and protein 
isoforms expressed do instill uncertainty to extrapolation across species.  Some of the 
potential differences between rat and human thyroid hormone homeostasis mechanisms are 
described here, as well as the potential human plausibility of the MOA described in rat and in 
vitro models. 
9a.  Potential relevance to humans: differences in TH homeostasis between rats and 
humans 
Thyroid hormones are maintained in circulation primarily bound to serum binding 
proteins and are cleared from the system at some constant rate as a result of hepatic 
catabolism and excretion. There are substantial differences in the relative expression of 
serum binding proteins and the half-life of T4 between humans and rats.  In contrast to 
humans, thyroxine-binding globulin (TBG) is only expressed during development and early 
postnatal life in rats (Savu et al., 1987; Vranckx et al., 1994; Vranckx et al., 1990), and 
following this period the primary serum binding protein is transthyretin (TTR) (Savu et al., 
1987; Vranckx et al., 1994).  TTR has a lower binding affinity and reduced half-life 
compared to TBG, resulting in a shortened plasma half-life for rat T4 that is 12-24 hours 
instead of 5-9 days in humans.  This decreased T4 half-life in rats may make them more 
susceptible to thyroid disruption than humans (Capen, 1994). 
The inducibility of TSH also varies between rats and humans.  Decreased thyroid 
hormones in circulation initiates an up-regulation of TSH in rodents that can excessively 
stimulate the thyroid and result in thyroid tumors (Hill et al., 1998).  Humans are thought to 
be much less sensitive to this MOA due to a larger circulating pool of THs and a larger 
luminal supply of THs in the thyroid gland (Capen, 1994; Hill et al., 1998). 
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An additional uncertainty in using rats to model human TH homeostasis is enterohepatic 
recirculation of thyroid hormones, which may change the relative excretion pathway and 
rates between species.  The hypothesis we explore in this work is that TCS up-regulates 
hepatic catabolism and excretion of thyroid hormones; however, it is possible that some 
fraction, potentially divergent between species, is recirculated rather than exiting via biliary 
excretion.  It is fairly well accepted that rats conjugate thyroid hormones largely by 
glucuronidation in preparation for a large fraction to be fecally excreted via the bile (Beetstra 
et al., 1991; de Herder et al., 1988; Kaptein et al., 1997; Visser, 1996; Visser et al., 1993; 
Visser et al., 1990).  In vivo rat studies have demonstrated that bile recirculates to the 
intestine, where hydrolysis of thyroid hormone and predominantly T4-glucuronide (Visser et 
al., 1990) may enable as much as 50% of thyroid hormone entering the intestine to be 
reabsorbed, with the rest eliminated fecally (DiStefano et al., 1988).  In contrast to the 
findings of DiStefano and Visser, Galton and Nisula (1972) found no net resorption of 
thyroid hormone from the gastro-intestinal tract of rats (Galton et al., 1972).  A separate 
study confirmed that the majority of thyroid hormone conjugate excreted into bile is T4-
glucuronide, and that though this conjugate is enterally recirculated, this conjugate has a high 
affinity for bile, with very little actually re-entering systemic circulation (Bastomsky, 1972). 
Limited evidence from human patients suggests that enterohepatic recirculation of thyroid 
hormone and its conjugates occurs, but that only 30% is reabsorbed in the intestine, with 
70% of the thyroid hormone pool in the bile exiting fecally (Myant, 1956).  Differences in 
reabsorption of thyroid hormone in the intestine may constitute a kinetic difference in thyroid 
hormone maintenance between rats and humans.  However, comparison between species is 
difficult due to the limited number of studies particularly for humans. 
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9b.  Potential relevance to humans: evidence for thyroid disruption in humans by 
microsomal enzyme inducers 
Increased hepatic catabolism and elimination of thyroid hormones via microsomal 
enzyme induction is one MOA for thyroid hormone disruption that has been increasingly 
noted in rodent models of thyroid toxicology (Barter et al., 1994; Brucker-Davis, 1998; Guo 
et al., 2002; Hood et al., 2003; Hood et al., 1999; Hood et al., 2000; Hurley, 1998; Johnson et 
al., 2002a; Lecureux et al., 2009; Liu et al., 1995; Vansell et al., 2001).  This MOA is 
potentially relevant to humans because similar glucuronidation and sulfation catabolic 
pathways also lead to increased thyroid hormone turnover.  There are also analagous 
xenobiotic nuclear receptors in rats and humans that regulate similar functional domains to 
include Phase I, Phase II, and hepatic transport expression.   
In vivo evidence for the plausibility of the hypothesis that thyroid disrupting chemicals 
can decrease serum thyroid hormones in humans comes primarily from the toxic side-effects 
of therapeutic drugs.  A number of drugs, including lithium (anti-depressant) (Gittoes et al., 
1995) and the anti-convulsant sedatives carbamazepine, phenytoin, and phenobarbital, are all 
known to decrease thyroid hormones (Gittoes et al., 1995; Simko et al., 2007).  
Carbamazepine decreased systemic T4 via activation of hepatic microsomal enzymes and 
displacement and also potentially by competitive binding to TBG (Simko et al., 2007); 
carbamazepine induces CYP3A4 and UGT1A1 (Oscarson et al., 2006), and is a PXR agonist 
(Luo et al., 2002), suggesting that it can up-regulate glucuronidation and other catabolic 
processes to increase elimination of thyroxine.  Phenobarbital is also thought to increase 
glucuronidation of T4 via activation of CAR, and increases expression and activity of 
UGT1A1 in human hepatocytes (Ritter et al., 1999), though at concentrations that exceed 
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therapeutic serum concentrations by at least 10-fold (Strolin et al 2005).  In addition to 
increased glucuronidation activity, phenytoin may increase peripheral conversion of T4 to T3 
(Strolin et al 2005).  The therapeutic use of anti-convulsant sedatives appears to mediate 
moderate inductive effects on metabolic enzymes and the potential for thyroid hormone 
disruption (Strolin et al. 2005, (Perucca et al., 1984; Simko et al., 2007).  On this basis, it 
appears possible to elevate glucuronidation activity to coincide with serum T4 decreases in 
humans, provided a high enough dose of the microsomal enzyme inducer is employed. 
 Several epidemiological studies have tried to retrospectively correlate the serum 
concentrations of known thyroid disrupting toxicants with serum thyroid hormone 
concentrations, with varying success.  Chevrier et al. (2010) found an inverse correlation 
between the serum concentration of polybrominated diphenyl ethers (PBDEs) and maternal 
serum TSH, which does not correspond to the expected relationship that PBDEs decrease 
serum T4 and T3 concentrations with no effects on TSH as seen in rodents (Zhou et al., 
2002).  An inverse correlation between the serum concentrations of hydroxylated PCBs in 
mothers and children and markers of neurodevelopment was demonstrated in a cohort from 
Slovakia (Park et al., 2009).  Similar reports are counterbalanced by reports that demonstrate 
little or no correlation between thyroid hormone disruptor burden in maternal and/or child 
tissues and neurodevelopment and thyroid hormone concentrations in the children (Darnerud 
et al., 2010).  Thus, there is some suggestion that body burden of thyroid disrupting 
compounds may correspond to thyroid hormone and/or neurological outcomes, but these 
associations are weakly correlative at best, likely due, in part, to the epidemiological 
experimental approach and confounding factors. 
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10.  Summary and human health significance 
Currently, there is a veritable dearth of evidence regarding the potential risks to 
human health posed by widespread TCS environmental contamination.  Detection of TCS in 
ecosystems and human tissue samples globally creates an imperative to determine the dose-
response relationship for thyroid hormone disruption by TCS, the MOA of TCS-induced 
hypothyroxinemia, and the potential effects of TCS on the developing neonate.  TCS may 
interact with hepatic xenobiotic nuclear receptors, specifically CAR and/or PXR, and 
produce downstream hepatic enzyme induction that may alter thyroid hormone homeostasis.      
Currently, there is a lack of information regarding the MOA for TCS-induced 
hypothyroxinemia in the rat.  Knowledge of the MOA in in vivo laboratory models is 
extremely useful for determination of the human relevance of TCS-induced 
hypothyroxinemia (Boobis et al., 2008; Crofton et al., 2005b).   Common hazard assessment 
practice assumes human relevance of animal data; analysis of the key events of the MOA in 
rat models and in vitro human models enables testing of the hypothesis that TCS-induced 
hypothyroxinemia is relevant to humans. 
11.  Experimental Design 
 In vivo oral administration of TCS to rats is used in this research in order to model 
human oral exposures that would potentially occur through drinking water or oral hygiene 
products.   In addition, in vitro experiments were used to address specific mechanistic 
questions regarding the potential activation of xenobiotic nuclear receptors by TCS and the 
contribution of functional hepatic transport to the hypothesized MOA.  In vivo, whole animal 
exposures were used to identify the target tissue; the liver was identified as critically 
involved in mediating the observed systemic thyroid hormone disruption.  Initially a short-
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term exposure of four days was employed to assess the potential for TCS to decrease thyroid 
hormones in young female rats, as a screen for thyroid hormone disruption, and to identify an 
appropriate dose range for further characterization of the MOA for TCS-induced thyroid 
hormone disruption in rats.  A developmental exposure paradigm was used to model the 
potential exposure and effects of TCS on the developing organism; rat dams were exposed 
perinatally to TCS via oral gavage, such that offspring only received TCS through 
transplacental transfer and/or milk consumption.  This was a more appropriate model for the 
subpopulation of concern: human neonates receiving TCS via transplacental transfer and 
lactation. Finally, the human relevance of the in vivo rat work was assessed by comparative 
in vitro models of the initiating key event of the MOA hypothesis: xenobiotic nuclear 
receptor activation, as indicated by species-specific receptor-reporter assays. 
 The second chapter of this work describes the effects of a four-day TCS exposure on 
the thyroid hormone system and biomarkers of hepatic catabolism of thyroid hormones.  
Hepatic microsomal activity assays and RT-PCR were used to assess the contribution of 
hepatic catabolism, i.e. glucuronidation and sulfation, and transport, to the observed systemic 
decreases in thyroid hormones.  The third chapter of this work details study of the susceptible 
population model: the developing fetus and neonate.  This work provided an initial focus on 
the potential for thyroid hormone disruption during the lactation period.  The fourth chapter 
includes an extension of the initial finding that TCS decreases thyroxine (T4) during 
postnatal development to include assessment of fetal thyroxine during gestation, an 
examination of the hypothesized MOA in multiple life-stages, and an assessment of the 
internal doses of TCS received at the various life-stages.  Receptor-reporter assays indicating 
xenobiotic nuclear receptor activation, and providing critical interspecies comparison data 
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between rat and humans, are described in the fifth chapter of this work.  The sixth chapter of 
this work summarizes the major findings of the research project, implications, and future 
directions of this work.  Finally, an appendix details the effects of TCS on in vitro functional 
hepatic transport in sandwich-cultured rat hepatocytes as an addendum to Specific Aim 1. 
 
Global hypothesis: TCS induces hypothyroxinemia via activation of xenobiotic nuclear 
receptors, resulting in up-regulation of hepatic catabolism and excretion of thyroid hormones 
and subsequent systemic thyroid hormone concentration decreases. 
Hypothesis 1: Short-term TCS exposure decreases T4 with coincident up-regulation of 
markers of hepatic catabolism and transport of thyroid hormones, suggesting that the MOA 
of TCS-induced hypothyroxinemia is increased hepatic catabolism and excretion of T4. 
Specific Aim 1: Determine whether triclosan affects hepatic catabolism and transport of 
thyroxine in rats.  Assessment of hepatic Phase I and Phase II gene expression and enzymatic 
markers reflective of nuclear receptor activation was performed using quantitative reverse 
transcriptase PCR (qRT-PCR) and hepatic microsomal assays.  The potential contribution of 
hepatic transport to the proposed MOA was measured by qRT-PCR of key hepatic transport 
proteins (Phase III).  Follow-up studies of hepatic transport function were performed in an 
additional set of in vitro experiments in sandwich-cultured rat hepatocytes. 
Hypothesis 2: Perinatal TCS exposure decreases T4 in dams and offspring via a similar 
proposed MOA: increased hepatic catabolism and elimination of thyroid hormones as a result 
of xenobiotic nuclear receptor activation by TCS. 
Specific Aim 2: Determine the effect of perinatal maternal exposure on thyroxine 
concentrations and metabolism in dams and offspring.  The dose-response relationship for 
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perinatal maternal TCS exposure and T4 decreases was determined in dams and pups; 
analysis of TCS in the serum and liver of exposed animals provided additional support for 
these relationships.  Hepatic microsomal activity assays were employed to study markers of 
Phase I and II metabolic enzyme activity, and the mRNA expression of Phase I, II, and III 
hepatic metabolic enzymes was evaluated using quantitative PCR (qPCR).  Gene expression 
markers of tissue-level thyroid hormone changes were assessed for hepatic mRNA by qPCR. 
Hypothesis 3: TCS activates rat and human xenobiotic nuclear receptors as the initiating key 
event in a MOA for TCS-induced hypothyroxinemia. 
Specific Aim 3: Determine whether TCS activates the constitutive androstane and pregnane 
X receptors (CAR and PXR) in models of the human and rat receptors.  The in vitro 
activation of human and rat PXR was measured using commercially available (Puracyp, Inc.; 
Carlsbad, CA) human and rat hepatoma cell lines containing full-length PXR and a 
luciferase-based reporter construct.   Cell-based receptor-reporter assays in human embryonic 
kidney cells (HEK293T) (INDIGO BioSciences) were used to evaluate the ligand-binding 
potential of TCS for all three active human CAR splice variants (hCAR1, hCAR2, hCAR3), 
rat CAR, mouse CAR, and human, rat, and mouse PXR. 
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1.  Abstract 
 
Triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol) is a chlorinated phenolic 
antibacterial compound found in consumer products.  In vitro human pregnane X receptor 
(PXR) activation, hepatic Phase I enzyme induction, and decreased in vivo total thyroxine 
(T4) suggest adverse effects on thyroid hormone homeostasis. Current research tested the 
hypothesis that triclosan decreases circulating T4 via upregulation of hepatic catabolism and 
transport.  Weanling female Long-Evans rats received triclosan (0-1000 mg/kg/day) by 
gavage for four days. Whole blood and liver were collected 24 hrs later. Total serum T4, 
triiodothyronine (T3), and thyroid-stimulating hormone (TSH) were measured by 
radioimmunoassay. Hepatic microsomal assays measured ethoxyresorufin-O-deethylase 
(EROD), pentoxyresorufin-O-deethylase (PROD), and uridine diphosphate 
glucuronyltransferase (UGT) enzyme activities. The mRNA expression of cytochrome P450s 
1a1, 2b1/2, and 3a1/23, UGTs 1a1, 1a6, and 2b5, sulfotransferases 1c1 and 1b1, and hepatic 
transporters Oatp1a1, Oatp1a4, Mrp2, and Mdr1b was measured by quantitative RT-PCR.  
Total T4 decreased dose-responsively, down to 43% of control at 1000 mg/kg/day.  Total T3 
was decreased to 89% and 75% of control at 300 and 1000 mg/kg/day.  TSH did not change.  
Triclosan dose-dependently increased PROD activity up to 900 percent of control at 1000 
mg/kg/day. T4-glucuronidation increased nearly 2-fold at 1000 mg/kg/day. Cyp2b1/2 and 
Cyp3a1/23 mRNA expression levels were induced 2-fold and 4-fold at 300 mg/kg/day. 
Ugt1a1 and Sult1c1 mRNA expression increased 2.2-fold and 2.6-fold at 300 mg/kg/day. 
Transporter mRNA expression levels were unchanged.  These data denote important key 
events in the mode-of-action for triclosan-induced hypothyroxinemia in rats, and suggest that 
this effect may be partially due to upregulation of hepatic catabolism, but not due to mRNA 
expression changes in the tested hepatic transporters.   
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2.  Introduction 
 
Triclosan is a chlorinated phenolic bacteriocide used as an active ingredient in 
personal care products, including soaps, toothpastes, toys, and clothing (Bhargava & Leonard 
1996, Dayan 2007, McClanahan & Bartizek 2002).  Due to broad use, environmental fate and 
transport, triclosan is an environmental contaminant (Kolpin et al. 2002, Paxeus 1996). 
Triclosan contamination of effluents is one of several potential sources for human exposure, 
along with personal care product exposure (Sandborgh-Englund et al. 2006, Allmyr et al. 
2006). 
Triclosan is readily absorbed from the gastrointestinal tract and oral mucosa (Sandborgh-
Englund et al. 2006).  Triclosan has been detected in human breast milk, at levels ranging 
from 0 – 2100 µg/kg-lipid (Adolfsson-Erici et al. 2002, Allmyr et al. 2006, Dayan 2007), in 
serum (Allmyr et al. 2006, Hovander et al. 2002), and as triclosan metabolites in urine 
(Calafat et al. 2008, Wolff et al. 2007).    These data demonstrate exposure in humans, and 
underscore the importance of using models to assess any potential effects resulting from 
human triclosan exposure. 
Laboratory studies have documented that triclosan disrupts thyroid systems in rats and 
frogs.   (Crofton et al. 2007, Zorrilla et al. 2009, Veldhoen et al. 2006).  In vitro evidence also 
suggests that triclosan may be an antagonist (Gee et al. 2008, Ahn et al. 2008) or weak 
agonist (Houtman et al. 2004) of the estrogen receptor, and/or a weak antagonist of the 
androgen receptor (Chen et al. 2007).   
Adverse effects of triclosan on thyroid hormone (TH) homeostasis have been reported in 
rats and frogs.   Short-term oral triclosan exposure resulted in hypothyroxinemia in weanling 
rats (Crofton et al. 2007).  Stoker and colleagues reported that triclosan decreased T4 without 
significantly affecting thyroid stimulating hormone (TSH) following a 31-day oral triclosan 
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exposure (Zorrilla et al. 2009).  Veldhoen et al. (2006) reported increased thyroid receptor β 
(TRβ) mRNA expression in Xenopus laevis XTC-2 cells when co-exposed to T3, and 
accelerated hind limb development in vivo in Rana catesbeina (Veldhoen et al. 2006).  The 
mode-of-action for thyroid disruption by triclosan is currently undefined. 
Thyroid disruption may occur via several mechanisms, including disruption of TH 
synthesis via inhibition of thyroperoxidase or iodide uptake; binding to TH transport 
proteins; xenobiotic interactions with the TH receptor or thyroid stimulating hormone 
receptor; upregulation of iodothyronine deiodinases; and increases in TH clearance (Boas et 
al. 2006, Crofton 2008, Capen 1994).  Evidence suggests that triclosan may upregulate 
hepatic catabolism of THs, a known key event in a mode-of-action leading to decreased THs 
(Crofton 2008, Crofton & Zoeller 2005, Hill et al. 1998, McClain et al. 1989). The initiating 
event in this mode-of-action is the activation of hepatic nuclear receptors (Crofton & Zoeller 
2005, Hill et al. 1998, McClain 1989, Barter & Klaassen 1994, Hood & Klaassen 2000).  
Nuclear receptors PXR and CAR regulate hepatic catabolic and transport activity 
(Kretschmer & Baldwin 2005), suggesting that potential agonism or antagonism of 
CAR/PXR results in downstream metabolic changes that affect serum TH levels.  In PXR 
reporter assays, triclosan moderately activated human PXR relative to the prototypical 
inducer, rifampicin (Jacobs et al. 2005).  Further, triclosan increased Cyp2b1/2 and Cyp3a1 
protein and enzymatic activity markers of CYP activity including pentoxyresorufin-O-
depentylase (PROD), benzyloxyresorufin-O-debentylase (BROD), and ethoxyresorufin-O-
deethylase (EROD) in hepatocytes in vitro and in hepatic microsomes ex vivo (Jinno et al. 
1997, Zorrilla et al. 2009, Hanioka et al. 1996).  Triclosan inhibited diiodothyronine (T2) 
sulfotransferases in rat and human hepatocytes in vitro, suggesting interference with thyroid 
hormone sulfation (Wang & James 2006, Wang et al. 2004).  Available evidence suggests 
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activation of hepatic nuclear receptors by triclosan, with subsequent upregulation of hepatic 
metabolism, which contributes to the maintenance of thyroid homeostasis (Capen 1994, Hill 
et al. 1998, DeVito et al. 1999). 
The current work tested the hypothesis that triclosan decreased serum T4 in vivo by 
upregulation of hepatic catabolism and altered expression of cellular transport proteins. A 
four-day exposure weanling rat model was employed, as this protocol has been used to 
characterize thyroid disrupting chemicals (Zhou et al. 2001, Craft et al. 2002, Crofton 2004), 
and demonstrate triclosan-induced hypothyroxinemia (Crofton et al. 2007) and hepatic 
enzyme induction (Hanioka et al. 1996).  Serum total T4, T3, and TSH were measured.  
Cytochrome P450 markers of Phase I metabolism were analyzed enzymatically and as 
mRNA expression levels by quantitative RT-PCR.  UGT activity and the expression of UGT 
and SULT isoforms were also measured as indicators of Phase II catabolic pathways.  
Finally, mRNA expression levels of several hepatic transporters were measured to determine 
the contribution of hepatic transport to the hypothesized mode-of-action for triclosan 
disruption of T4.   
3.  Methods 
 
Animals.  Long-Evans female rats (n=120) at 21-23 days of age were obtained from Charles 
River Laboratories Inc. (Raleigh, NC), and were allowed 2-4 days of acclimation in an 
American Association for Accreditation of Laboratory Animal Care (AALAC)-approved 
animal facility prior to treatment.  Animals were housed two per plastic hanging cage (45 cm 
x 24 cm x 20 cm), with heat sterilized pine shavings bedding (Northeastern Products Corp., 
Warrenton, NC).  Colony rooms were maintained at 21 ±2°C with 50 ±10 % humidity on a 
photo-period of 12L:12D (0600-1800hr).  Food (Purina Rodent Chow #5001,) and water 
were provided ad libitum.  Tap water (Durham, NC water) was filtered through sand, then 
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activated charcoal, and finally re-chlorinated to 4-5 ppm Cl- before use in the animal facility. 
All animal procedures were approved in advance by the Institutional Animal Care and Use 
Committee of the National Health and Environmental Effects Research Laboratory of the US 
EPA.  
The current work included hepatic tissue and serum samples from a previous 
publication (Crofton et al. 2007) that reported only serum T4, body weight, and liver weight 
values.  The two experimental blocks from the previous study (Crofton et al. 2007) were 
combined with the additional block performed in the current study for T4 and hepatic 
enzyme assays; this yielded total sample sizes of n=24, 8, 24 , 24, 24, 16 for the vehicle 
control, 10, 30, 100, 300, and 1000 mg/kg/day, respectively.  Only samples for the second 
block (n=8/treatment group) were used for mRNA analyses; therefore, no tissue from the 
1000 mg/kg/day group was used.  Only samples for the third block were used for T3 and 
TSH analyses (n=8/treatment group), so no tissue from the 10 mg/kg/day group was used. 
Chemicals and treatment.  Triclosan (5-Chloro-2-(2,4-dichloro-phenoxy)phenol, 
CAS#3380-34-5, LOT#06415CD) was obtained from Aldrich Chemical Company (St Louis, 
MO, Cat#524190-10G).  Mass spectrometry, employed to analyze the triclosan sample, 
revealed: 98.2% triclosan, 0.05% iso-triclosan, 0.12 % 2,8,-dichlorodibenzodioxin, and 0.1% 
2,4,8-trichlorodibenzodioxin. The dosing solutions (0, 10, 30, 100, 300, and 1000 mg/kg/day) 
were prepared in corn oil (Sigma, Lot#117K0127) and sonicated for 30 min at room 
temperature.  The 1000 mg/kg/day dose precipitated within 24 hrs and was therefore 
sonicated daily before use.  Dosing volume was 1.0 ml corn oil/kg body weight. Rats (27-29 
days of age) were exposed via gavage for four consecutive days.  Rats were randomly 
assigned to treatment groups to balance body weights at the start of dosing.  Body weights 
were recorded and dosing volumes adjusted daily by weight.  Approximately 24 hrs after the 
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final treatment rats were moved into a holding room, weighed, and acclimated for a 
minimum of 30 min.  Trunk blood and liver were collected between 0900 and 1100 hrs in an 
adjacent room with a separate air supply.  Blood was collected into serum separator tubes 
(Beckton Dickinson, 36-6154).  Serum was obtained after clotting whole blood for 30 min on 
ice, followed by centrifugation at 1278x g at 4°C for 30 min.  Livers were weighed and then 
quick frozen in liquid nitrogen.  Serum and liver samples were stored at -80°C until analysis. 
Thyroid hormone assays.  Serum total T4 and serum total T3 were measured in duplicate by 
standard solid-phase Coat-A-Count radioimmunoassay (RIA) kits (Siemens Medical 
Solutions Diagnostics, Los Angeles, CA).  Serum TSH concentrations were analyzed in 
duplicates with a double antibody RIA method (Greenwood et al. 1963) with some 
modification (Zorrilla et al. 2009).  The TSH radioimmunoassays were performed using 
materials supplied by the National Hormone and Pituitary Agency: iodination preparation (I-
9-TSH); reference preparation (RP-3); and antisera (S-6-TSH).  Iodination material was 
radiolabeled with 125I (Perkin Elmer, Shelton, CT).  Assay variation was assessed using the 
multivalent control module (Siemens Medical Solutions Diagnostics, Los Angeles, CA; 
Lot021) to measure low, medium, and high total T4, T3, and TSH values before and after 
measuring the experimental samples.  Intra- and inter-assay coefficients of variance for all 
assays were below 13%.   Total serum T4 and TSH were calculated as ng T4/ml serum, and 
total serum T3 was calculated as ng T3/dL serum.   
Microsome preparation and EROD and PROD assays. Liver microsomal fractions, 
prepared as described previously (DeVito et al. 1993), were standardized using total protein 
(Bio-Rad, Richmond, CA). Hepatic microsomal EROD and PROD activities were assayed 
using a fluorometric microplate reader (Spectramax Gemini XPS, Molecular Devices/MDS 
Analytical Technologies,Toronto, Canada).  Each well in polystyrene 96-well plates (Nunc 
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ThermoFisherScientific, Rochester, NY) contained a total of 235 ul, including 50 ul of 
substrate (1.5 nM ethoxyresorufin or pentoxyresorufin), 50 µL of diluted microsomes, and 
110 µL of 0.05 mM Tris buffer (pH 8.0).  Microsomes were diluted 1:10 for samples and 
1:100 for the positive control in order to maintain data points within the linear region of the 
standard curve.  An aliquot (25 µL) of NADPH was added to initiate the reaction.  The 
fluorescence signal was measured every 33 seconds for five min at 37ºC after reaction 
initiation. The rate of resorufin formation was estimated by calculating Vmax/min, using a 
resorufin standard curve to extrapolate resorufin concentrations in the reaction.  A similar 
method was used to measure hepatic microsomal PROD activity, using pentoxyresorufin as a 
substrate. Both EROD and PROD values were calculated as picomoles (pmol) resorufin per 
milligram protein per minute.  A positive control, comprised of pooled microsomes from rats 
acutely exposed to 10 µg/kg 2,3,7,8-tetrachlorodibenzo-p-dioxin or 300 mg/kg Aroclor, was 
used to facilitate inter-assay comparison.  
UGT activity assay.  UGT activity for T4 was measured by the method of (Beetstra et al. 
1991) as modified by (Zhou et al. 2001).  Detergent such as Brijj 56 was not included due to 
the potential for increased basal T4 glucuronidation (Craft et al. 2002).  A positive control 
microsome pool, comprised of microsomes from rats that received a single 10 µg/kg 2,3,7,8-
tetrachlorodibenzo-p-dioxin dose or a single 300 mg/kg Aroclor 1254 dose, was used during 
each trial to enable inter-assay comparison. 
mRNA preparation and analysis.  Approximately 0.2 g of frozen tissue was homogenized 
in 2 mL of TRI Reagent (Molecular Research Center, Cincinnati, OH; Cat. No. TR 118).  
Total RNA was extracted per the protocol provided by the Molecular Research Center 
(Chomczynski & Sacchi 1987).  RNA extraction was processed in duplicate.  Protein, nucleic 
acid content, and approximate RNA concentrations were estimated with a DU800 Beckman-
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Coulter Spectrophotometer via measurement of absorbance at 260 nm and 280 nm for each 
sample.  Analysis of RNA integrity was performed using an Agilent RNA 6000 Nano Kit and 
Bioanalyzer, according to the instructions provided (Part Number: G2938-90033).  Samples 
used in qRT-PCR experiments were selected from duplicates based on optimizing the 
260/280 ratio to 2.0 (range =: 2.00 – 2.14).    The average 28s/18s ratio for samples used was 
2.2 (range = 1.9-3), and the average assigned integrity rating (RIN) was a 9.4 out of 10 
(range = 8.2-10).   
Gene expression assays were performed using Taqman ® One-step RT-PCR Master 
Mix Reagent kits (Applied Biosystems, Foster City, CA; Cat.#: 4309169), which include 
AmpliTaq Gold ® DNA Polymerase, dNTPs including dUTP, passive reference, and 
optimized buffer components for both the reverse transcriptase (RT) and DNA polymerase 
reactions.  Also included is the RT enzyme mix, containing the MultiScribeTM Reverse 
Transcriptase and RNase inhibitor.  Taqman Gene Expression Assays (Applied Biosystems) 
were used to test the mRNA expression of specific genes involved in hepatic catabolism and 
transport (Table 1).  Each 20 µL reaction contained 900 nM of the gene-specific primer and 
125 ng of RNA sample, except for OATP1a4 and MDR1b, which contained 400 ng of RNA 
per reaction.  The 96-well plates were maintained at 4ºC during pipetting using a 
thermocycler block.  Samples were analyzed in triplicate using the experimental probe and in 
triplicate using the endogenous control gene on each plate.  Samples positions distributed 
across the plate based on a semi-random design, where each plate contained the same number 
of samples from a dose group, but the samples were randomly selected and assigned to well 
positions within the plate.  Following sample loading, plates were centrifuged at 1400 rpm, 
24ºC, for 3 min before being placed in a Stratagene MxPro3005P QPCR Detection System 
(Stratagene, Agilent Technologies, Cedar Creek, TX). The thermal profile was as follows: 
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reverse transcriptase reaction at 48ºC  for 45 min, an initial 10 min denaturation period at 
95ºC, followed by 60 PCR cycles of 15 sec denaturation at 94ºC, and 1 min annealing and 
extension at 60ºC.   
The amplification efficiencies for all of the genes used in qRT-PCR experiments were 
confirmed using pooled, untreated control RNA extracted from female rat liver.  
Amplification efficiency was calculated according to the equation, Efficiency = (10(-1/m)
 
-1) x 
100, where m = the slope of the plot of Threshold CT (dRn) vs. Log[RNA concentration] 
(Table 2.1) (Applied Biosystems Publication 127AP05-03).   
qRT-PCR data sets were analyzed using a relative quantification method (2-∆∆CT) to 
describe the change in expression of the target experimental gene relative to an endogenous 
reference gene (Livak & Schmittgen 2001).  Choice of an endogenous reference gene was 
based onconstant gene expression across all of the dosing groups (Dunn & Klaassen 1998), 
and tissue-specific amplification efficiency (Livak & Schmittgen 2001). The endogenous 
reference gene, Rps18, was selected after determining the amplification efficiencies of 
multiple candidate genes (Pohjanvirta et al. 2006), including GAPDH, β2-microglobulin, 
Rps18, and Rpl13a.  Choice of genes was contingent upon twocriteria: involvement of the 
isoform in TH metabolism and transport in rats, as well as regulation of the isoform by CAR 
and/or PXR  
Data analysis.  All three study blocks with a combined n=120 were analyzed using a two-
way analysis of variance (SAS 9.1, SAS Institute, Cary, NC), with dose and block as 
independent variables, and T4, EROD activity, PROD activity, UGT activity as dependent 
variables.  Significant treatment effects were followed by mean contrast testing using 
Duncan’s New Multiple Range Test (p<0.05).  T4, UGT, EROD, and PROD data were 
analyzed as mean percent of control in order to normalize the data across the three study 
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blocks.   qRT-PCR data (Block 2 only) were analyzed using a two-way analysis of variance, 
with dose and plate number as independent variables, and 2-∆∆CT as the dependent variable. 
T3 and TSH data (Block 3 only) were analyzed using one-way analysis of variance, with 
dose as the independent variable and hormone as the dependent variable (SAS 9.1, SAS 
Institute, Cary, NC).   
 Benchmark dose (BMD) and lower-bound confidence limit (BMDL) estimates were 
determined using USEPA Benchmark Dose Software (BMDS Version 2.0.0.33) as 
previously described  (Crofton et al. 2007, Zhou et al. 2002, Zhou et al. 2001).  BMD 
analyses were performed to further define dose-dependent effects that are not discernible 
using only information on the statistically significant effects found using ANOVA.    Use of 
BMDs enables estimation of the dose at which a specified effect, or benchmark response 
(BMR) may occur. The BMR was set at a 20% decrease for T4 and T3 data (Crofton et al. 
2007, Zorrilla et al. 2009), 50% for increases in hepatic PROD activity, and 20% for changes 
in mRNA expression and UGT activity data (Schlecht et al. 2006).  These BMRs were 
selected based on previous use in the literature, a need to balance the statistical and perceived 
biological significance of a change in the measured endpoint, and known mechanistic 
relationships (e.g., UGT and T4) (EPA 2000).  The BMDs were calculated from the model 
fits to the data. The BMDL (lower-bound confidence limit) was calculated as the 95% lower 
confidence interval.   
4.  Results 
No clinical signs of toxicity were observed in the rats following the 4 days of 
triclosan treatment.  Effects on liver weight and liver-body weight ratio were consistent with 
a previously published four-day triclosan exposure model (Crofton et al. 2007). There was a 
main effect of dose [F(5,105)=2.57, p<0.0309] and study block [F(2,105)=6.24, p<0.0027] 
  
66 
 
on liver weight that resulted in a 12% increase liver weight in the 1000 mg/kg/day dose 
group.  Increases in liver weight, and non-significant decreases in body weight gain of 
approximately 10% in the high dose group, were reflected in the main effect of dose [F(5, 
105)=18.62, p<0.001] and study block [F(5, 105)=3.50, p<0.0338] on the liver-body weight 
ratio, which resulted in approximately a 13% increase in the liver-body weight ratio for the 
1000 mg/kg/day dose group (Table 2.2). 
Total serum T4 and total serum T3 both decreased in a dose-responsive manner, with 
decreases of 26%, 35%, and 57% relative to control at 100, 300, and 1000 mg/kg/day for T4, 
and decreases of 12% and 25% at 300 and 1000 mg/kg/day for T3, respectively (Figure 2.1).  
TSH was unchanged.  For T4, there was a main effect of dose [F(5, 105)=37.46, p<0.0001], 
but no effect of  study block (p<0.05), or dose-by study block interaction (p<0.05).  Mean 
contrast tests revealed significant T4 decreases in the 100, 300 and 1000 mg/kg/day groups 
(p<0.05). There was also a main effect of dose on T3 concentrations [F(4, 35)=12.80, 
p<0.0001]; mean contrast tests demonstrated significant decreases at 300 and 1000 
mg/kg/day only (p<0.05).  The no-observed effect level (NOEL) for T4 decreases was 30 
mg/kg/day, and 100 mg/kg/day for T3 decreases.  Using a BMR equal to a 20% decrease in 
thyroid hormones, Hill model fits to the data predicted BMDs of 99.4 and 606 mg/kg/d, with 
95% lower confidence limits of 65.6 and 335 mg/kg/day, for T4 and T3 respectively. 
EROD activity was depressed by triclosan exposure in a non-dose responsive manner 
(Figure 2.2a), with a 25-32% decrease for all dose groups except 10 mg/kg/day.  There was a 
significant main effect of dose [F(5, 105)=7.34, p<0.0001],  but no main effect of study 
block (p<0.05), or dose-by study block interaction (p>0.05).  PROD activity was 
significantly elevated in a dose-dependent manner (2.2b).  The 100, 300, and 1000 
mg/kg/day groups were increased by 249, 814, and 937 percent of control, respectively.  
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These conclusions are supported by a main effects of dose [F(5,104)=29.95, p<0.0001] and  
a dose-by study block interaction [F(7,104)=4.86, p<0.0001].  The interaction of study block 
and dose was due to a higher baseline activity in block 3 and a slightly greater induction 
compared to study blocks 1 and 2.  Note that there was significant induction of PROD in all 
three study blocks. Mean contrast tests revealed significant effects in the 300 and 1000 
mg/kg/day group (p<0.05).  Using a BMR equivalent to a 50% increase in PROD activity, a 
Hill model fit to the data predicted a BMD of 70.8 mg/kg/day, with a 95% lower confidence 
limit of 48.6 mg/kg/day.  The increased EROD (22-fold) and PROD (3.5-fold) activity in the 
positive control were consistent with laboratory historical control data. 
Expression levels of hepatic microsomal CYP mRNA were differentially altered by 
triclosan exposure (Figure 2.3).   There was no significant effect of triclosan on relative 
mRNA expression of Cyp1a1.  Cyp2b1/2 and Cyp3a1/23 increased in a dose-dependent 
manner.  There were main effects of dose for both Cyp2b1/2 [F(4,35)=3.30, p<0.0214] and 
Cyp3a1/23 [F(4, 35)=9.52, p<0.0001].  Mean contrast tests revealed significant increases of 
Cyp2b1/2 mRNA of 2-fold at 300 mg/kg/day only. Cyp3a1/23 was significantly increased 
2.5- and 4.1-fold in the 100 and 300 mg/kg/day groups, respectively.  Using a BMR 
equivalent to 20% increase in mRNA expression, the BMD and BMDL for Cyp2b2 were 
45.3 mg/kg/day and 24.0 mg/kg/day, and the BMD and BMDL for Cyp3a1/23 were 62.3 and 
7.3 mg/kg/day, respectively.  The Cyp2b1/2 expression data was best fit with a linear model, 
whereas the Hill model provided the best fit for the Cyp3a1/23 expression data.   
T4-glucuronidation activity increased with triclosan treatment (Figure 2.4).  There 
were main effects of dose [F(5,104)=2.38, p<0.0435] and block [F(2,104)=5.20, p<0.0070], 
but no dose-by study block interaction (p<0.05). Mean contrast testing revealed a significant 
82% increase at 1000 mg/kg/day.  BMDS did not fit the data using linear, Hill, polynomial, 
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or exponential models. 
Triclosan exposure induced isoform-specific increases in UGT and SULT mRNA 
expression (Figure 2.5 and 2.6). There was a main effect of dose on Ugt1a1 mRNA 
expression [F(4, 35)=5.98, p<0.0009], but no significant effects on Ugt1a6 and Ugt2b5.   
Mean contrast tests revealed significant 1.7- and 2.3-fold increases at 100 and 300 
mg/kg/day, respectively.  Using a BMR equivalent to a 20% increase in mRNA expression, 
the BMD and BMDL were 22.7 and 6.4 mg/kg/d, respectively.  Triclosan increased Sult1c1 
mRNA expression [F(4, 35)=6.34, p<0.0006] approximately 2.5-fold in the 100 and 300 
mg/kg/day groups (Figure 2.6).  The significant main effect of triclosan on Sult1b1 mRNA 
expression [F(4, 34)=4.63, p<0.0043], was caused by small but significant decreases at 30 
and 100 mg/kg/day (p<0.05).  Linear, Hill, polynomial, and exponential models failed to 
significantly fit the mRNA expression data for Sult1b1 and Sult1c1. 
Triclosan treatment did not significantly alter mRNA expression of any of the 
measured hepatic transporters: Oatp1a1 (Oatp1), Oatp1a4 (Oatp2), Mrp2, or Mdr1b (Figure 
2.7).  
5.  Discussion 
The current work tested the hypothesis that triclosan decreased serum T4 via 
upregulation of hepatic catabolism and altered expression of cellular transport proteins.  
Consistent with this hypothesis we report here that triclosan upregulates both mRNA 
expression and activity of some Phase I and II hepatic enzymes.  Contradictory to this 
hypothesis was the lack of effects on any measured hepatic cellular transporters.   
Furthermore, the pattern of effects on hepatic mRNA for CYP and UGT isoforms suggests 
that the initiating event in the mode-of-action for triclosan-induced hypothyroxinemia is 
activation of hepatic CAR and PXR receptors.   
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Consistent with previous reports, oral exposure to triclosan produced 
hypothyroxinemia.  Dose-responsive T4 decreases have been observed following both 4-day 
(Crofton et al. 2007) and 31-day exposures (Zorrilla et al. 2009).  Effective doses that 
reduced T4 by 20% in the four-day exposures used in this work (BMD = 99.4 mg/kg/day) 
were higher compared to the smaller four-day assay data set published previously by this 
laboratory (BMD=69.7 mg/kg/day) (Crofton et al. 2007). The effective dose that reduced T4 
by 20% following a 31-day triclosan exposure (BMD = 14.5 mg/kg/day) was much lower 
(Zorrilla et al. 2009) than the effective doses in the current study, likely due to the differences 
in exposure duration, as well as the sex, age, and strain of rats used.  Strain may be a 
particularly important uncertainty in directly comparing studies of thyroid disruption, as 
background levels of thyroid hormones and metabolic responses may differ between strains 
(Lecureux et al. 2009).   
 T3 and TSH were also assessed to more fully characterize the impact of triclosan on 
circulating thyroid and pituitary hormones.  The decreases (12-25%) in T3 observed at 300 
and 1000 mg/kg/day were consistent with the previous reports that T3 was decreased 
approximately 20% after 31-days of 200 mg/kg/day triclosan treatment (Zorrilla et al. 2009).  
No change in TSH with triclosan treatment is also consistent with a previous report (Zorrilla 
et al. 2009).  Other chemicals including polychlorinated biphenyls and 3-methylcholanthrene 
have significantly decreased T4 with no effects on TSH (Hood et al. 1999, Liu et al. 1995); 
this phenomenon of decreased T4 without compensatory TSH increase, while not well 
understood, has been hypothesized to result from a lack of induction of T3-glucuronidation 
(Barter & Klaassen 1994, Hood & Klaassen 2000).   
Triclosan exposure increased enzymatic and mRNA markers of activity and 
expression of Cyp2b1/2 and Cyp3a1/23, suggesting that triclosan may activate nuclear 
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receptors CAR and/or PXR.  Increased PROD activity implies increased Cyp2b1/2 protein. 
This is consistent with previous in vitro and in vivo observations of triclosan-induced PROD 
activity and Cyp2b1/2 protein (Hanioka et al. 1997, Hanioka et al. 1996, Jinno et al. 1997, 
Zorrilla et al. 2009).  Zorrilla et al. also found PROD activity increases in vivo following 31-
day exposures (BMD =14.31 mg/kg/day )(Burke et al. 1994), compared to 70.8 mg/kg/day, 
obtained in the present study.  Relative mRNA expression of Cyp2b1/2 and Cyp3a1/23 
increased significantly.  This suggests that triclosan may be capable of interacting with both 
CAR and PXR, consistent with activation of PXR in vitro in a human (HuH7 culture) 
receptor reporter assay (Jacobs et al. 2005).  Currently, there are no published reports of 
triclosan activity toward CAR.  However, our observations of increased Cyp2b1/2 activity 
and expression indicate potential CAR activation (Sueyoshi et al. 1999, Qatanani et al. 2005). 
EROD activity decreased slightly, and was not dose-responsive, corresponding well 
to the lack of significant changes to Cyp1a1 mRNA expression; collectively these data imply 
that AhR activation is not a key step in this mode-of-action.  No constitutive expression of 
Cyp1a1 protein in rat liver and no induction of Cyp1a1 mRNA with triclosan treatment 
suggest that these EROD decreases  do not reflect Cyp1a1 activity inhibition, but rather the 
inhibition of one or more of several CYPs, including Cyp2c11 (Burke et al. 1994).  Previous 
work with rat liver microsomes demonstrated that triclosan competitively inhibited EROD 
induction by 3-methylcholanthrene, a prototypical microsomal enzyme inducer of EROD and 
Cyp1a1 activities (Hanioka et al. 1996). However, the failure of triclosan to induce EROD is 
inconsistent with a report of triclosan agonism of AhR; triclosan activated AhR to 40% of the 
level of activation of TCDD, and inhibited TCDD activation by 30%, suggesting a 
competitive interaction (Ahn et al. 2008). 
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Importantly, the lack of Cyp1a1 induction demonstrates that the minor dioxin 
contaminates found in the triclosan sample used in this study, 2,8,-dichlorodibenzodioxin and 
2,4,8-trichlorodibenzodioxin, did not induce AhR-mediated effects on Phase I and Phase II 
hepatic enzymes. 2,8-dichlorodibenzodioxin is a very weak AhR agonist in vitro, and failed 
to induce EROD in vivo (Mason & Safe 1986). 
Phase II glucuronidation and sulfation are upregulated by triclosan treatment, 
suggesting triclosan treatment increases hepatic T4 conjugation. Observations of a two-fold 
increase in glucuronidation activity of T4 and a 2.2-fold increase in Ugt1a1 mRNA 
expression suggest small increases in T4-UGT activity result from triclosan exposure. 
Increases in glucuronidation result in increased biliary excretion of conjugated hormone 
(Vansell & Klaassen 2002, Vansell & Klaassen 2001, Liu et al. 1995, Barter & Klaassen 
1994).  Previous work in this laboratory and others has found that UGT activity may not have 
a clear linear relationship with T4 concentrations (Craft et al. 2002, Hood & Klaassen 2000).  
Another major uncertainty regarding the testing of UGT isoforms for mRNA expression 
levels is the choice of isoforms to test. This work tested isoforms responsible for hepatic 
conjugation of T4 in rat: Ugt1a1 and Ugt1a6 (Vansell & Klaassen 2002), as well as a marker 
of T3-glucuronidation, Ugt2b5 (Vansell & Klaassen 2002, Richardson et al. 2008).  Whereas 
mRNA expression of Ugt1a1 and Ugt1a6 can be found in the liver, Ugt1a7, which also 
conjugates T4, appears to be constitutively expressed mainly in the intestine of rats (Shelby 
et al. 20032004), and inducible in liver by AhR agonists (Metz et al. 2000).  Thus, Ugt1a7 
was excluded from analysis, as an amplification efficiency in the appropriate range could not 
be determined for analysis by qRT-PCR.  No changes in expression were observed for 
Ugt1a6 or Ugt2b5.  In comparing the T4-UGT activity and mRNA expression data, it 
appears likely that the approximately 2-fold increase in T4- UGT activity may be attributed 
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to increases observed in Ugt1a1 mRNA expression.  
While increased activity and expression of UGT isoforms supports the overall 
hypothesis that triclosan treatment induces glucuronidation of TH, these data do not confirm 
a particular nuclear receptor pathway, as CAR, PXR,  and the glucocorticoid receptor (GR), 
all transcriptionally regulate isoform Ugt1a1 (Sugatani et al. 2005).  Ugt1a6 is more 
exclusively controlled by the AhR (Auyeung et al. 2003); the lack of expression change for 
Ugt1a6 complements the unchanged expression of Cyp1a1 and EROD activity. This is 
consistent with the lack of AhR activation by triclosan and the lack of an AhR contribution to 
the endpoints measured in the current work. 
Triclosan exposure increased sulfotransferase Sult1c1 mRNA expression 2.6-fold, 
indicating that increased sulfation and biliary excretion of T4 may occur. Sulfation 
deactivates T4 and increases its biliary excretion via enhancement of inner ring deiodination 
and blockage of outer ring deiodination for reactivation (Kester et al. 2003).  Triclosan 
noncompetitively inhibits the in vitro human hepatic microsomal sulfation of 3-
hydroxybenzo(a)pyrene (3-OH-BaP), bisphenol A (BPA), p-nitrophenol, and acetaminophen 
with IC50 concentrations in the low micromolar concentration range; competitive inhibition 
of the glucuronidation of 3-OH-BaP, BPA and acetaminophen was also observed (Wang et 
al. 2004).  Thus, triclosan may exert an inhibitory action on SULT and UGT catabolic 
enzymes, affecting the overall activity profile of UGTs and SULTs in vivo.  An uncertainty 
in our analysis is choice of sulfotransferases to test; sulfation of thyroid hormones is 
catalyzed primarily by Sult1b1 and Sult1c1 in the rat, though the preferred substrate for these 
enzymes is actually not the physiologically relevant thyroid hormone (T3), but rather a T3
 
metabolite (T2) (Kester et al. 2003). Any future use of this data in extrapolation to potential 
human effects is complicated by the sex dependence of Sult1c1 expression in rats (Wong et 
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al. 2005), which signals a potentially sexually dimorphic response to triclosan with respect to 
sulfotransferase expression changes.  Male-dominant expression of Sult1c1 reflects sex-
dependent T3 sulfation in rats, which is not known to occur in humans (Kaptein et al. 1997).  
Our observations report mRNA expression changes in female rats; however, the major 
change noted in sulfotransferases activity for triclosan treatment groups was up-regulation of 
Sult1c1, which is expressed predominantly in male rat liver, kidney, and intestine; expression 
of Sult1b1 is equivalent between rat sexes (Kester et al. 2003).    
No statistically significant changes were observed in the mRNA expression of hepatic 
transporters, including Oatp1a1, Oatp1a4, Mrp2, and Mdr1.  These particular transporters 
were chosen for analysis based on their functional activity and affinity for iodothyronines 
(Wong et al. 2005), as well as several previous literature reports of microsomal enzyme 
inducer effects on these transporters (Cheng et al. 2005, Kretschmer & Baldwin 2005, Wong 
et al. 2005, Klaassen & Slitt 2005, Johnson & Klaassen 2002b).  These mRNA expression 
results suggest that transporter expression changes do not contribute to the observed T4 
decreases.  However, these results do not exclude the possibility that hepatic transporter 
protein activity is altered by triclosan treatment via receptor-mediated post-translational 
modifications (Cherrington et al. 2002).  The mRNA expression of Mrp2 may not be 
indicative of the in vivo protein expression, as PXR ligands that induce Cyp3a have been 
shown to increase Mrp2 protein without increasing Mrp2 expression (Johnson & Klaassen 
2002a).  Other PXR ligands, including DMP-904 (Wong et al. 2005), PCN, and 
spironolactone (Cheng et al. 2005), and CAR ligands including phenobarbital (Cherrington et 
al. 2002) have previously demonstrated effects on the regulation of hepatic transporter 
mRNA expression.  Further characterization of the hepatic transporter activity of the liver in 
response to triclosan treatment will be necessary to conclude definitively that transporters are 
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or are not involved in triclosan-induced hypothyroxinemia. 
This work suggests that triclosan triclosan upregulates Phase II glucuronidation and 
sulfation, and that this increased catabolism may be at least partially responsible for the 
triclosan-induced hypothyroxinemia observed. This is consistent with other microsomal 
enzyme inducers including phenobarbital, polychlorinated biphenyls, pregnenolone-16α-
carbonitrile, dioxins, and others (Liu et al. 1995, Schuur et al. 1998).  Correlation plots (not 
shown) of T4 concentration versus UGT activity, and Ugt1a1 and Sult1c1 expression 
revealed significant linear model fit (p<0.05), but  poor R-squared values (R2=0.07-0.18), 
suggesting that other mechanisms contribute to the T4 decreases observed.  Triclosan may 
exert a direct effect on the thyroid and TH synthesis; however, preliminary data in ex vivo 
porcine thyroid peroxidase assays indicate no effect of triclosan (Dr. Michael Hornung, 
personal communication).  Other mechanisms that could contribute to the observed 
hypothyroxinemia, including inhibition of iodide uptake, competition with TH serum binding 
proteins and upregulation of deiodinase activity, have not been assessed. 
Extrapolation of the current findings to humans should be tempered by a number of 
uncertainties, including the dose range used herein, versus estimated human exposures. The 
BMDL for a 20% decrease in T4 calculated from the data presented is 65.6 mg/kg/day in a 4-
day exposure scenario.  This short-term exposure model is intended for use as a tool in 
exploring mechanisms of thyroid disruption, and does not model prolonged daily human 
exposure.  The target human population of interest, due to the presence of triclosan in breast 
milk and its potential to disrupt thyroid hormone, and subsequent adverse impacts on 
neurological development, is the developing neonate and infant.  Human infant daily oral 
exposure is estimated is to be 0.005 mg/kg/day (USEPA 2008).  Thus, comparing our BMDL 
to this daily intake yields a margin of exposure of approximately 13,000-fold.  Note that this 
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does not take into account uncertainty factors used in the extrapolation of data obtained in 
rats to human risk; pharmacodynamic and pharmacokinetic differences in triclosan 
metabolism between species may greatly impact the relative effects. 
The present work confirms the conclusion that triclosan disrupts thyroxine and 
triiodothyronine in the rat.  Furthermore, the effects of triclosan on hepatic mRNA and 
enzymatic activity point out important key events in one potential mode-of-action of 
triclosan-induced hypothyroxinemia in rats, and suggest that CAR/PXR activation, with 
subsequent upregulation of hepatic catabolism of T4, may be one mechanism that contributes 
to the observed hypothyroxinemia.  In order to improve the ability to extrapolate these 
findings to humans, future research should characterize interspecies similarities and 
differences in these key events.  
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Supplemental Data Table (Appendix 1) lists the group mean, number of samples per group, 
and standard deviation for  serum thyroid hormone concentrations; EROD, PROD, and UGT 
microsomal activities; and the qRT-PCR results, including fold change and ddCt data for 
each gene expression assay reported.    Raw data files can be obtained by contacting the 
corresponding author. 
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Figure 2.1. Triclosan decreases total serum T4 (A) and T3 (B), with no change in TSH (C), 
represented as group mean values (± SE) percent of vehicle control (V) for each study cohort. 
(V = vehicle control, corn oil; for T4: n = 24 for V, 30, 100, and 300 dose-groups, n = 16 for 
1000 dose-group, n = 8 for 10 dose-group; for T3 and TSH: n=8 for V, 30, 100, 300, and 
1000 dose-groups; * = significantly different from vehicle controls , p>0.05. 
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Figure 2.2. Dose-response curves for the effects of a 4-day exposure to triclosan on liver 
microsomal EROD activity (A), and PROD activity (B).  Data are presented as group mean 
(± SE) percent of vehicle control (V) for each respective study block.(Activity = pmol 
resorufin/mg protein/min; V = vehicle control, corn oil; PC = positive control, single 10 
µg/kg 2,3,7,8-Tetrachlorodibenzo-p-dioxin dose and single 300 mg/kg Aroclor dose; n = 24 
for V, 30, 100, and 300 dose-groups, n = 16 for 1000 dose-group, n = 8 for 10 dose-group; * 
= significantly different from vehicle control p>0.05). 
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Figure 2.3. Dose-response curves for the effects of a 4-day exposure to triclosan on liver 
mRNA expression of CYP isoforms.  Data are plotted as the mean (± SE) fold change (2-
∆∆Ct) from control for the genes assayed: Cyp1a1 (A), Cyp2b2 (B), Cyp3a1/23 (C).  (V = 
vehicle control, corn oil; n = 8 per dose-group; * = significantly different from vehicle 
control p>0.05). 
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Figure 2.4. Dose-effect curve for the effects of a 4-day exposure to triclosan on liver 
microsomal UGT activity.  Data are presented as group mean (± SE) percent of vehicle 
control (V) for each respective study block. (UGT activity = pmol T4-G/mg protein/min; V = 
vehicle control, corn oil; PC = positive control, single 10 µg/kg 2,3,7,8-Tetrachlorodibenzo-
p-dioxin dose and single 300 mg/kg Aroclor dose; n = 24 for V, 30, 100, and 300 dose-
groups, n = 16 for 1000 dose-group, n = 8 for 10 dose-group; * = significantly different from 
vehicle control  p>0.05). 
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Figure 2.5. Dose-response curves for the effects of a 4-day exposure to triclosan on liver 
mRNA expression of UGT isoforms.  Data are plotted as the mean (± SE) fold change (2-
∆∆Ct) from control for the genes assayed: Ugt1a1 (A), Ugt1a6 (B), Ugt2b5 (C).  (V = vehicle 
control, corn oil; n =8 per dose-group; * = significantly different from vehicle control , 
p>0.05). 
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Figure 2.6. Dose-response curves for the effects of a 4-day exposure to triclosan on liver 
mRNA expression of SULT isoforms.  Data are plotted as the mean (± SE) fold change (2-
∆∆Ct) from control for the genes assayed: Sult1b1 (A), Sult1c1 (B).  (V = vehicle control, corn 
oil; n =8 per dose group, with the exception of n = 7 for V dose group of Sult1b1; * = 
significantly different from vehicle control , p>0.05). 
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Figure 2.7. Dose-response curves for the effects of a 4-day exposure to triclosan on liver 
mRNA expression of transporters.  Data are plotted as the mean (± SE) fold change (2-∆∆Ct) 
from control for the genes assayed: Oatp1a1 (A), Oatp1a4 (B), Mdr1b (C), Mrp2 (D).  (V = 
vehicle control, corn oil; n = 8 per dose-group).  
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Category Gene Abbreviation Slope R-Squared Efficiency Taqman Assay ID 
Endogenous 
reference 
Ribosomal protein 
S18 
Rps18 -3.2493 0.9494 103.1% Rn01428915_g1 
Phase I 
markers 
Cytochrome P450, 
family 1, subfamily 
a, polypeptide 1 
Cyp1a1 -3.6424 0.8690 88.2% Rn00487218_m1 
Cytochrome P450, 
family 2, subfamily 
b, polypeptide 2 
Cyp2b1/2 -3.1757 0.9680 106.4% Rn02783833_m1 
Cytochrome P450, 
subfamily 3A, 
polypeptide 1 
Cyp3a1/23 -3.4391 0.9790 95.3% Rn01640761_gH 
Phase II 
markers 
UDP-
glycosyltransferase 
1 family, 
polypeptide A1 
Ugt1a1 -3.3699 0.9529 98.0% Rn00754947_m1 
UDP-
glycosyltransferase 
1 family, 
polypeptide A6 
Ugt1a6 -3.4287 0.9535 95.7% Rn00756113_mH 
UDP-
glucuronosyltransf
erase 2 family, 
member 5 
Ugt2b5 -3.2953 0.8786 101.1% Rn01777314_s1 
Sulfotransferase 
family 1B, member 
1 
Sult1b1 -3.2091 0.9143 104.9% Rn00673872_m1 
Sulfotransferase 
family, cytosolic, 
1C, member 1 
Sult1c1 -3.2282 0.9747 104.1% Rn00581955_m1 
Phase III 
markers 
Solute carrier 
organic anion 
transporter family, 
member 1a1 
Oatp1a1 or 
Oatp1 
-3.3182 1.0016 100.2 Rn00755148_m1 
Solute carrier 
organic anion 
transporter family, 
member 1a4 
Oatp1a4 or 
Oatp2 
-3.0310 1.1376 113.8% Rn00756233_m1 
ATP-binding 
cassette, subfamily 
C (CFTR/MRP), 
member 2 
Mrp2 -3.3033 1.0078 100.8% Rn00563231_m1 
ATP-binding 
cassette, subfamily 
B (MDR/TAP), 
member 1B 
Mdr1b -3.6001 0.8957 89.6% Rn00561753_m1 
 
Table 2.1. Summary of Taqman Gene Expression Assays and Amplification Efficiencies.  
The endogenous reference gene Rps18 was used to standardize all of the gene expression 
assays.  The slope presented is the slope value obtained from a plot of the threshold Ct (dRn) 
versus Log(RNA concentration), and R-squared value is the square of the correlation 
coefficient of the line obtained by the plot (Applied Biosystems Publication 127AP05-03). 
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Dose 
(mg/kg/d) 
N per 
dose 
Mean BW gain,  
% of control ± standard 
deviation 
Mean liver weight,  
%control ± standard 
deviation 
Mean liver-to-BW ratio,  
%control ± standard 
deviation 
0 24 100 ± 16 100 ± 9.3 100 ± 4.9 
10 8 102 ± 12 104 ± 18 105 ± 4.1 
30 24 108 ± 16 103 ± 11 102 ± 4.7 
100 24 105 ± 14 101 ± 12 101 ± 4.7 
300 24 105 ± 24 105 ± 13 104 ± 5.2 
1000 16 92 ± 20 112 ± 12*  113 ± 4.9* 
 
Table 2.2. Doses, group sizes, and block-controlled body weight gain, liver weight, and 
liver-to-body-weight ratio with standard deviation values.  Significant increases of nearly 
12% and 13% occur in the 1000 mg/kg/day dose group for liver weight and liver-to-body-
weight ratio, respectively (* = significantly different from vehicle control by ANOVA, 
p>0.05). 
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 1.  Abstract 
 
Disruption of maternal thyroid hormones during fetal development may result in 
irreversible neurological consequences in offspring.  The current work tested the hypothesis 
that perinatal triclosan exposure of dams decreases thyroxine in dams and offspring prior to 
weaning.  Pregnant Long-Evans rats received triclosan by oral gavage (0-300 mg/kg/day) in 
corn oil from gestational day (GD) 6 through postnatal day (PND) 21. Serum was obtained 
from pups on PND4, 14, and 21, and from dams on PND22.  Serum T4 was reduced 31% in 
dams on PND22.  In pups, a unique pattern of hypothyroxinemia was observed; serum T4 
decreased 27% in PND4 pups with no significant reduction observed on PND14 or PND21.  
Comparable reductions of approximately 30% in serum T4 at 300 mg/kg/day for dams and 
PND4 neonates and a lack of effect at PND14 and PND21 suggest that toxicokinetic or 
toxicodynamic factors may have contributed to a reduced exposure or a reduced toxicological 
response during the lactation period.   
2.  Introduction 
 
Proper regulation of thyroid hormones is critical to the development and maturation of 
the nervous system in many vertebrates, including mammals.   Haddow et al. demonstrated 
that low maternal serum T4 during gestation correlated with 4-10 point IQ deficits in children 
(Haddow et al., 1999).  The adverse impact of subclinical T4 concentration decreases during 
human development is unequivocal (Kooistra et al., 2006; Pop et al., 2003; Pop et al., 1999).  
The correlation between maternal and neonatal hypothyroxinemia and neuronal development 
is also well established in the rat, making it an appropriate model of developmental TH 
insufficiency (Howdeshell, 2002; Miller et al., 2009; Rice et al., 2000; Zoeller et al., 2000). 
Hypothyroxinemia during critical periods of neurodevelopment has been shown to result in 
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permanent effects, including sensory and motor deficits (Anderson, 2008; Crofton et al., 
2005; Morreale de Escobar et al., 2004).  While the precise mechanistic cascade of events 
that lead from decreased serum hormone levels to adverse neurodevelopmental outcomes is 
not yet known, measurement of circulating T4 in dams and offspring serves as a qualitative 
predictor of neurodevelopmental deficits (Crofton, 2004; Miller et al., 2009). 
Triclosan is a bacteriostatic agent used in a variety of commercial personal care products.  
Widespread use and environmental transport has led to its detection as contaminant in 
surface water and wastewater treatment plant effluents at ng/L concentrations (Chalew et al., 
2009; Kanda et al., 2003; Kolpin et al., 2002; Loraine et al., 2006; McAvoy et al., 2002; 
Waltman et al., 2006), in wildlife samples including fish (Adolfsson-Erici et al., 2002; 
Balmer et al., 2004; Houtman et al., 2004), and also in human tissues including serum, urine, 
and milk (Adolfsson-Erici et al., 2002; Allmyr et al., 2006; Allmyr et al., 2008; Calafat et al., 
2008; Hovander et al., 2002; Wolff et al., 2007).  Triclosan is an endocrine disruptor, 
reported to exert weak estrogenic effects on frogs and fish (Foran et al., 2000; Ishibashi et 
al., 2004; Matsumura et al., 2005; Raut et al., 2009), and to disrupt thyroid-mediated 
development in frogs (Veldhoen et al., 2006) .  Recent research using juvenile and weanling 
rat exposure models has demonstrated that triclosan exposure decreases thyroid hormone 
concentrations in mammalian models (Crofton et al., 2007; Paul et al., 2010; Zorrilla et al., 
2009).  The endocrinological effects of triclosan exposure during rat development are 
currently unknown.  The finding that triclosan is present in human milk at concentrations up 
to 2100 µg/kg-lipid (Dayan, 2007) has raised concern due to the documented relationship 
between thyroid disruption during development and irreversible adverse neurological 
outcomes in children.  
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Susceptibility to triclosan-induced hypothyroxinemia may differ between life stages due 
to potential differences in the toxicodynamic and toxicokinetic responses to triclosan during 
pregnancy and development.  The current study was designed to test the hypothesis that 
perinatal triclosan exposure will alter circulating thyroid hormone levels in pups during early 
postnatal development and in dams at the conclusion of lactation.  As only dams received 
triclosan directly, this study models the exposure of human mothers during gestation and 
nursing, and the potential combined in utero and nursing exposures to offspring. 
3.  Methods 
Animals. Time-pregnant Long-Evans female rats (n=40), approximately 80-90 days of age, 
were obtained from Charles River Laboratories Inc. (Raleigh, NC) on gestation day (GD) 1 
(defined as the day after vaginal plugs were observed), and were allowed five days of 
acclimation in an American Association for Accreditation of Laboratory Animal Care 
International (AALAC) approved animal facility prior to initiation of treatment on GD6.  
Animals were housed individually in plastic hanging cages (45 cm x 24 cm x 20 cm), with 
heat sterilized pine shavings bedding (Northeastern Products Corp., Warrenton, NC).  Colony 
rooms were maintained at 21 ± 2°C with 50  ± 10 % humidity on a photo-period of 12L:12D.  
Food (Purina Rodent Chow #5001, Barnes Supply Co., Durham, NC) and water were 
provided ad libitum.  Tap water (Durham, NC water) was filtered through sand, then 
activated charcoal, and finally re-chlorinated to 4-5 ppm Cl- before use in the animal facility. 
All animal procedures were approved in advance by the Institutional Animal Care and Use 
Committee of the National Health and Environmental Effects Research Laboratory of the US 
EPA.  
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 Dams (n=10/treatment for 0, 30, 100, 300 mg/kg/day treatment groups) were orally 
exposed via gavage each day between 0800 and 1000 hr, with the exception of GD21, when 
chemical was not administered to animals if there were signs of parturition.  On GD21, dams 
were checked for the number of pups delivered at 0800, 1000, 1200, and 1500 hrs, and pups 
were aged as postnatal day (PND) 0 on the date of birth. All pups born from within a 24 hr 
period were considered to be the same age. On PND4, 14, and 21, offspring were counted, 
sexed, and group-weighed by sex.  Average pup weight by sex was calculated by dividing the 
group weight by the number of pups.  On PND4, litters were culled to 8 pups per litter, with 
the exception that litters comprised of fewer than 8 pups were not culled. Eye opening, 
determined as at least one eye open, was monitored once daily from PND11-17.   
Chemicals and treatment.  Triclosan (5-chloro-2-(2,4-dichloro-phenoxy)phenol 
(CAS#3380-34-5; 98+ % pure) was obtained from Sigma-Aldrich Chemical Company (St 
Louis, MO, LOT#06415CD, Cat#524190-10G) and Ciba Grenzach GmbH (Germany, 
Lot#60023CL7).  Mass spectrometry analysis revealed that the triclosan used was greater 
than 98.2% pure triclosan; the sample also contained 0.05% iso-triclosan, 0.12% 2,8-
dichlorodibenzodioxin, and 0.1% 2,4,8-trichlorodibenzodioxin, but was free of biologically-
active dioxin compounds.  The dosing solutions (0, 30, 100, and 300 mg/mL) were prepared 
in corn oil (Sigma, Lot#117K0127), sonicated for 30 minutes, and stored in amber vials at 
room temperature.  Solutions were prepared every 5-7 days.  The 300 mg/kg/day dose 
partially precipitated within 24 hours and was therefore sonicated daily before use.  All doses 
were mixed on a stir plate during the dosing period each morning. Dams were randomly 
assigned to treatment groups by counter-balancing body weights.  Administered volume was 
1.0 ml corn oil/kg body weight; body weights were recorded daily, and administered volumes 
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were adjusted daily by weight. Prior to the sacrifice of pups on PND4 (only culled pups), 14 
and 21 (one pup per sex per litter), animals were moved to a holding room, dams were 
weighed and dosed, pups were weighed, and all animals were acclimated for a minimum of 
30 min.  Tissue collection was conducted between 0800 and 1200 hrs in an adjacent room 
with a separate air supply.  The time of necropsy within the 4-hr period was balanced among 
dose groups to control for time-of day effects on thyroxine levels (Dohler et al., 1979; Jordan 
et al., 1980). Trunk blood was collected from one male and one female pup per litter and 
pooled into one tube.  Blood from dams was collected after decapitation on PND22, 24 hr 
after the final dose.  Blood was collected into serum separator tubes (Beckton Dickinson, 36-
6154).  Serum was obtained after clotting whole blood for 30 min on ice, followed by 
centrifugation at 1278x g at 4°C for 30 min. Serum samples were stored at -80°C until 
analysis. 
Thyroxine assay.  Serum total T4 was measured in duplicate by standard solid-phase Coat-
A-Count radioimmunoassay (RIA) kits (Siemens Medical Solutions Diagnostics, Los 
Angeles, CA).  Assay variation was assessed using the multivalent control module (Siemens 
Medical Solutions Diagnostics, Los Angeles, CA) to measure low, medium, and high total 
T4 values before and after measuring the experimental samples.  The intra-assay CV ranged 
from 4 to 5%. The inter-assay CV for three separate assays conducted over a one year period 
was 4.9%.   Total serum T4 was calculated as ng T4/mL serum. 
Data analysis.   Dam bodyweight data (total n=38, one dam in the high dose group died of 
unknown causes and one dam failed to deliver live pups) for prenatal and postnatal stages 
were analyzed separately using repeated measures ANOVAs (SAS 9.1, SAS Institute, Cary, 
NC), followed by mean contrast testing with Duncan’s New Multiple Range Test (p<0.05), 
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with dose and animal as independent variables.  All other data were analyzed by ANOVAs, 
with significant main effects followed by Duncan’s New Multiple Range Test. Gestation 
length was defined as the period from GD0 to the day of birth.  The viability index was 
calculated as the number of pups alive on PND0 divided by the number alive on PND4 per 
litter prior to culling.  Sex ratio was calculated as the number of female pups divided by the 
number of male pups. Eye opening was calculated as mean percent of pups with at least one 
eye open in a litter for each treatment.  
 Benchmark dose (BMD) and lower-bound confidence limit (BMDL) estimates were 
determined using USEPA Benchmark Dose Software (BMDS Version 2.0beta) as previously 
described (Crofton et al., 2007; Zhou et al., 2001; Zhou et al., 2002). The benchmark 
response (BMR) (EPA, 2000) was set at a 20% decrease in thyroxine, reflecting previous use 
of this BMR in the literature (Crofton et al., 2007; Paul et al., 2010; Zhou et al., 2001; Zhou 
et al., 2002; Zorrilla et al., 2009).  The BMD was calculated from a model fit to the data. The 
BMDL (lower-bound confidence limit) was calculated as the 95% lower confidence interval. 
4.  Results 
Perinatal maternal triclosan exposure did not affect any reproductive parameters (Table 
3.1), including: gestation length [F(3,35) = 0.00, p<0.9998], litter size [F(3,35)=0.48, 
p<0.6949], viability index [F(3,34)=0, p=1], or sex ratio [F(3,34)=0.76, p<0.5228]. 
Treatment did not elicit effects on the day of eye opening [F(3,33)=0.09, p<0.9650] (Table 
1).  Further, no gross terata were observed in any of the pups, and viability was unaffected by 
treatment. 
 No clinical signs of toxicity were observed in the dams or pups during the 36 days of 
triclosan treatment.  There was a 7-10% decrease in body weight observed for dams in the 
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300 mg/kg/day treatment group from GD14 through GD20 that was not statistically different 
from control; there was no main effect of treatment [F(3,34)=2.56, p<0.0715], nor was there 
an interaction of  prenatal-day and treatment (F(42,63)=1.05, p<0.4264).  Dam body weights 
decreased by approximately 10% throughout the postnatal period (Figure 3.1). This 
observation is supported by a main effect of treatment on the body weight of dams 
[F(3,32)=4.63, p<0.0084] and no treatment by postnatal day interaction [F(60,40)=0.86, 
p<0.7005].  Mean contrast testing demonstrated a significant difference between the control 
and 300 mg/kg/day treatment (p<0.05).  There were no effects of treatment on pup body 
weight, male or female, at ages PND4, PND14, or PND21 (data not shown). 
Serum total T4 decreased 31% on PND22 in dams treated with 300 mg/kg/day 
(Figure 3.2) [F(3,34)=4.36, p<0.0105] (see Supplemental Data table, Appendix 2, for group 
statistics). The no-observed effect level (NOEL) for triclosan and T4 was 100 mg/kg/day.  
Although several BMD models fit the data, a second degree polynomial model had the 
lowest residual values and predicted a BMD of 229 mg/kg/day, with a 95% lower confidence 
limit of 104 mg/kg/d (Table 2.2). 
Maternal exposure to triclosan reduced serum total T4 in neonates.  This effect was 
restricted to pups on PND4, when there was a 27% decrease in the 300 mg/kg/day group 
relative to controls [F(3,31)=3.57, p<0.0252].  There were no effects of triclosan on pup 
serum T4 concentrations at PND14 or PND21; pups born to the 300 mg/kg/day dam 
treatment group had only non-significant decreases in T4 of 16% and 8% at PND14 and 
PND21, respectively. The NOEL for triclosan dose to the dam and T4 in PND4 pups was 100 
mg/kg/day.  A second degree polynomial model fit to the data predicts a BMD of 113 
mg/kg/day, with a 95% lower confidence limit of 58 mg/kg/day (Table 1).  Although several 
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BMD models fit the data appropriately, the second degree polynomial model yielded the 
lowest scaled residuals.    
5.  Discussion 
 
Perinatal maternal exposure to triclosan resulted in hypothyroxinemia in dams and young 
neonates. The magnitude of the observed hypothyroxinemia is consistent with previous 
reports of decreased serum T4 in juvenile and weanling rats (Crofton et al., 2007; Paul et al., 
2010; Zorrilla et al., 2009). Importantly, T4 decreases were only observed in dams and PND4 
offspring with no effects observed in pups on PND14 or PND21, indicating a unique pattern 
of postnatal hypothyroxinemia. The highest dose of triclosan decreased dam body weights 
during the postnatal lactation period, but did not affect any of the other reproductive 
endpoints including pup survival, sex ratio, eye opening, or pup body weights.  
Thyroxine reduction in both dams and PND4 neonates demonstrates that both pups, 
during early postnatal development, and dams are susceptible to triclosan-induced 
hypothyroxinemia. Oral maternal triclosan exposure produced equivalent effects in dams at 
PND22 and neonates at PND4.  Decreases of approximately 30% in serum T4 at 300 
mg/kg/day in dams and developmentally exposed neonates are consistent with the serum T4 
changes and potency reported for weanling rats following a 4-day triclosan exposure 
(Crofton et al., 2007; Paul et al., 2010).  Exposures of juvenile rats to triclosan for thirty-one 
days demonstrated a greater potency, with significantly decreased T4 found at 30 mg/kg/day 
(Zorrilla et al., 2009).  The discrepancy between these studies is likely due to differences in a 
number of experimental variables, including: increased exposure duration, juvenile 
developmental stage, gender, and rat strain.   
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Perinatal maternal triclosan exposure resulted in decreased circulating serum T4 that was 
observed on PND4, but not observed on PND14 or PND21 (Figure 2.2). The lack of 
significant changes in serum total T4 during the later stages of lactation, at PND14 and 
PND21, was unexpected.  A number of previous studies on a variety of chemicals, including 
polybrominated diphenyl ethers, polychlorinated biphenyls, and 2,3,7,8-
tetrachlorodibenzodioxin (TCDD), have demonstrated that postnatal thyroid hormones are 
usually affected by perinatal (i.e., gestational and lactation) maternal xenobiotic exposure 
during the entirety of the postnatal lactation period (Crofton et al., 2000; Goldey et al., 1995; 
Morse et al., 1993; Zhou et al., 2001; Zhou et al., 2002).  In this study, the observed 
thyroxine decrease in pups on PND4, followed by recovery to controls levels by PND21, is a 
unique pattern of effects for perinatal maternal exposure to thyroid disrupting xenobiotics.  
Toxicokinetic and/or toxicodynamic factors may account for this observed postnatal pattern.  
The toxicokinetic distribution of triclosan may limit maternal transfer via milk, and thus 
exposure may diminish with increasing postnatal age. The effect of triclosan on PND4 pups 
could have resulted from transplacental exposure to triclosan.  Previous work with Aroclor 
1254 (Crofton et al., 2000), a commercial mixture of highly lipophilic PCBs, demonstrated 
that maternal prenatal-only exposure produced a similar pattern of effects on postnatal T4 
levels in pups, i.e., a larger effect on PND4, followed by a return to control values by 
PND21. While triclosan is known to be present in human milk (Adolfsson-Erici et al., 2002; 
Allmyr et al., 2006; Dayan, 2007), there are no published data on the toxicokinetic 
distribution of triclosan in rats.  Further work is required to address the hypothesis that pups 
receive less triclosan via lactation compared to placental transfer to the fetus.  Alternatively, 
triclosan may not produce an equivalent toxicodynamic effect in neonates.  This presupposes 
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that the hypothyroxinemia found in PND4 pups is due to the persistence of prenatal effects of 
triclosan that dissipate with increasing postnatal age. This hypothesis further suggests that 
triclosan does not up-regulate key hepatic catabolic mechanisms, i.e., glucuronidation or 
sulfation of thyroid hormones, responsible for thyroid disruption in weanling rats (Paul et al., 
2010).  While there are no published data on the effects of triclosan on early postnatal 
catabolic enzymes, data from a number of other studies of xenobiotics clearly demonstrate 
the inducibilty of hepatic microsomal enzymes in pups during the lactation period (Lucier et 
al., 1979; Morse et al., 1993; Zhou et al., 2002).  Testing this hypothesis will require 
measurement of hepatic Phase I and II enzymes in neonates following developmental 
exposures.   
This study provides the first report of triclosan-induced hypothyroxinemia following 
perinatal developmental exposure.  The observed postnatal pattern of hypothyroxinemia in 
pups was unique in that the early postnatal effects recovered to control levels by the end of 
weaning. This pattern suggests that toxicokinetic factors may have affected maternal 
disposition of triclosan into milk and thereby limited lactation exposure to pups, or that the 
triclosan may not have triggered the same toxicodynamic effects in offspring during the 
lactation period as in exposed weanlings or dams.  These data demonstrate that the maternal 
exposure to triclosan impacts thyroid hormones during development in the rat.  The relevance 
of these findings for humans and wildlife is tempered by both the relatively high doses used 
and possible species-specific metabolic and kinetic processes. Future research should 
characterize the dose of triclosan received by developing rats from placental and lactation 
exposure, as well as the hepatic catabolic responses of developing neonates to triclosan in 
order to explain the lack of effects of triclosan at later postnatal ages. 
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Figure 3.1.  Dam body weight during the gestational and lactation periods.  There is a 
statistically significant decrease of approximately 10% in the body weight of dams 
throughout the postnatal period for the 300 mg/kg/d dose group. [n = 10, 10, 9, 8 for 0, 30, 
100 and 300 mg/kg/day, respectively; * = significantly main effect of treatment for postnatal 
ages, and group mean differences between vehicle and 300 mg/kg/d, p>0.05.] 
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 Figure 3.2. Percent of control serum total T4 for: A) Dams and B) Pups, by age and oral 
maternal dose (mean ± SE).  [For Dams and PND21, n = 10, 10, 9, 8 for the 0, 30, 100 and 
300 mg/kg/day, respectively;  For PND14, n = 10, 10, 8, 8 for the 0, 30, 100 and 300 
mg/kg/day, respectively;  For PND4, n = 9, 9, 8, 8 for the 0, 30, 100 and 300 mg/kg/day, 
respectively;  * = significantly different from vehicle control by ANOVA, p>0.05.  Raw T4 
values in ng/mL (mean ± SE) for the 0 mg/kg/d and 300 mg/kg/d groups, respectively, were: 
49.6 ± 2.2 and 34.1 ± 3.7 for PND22 Dams; 9.63  ± 0.49 and 7.08 ± 0.64 for PND4 pups; 
48.4 ± 2.2 40.6 ± 2.3 for PND14 pups; and 38.9 ± 2.0 and 36.0 ± 1.8 for PND21 pups. 
 
 
 
 
 
 
 
 
 
 
 
  
Dose 
(mg/kg/day) 
Gestation 
Length 
Sex 
Ratio  
Litter Size 
(PND 0) 
Viability 
Index 
% Eye Opening (PND) 
13 14 15 16 
0 21.1 ± 0.1 1.21 ± 0.25 12.8 ± 0.71 100.0 ± 0.0 0.0 ± 0.0 24.0 ± 7.2 91.7 ± 3.7 100 ± 0.0 
30 21.1 ± 0.1 1.62 ± 0.44 11.8 ± 0.72 100.0 ± 0.0 0.0 ± 0.0 25.3 ± 7.1 91.7 ± 6.9 100 ± 0.0 
100 21.1 ± 0.1 1.09 ± 0.16 11.5 ± 1.17 100.0 ± 0.0 0.0 ± 0.0 24.1 ± 8.4 98.1 ± 1.8 100 ± 0.0 
300 21.1 ± 0.1 1.11 ± 0.12 11.1 ± 1.44 100.0 ± 0.0 0.0 ± 0.0 21.7 ± 8.1 97.9 ± 2.1 100 ± 0.0 
 
 
Table 3.1. Gestation length, gender ratio, litter size, viability and eye opening (mean ± SE).  None of the parameters shown 
were significantly changed by triclosan treatment.  Gestation Length is reported in days; Gender Ratio is the number of 
females divided by the number of males; Litter Size at PND0 includes only live born pups; Viability Index is the littersize at 
PND4 divided by the live born pups at PND0 multiplied by 100%; % Eye Opening is the percent of pups in each litter with at 
least one eye open. 
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Age NOEL BMD BMDL 
Dam 100 229 104 
PND4 100 113 58 
 
Table 3.2. NOEL and BMD dose levels for T4 effects by age (mg/kg/day ± SE).  US EPA 
Benchmark Dose Software (BMDS Version 2.0Beta) was used to determine the BMD and 
BMDL, with a 95% confidence limit, for the selected BMR = 20% reduction in serum T4. 
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1.  Abstract   
 
Perinatal triclosan (TCS) exposure decreases serum maternal and early neonatal 
thyroxine (T4) in the rat, but the mode-of-action (MOA) for these effects, and the potential 
for these effects during gestation in addition to postnatally, is unknown.  This work test the 
hypothesis that TCS decreases T4 via activation of the pregnane X and/or constitutive 
androstane receptors (PXR, CAR), resulting in up-regulation of hepatic catabolism of T4, 
and subsequent declines in circulating T4 and triiodothyronine (T3).  Time-pregnant Long-
Evans rats received TCS po (0-300 mg/kg/day) from gestational day (GD) 6 through weaning 
on postnatal day (PND) 21. Serum and liver were collected from dams on GD20 and PND22, 
and from offspring on GD20, PND4, PND14, and PND21.  Serum T4, T3, and thyroid 
stimulating hormone (TSH) concentrations were measured by radioimmunoassay.  Ethoxy-
O-deethylase (EROD), pentoxyresorufin-O-deethylase (PROD) and uridine diphosphate 
glucuronyltransferase (UGT) enzyme activities were measured in liver microsomes.  Custom 
low density Taqman qPCR arrays were used to measure hepatic mRNA expression of select 
cytochrome P450s, UGTs, sulfotransferases, transporters, and thyroid-hormone responsive 
genes at all developmental time points.  Parent and conjugated TCS were quantified by 
LC/MS-MS in serum and whole liver homogenate at all developmental time points.  Serum 
T4 decreased 30% in GD20 dams and fetuses, PND4 pups and PND22 dams at 300 
mg/kg/day.  Hepatic PROD activity increased 3-fold in PND22 dams and PND4 pups, and 
UGT activity was 1.5-fold higher in PND22 dams at 300 mg/kg/day.  Only minor gene 
expression changes were found with TCS exposure, centered primarily on up-regulated 
expression of Cyp2b and Cyp3a isoforms in dams.  Reductions of 30% in T4 for dams and 
GD20 and PND4 offspring with concomitant increases in PROD and UGT activity suggest 
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TCS may reduce T4 during development by a similar MOA to weanlings.  Increased 
expression of Cyp2b2 and Cyp3a isoforms in dams is consistent with our hypothesis that 
TCS activates CAR and/or PXR to perhaps transcriptionally up-regulate glucuronidation or 
sulfation of thyroid hormones in vivo.  Analytical measurements of TCS in sera and liver 
demonstrated that transplacental exposure occurs, and that it is a more important route of 
exposure that lactation in rats, with PND14 and PND21 rats demonstrating lower internal 
exposures.  This decreased exposure is consistent with the lack of any thyroid hormone 
changes at these ages.  Overall the data suggest that up-regulated hepatic catabolism, 
particularly in dams, contributes to the observed maternal and early neonatal 
hypothyroxinemia. 
2. Introduction 
 
Triclosan (2,4,4’-trichloro-2’-hydroxyphenylether) decreases thyroid hormones (THs) 
in rats (Crofton et al., 2007; Paul et al., 2010a; Paul et al., 2010b; Zorrilla et al., 2009).  This 
effect was hypothesized to result from the interaction of TCS with xenobiotic nuclear 
receptors, resulting in up-regulation of hepatic catabolism of THs and subsequent increased 
biliary excretion (Paul et al., 2010b). Previous work demonstrated modest maternal and early 
neonatal thyroxine (T4) decreases following oral administration to dams (Paul et al., 2010b), 
which is concerning because decreased maternal TH results in neurological deficits in rats 
(Gilbert et al., 2000; Goldey et al., 1998; Goldey et al., 1995), as well as irreversible 
decreases in neurodevelopment and motor function in human children (Haddow et al., 1999; 
Pop et al., 2003; Pop et al., 1999; Vermiglio et al., 2004). Therefore it is important to 
determine whether TCS alters fetal THs, and characterize the mode-of-action (MOA) for 
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these TH decreases in rats in order to assess the potential for TCS-induced hypothyroxinemia 
in humans. 
Maternal T4 concentration serves as a qualitative predictor of the neurological 
outcomes for offspring in rats and humans.  The general physiological mechanism for this 
relationship begins with decreased maternal T4, resulting in decrease in the availability of 
free T4 to the fetus, leading to a decrease in the fetal brain concentrations of T3, which is 
necessary to activate thyroid receptors (TRs) for transcriptional regulation of the expression 
of genes involved in neurodevelopmental processes including myelination, neuronal and glial 
cell differentiation and migration during and pregnancy and the early postnatal period 
(Bernal, 2007; Williams, 2008; Zoeller et al., 2004; Zoeller et al., 2007).  Supporting 
evidence for this observation comes from decades of epidemiological data that demonstrate a 
relationship between maternal hypothyroxinemia during the first trimester and early second 
trimester, typically defined as T4 below the 5-10 percentile, and decreased performance on 
psychomotor tests that evaluate mental ability, gross and fine motor skill coordination, and 
socialization of their children at 3 weeks (Kooistra et al., 2006), 10-30 months (Berbel et al., 
2009; Henrichs et al., 2010; Li et al., 2010; Pop et al., 1999) and at 1-2 years (Pop et al., 
2003). Maternal hypothyroidism and concomitant hypothyroxinemia during the early second 
trimester also corresponded to 4-10 point IQ deficits in children at 8 years of age (Haddow et 
al., 1999).  Taken together these data support the critical role of maternal T4 during human 
development, and that the impacts of early gestational maternal hypothyroxinemia are 
lasting.  Studies with rats also demonstrate a relationship between maternal 
hypothyroxinemia and altered neurodevelopmental outcomes in offspring, including changes 
in the cellular composition of several brain regions, expression of critical genes, and aberrant 
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neurobehavior.  Maternal hypothyroidism and hypothyroxinemia change the cellular 
structure and maturation of the cortex and hippocampus (Berbel et al., 2010; Gilbert, 2004; 
Lavado-Autric et al., 2003; Sharlin et al., 2008).  Maternal hypothyroxinemia during 
gestation, in the absence of hypothyroidism or thyroid hormone effects in offspring, altered 
cortical neuron migration in white matter tracts (Lavado-Autric et al., 2003).   Although fetal 
T4 production is active during the final week of gestation, maternal T4 supplements the fetal 
T4 supply to prevent altered cell migration in the cortex and hippocampus and decreased 
learning capacity (Berbel et al., 2010).  Gene expression changes in the cortex related to 
cellular development and synaptic function, and in the hippocampus related to myelination 
and calcium signaling, were altered with 1 ppm propylthiouracil administered perinatally to 
rats, which resulted in maternal T4 and neonatal (PND14) T4 deficits of 32% and 51%, 
respectively, with no T3 or TSH effects (Royland et al., 2008).  These examples demonstrate 
that maternal, fetal, and neonatal hypothyroxinemia disrupt neurodevelopment, though the 
degree of hypothyroxinemia necessary to elicit adverse neurodevelopmental effects has not 
been well characterized. 
Measurements of TCS in serum (Allmyr et al., 2008; Allmyr et al., 2006b; Allmyr et al., 
2009; Hovander et al., 2002), breast milk (Adolfsson-Erici et al., 2002; Allmyr et al., 2006a; 
Dayan, 2007), and TCS metabolites in urine (Calafat et al., 2008; Wolff et al., 2007) 
demonstrate that humans are exposed to TCS, and highlight the potential for developmental 
exposure via maternal TCS exposures.  A study of nursing mothers revealed that TCS 
concentrations in the serum of these mothers was 0.010 ng/g to 38 ng/g fresh weight (Allmyr 
et al., 2006a); of particular interest is that the TCS partitioned into serum at a much greater 
rate than into breast milk of these volunteers, suggesting that the oral dose to infants would 
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be more limited than the internal serum concentrations of the mothers (Allmyr et al., 2006a).  
For these mothers, TCS was detected in the women who had been exposed to personal care 
products containing TCS at much higher concentrations than mothers who had not been 
exposed to these types of products (Allmyr et al., 2006a).  However, since TCS was present 
in all mothers regardless of intentional personal care product exposure, this indicates that 
multiple sources of exposure contribute to the total TCS exposure of the human population.  
The range of TCS detected in the breast milk of the mothers in this study, both control and 
exposed, was less than 0.018 ng/g-lipid to 0.95 ng/g-lipid (Allmyr et al., 2006a).  In another 
study of five breast milk samples from Sweden, TCS concentrations ranged from less than 20 
µg/kg-lipid to 300 µg/kg-lipid (Adolfsson-Erici et al., 2002).    A study of 62 breast milk 
samples from milk donation banks in California and Texas demonstrated a range of TCS 
concentrations from below the limit of detection to 2100 µg/kg-lipid, with the majority of 
samples containing 200 µg/kg-lipid or less (Dayan, 2007).  Based on these findings, and the 
standard volume of milk consumed by infants (Butte et al., 1984; Butte et al., 2002; EPA, 
1997), Dayan used a conservative, high estimate of breast milk TCS concentration (1742 
µg/kg-lipid) to estimate the maximum infant exposure to TCS as approximately 7.4 µg/kg/d.  
These findings underscore the potential for human developmental exposure via breast milk, 
when the potential impact of TH disruption may be most deleterious. 
Previous work demonstrated that perinatal TCS exposure resulted in maternal and 
early neonatal hypothyroxinemia (Paul et al., 2010a); while the mechanism(s) responsible for 
the observed hypothyroxinemia during development have not been determined, we 
hypothesized that the MOA would be similar to that found in weanling rats exposed to TCS 
(Paul et al., 2010b). In a short-term exposure model with young adult rats, TCS decreased T4 
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and up-regulated markers hepatic catabolism, including uridine diphosphate 
glucuronyltransferase (UGT) activity, and Ugt1a1 and Sult1c1 expression (Paul et al., 
2010b), in addition to increased Cyp2b  and Cyp3a1 expression, suggestive of hepatic 
nuclear receptor-mediated pathway.  The main hypothesis of this work is that TCS decreases 
T4 in dams and offspring via up-regulation of hepatic catabolism, a demonstrated MOA for 
chemically-induced maternal and neonatal hypothyroxinemia (Zhou et al., 2002; Zoeller et 
al., 2005).  This work also tests the hypothesis that transplacental exposure supplies a higher 
dose to fetuses than lactation exposure provides to neonates, suggesting that the observed 
recovery of T4 to control values in PND14 and PND21 offspring (Paul et al., 2010a) stems 
from toxicokinetic rather than toxicodynamic differences between progeny exposed through 
development.   
 
3. Methods 
 
Animals. Time-pregnant Long-Evans female rats (n=155), approximately 80-90 days of age, 
were obtained from Charles River Laboratories Inc. (Raleigh, NC) on gestation day (GD) 1 
(defined as the day after vaginal plugs were observed), and were allowed five days of 
acclimation in an American Association for Accreditation of Laboratory Animal Care 
International (AALAC) approved animal facility prior to initiation of treatment on GD6.  
Animals were housed individually in plastic hanging cages (45 cm x 24 cm x 20 cm), with 
heat sterilized pine shavings bedding (Northeastern Products Corp., Warrenton, NC).  Colony 
rooms were maintained at 21 ± 2°C with 50  ± 10 % humidity on a photo-period of 12L:12D.  
Food (Purina Rodent Chow #5001, Barnes Supply Co., Durham, NC) and water were 
provided ad libitum.  Tap water (Durham, NC water) was filtered through sand, then 
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activated charcoal, and finally re-chlorinated to 4-5 ppm Cl- before use in the animal facility. 
All animal procedures were approved in advance by the Institutional Animal Care and Use 
Committee of the National Health and Environmental Effects Research Laboratory of the US 
EPA.  
 Dams were orally exposed via gavage each day between 0800 and 1000 hr, with the 
exception of GD21, animals chemical was not administered to animals if there were signs of 
parturition.  Figure 4.1 illustrates the dosing and tissue collection schedule.  On GD21, dams 
were checked for the number of pups delivered at 0800, 1000, 1200, and 1500 hrs, and pups 
were aged as postnatal day (PND) 0 on the date of birth. All pups born from within a 24 hr 
period were considered to be the same age. On PND4, 14, and 21, offspring were counted, 
sexed, and group-weighed by sex.  Average pup weight by sex was calculated by dividing the 
group weight by the number of pups.  On PND4, litters were culled to 8 pups per litter, with 
the exception that litters comprised of less than 8 pups were not culled. Eye opening, 
determined as at least one eye open, was monitored once daily from PND11-17.   
 The current work included some serum and liver samples from previous work (Paul et 
al., 2010a) that reported only reproductive toxicity parameters, body weights, and serum T4 
for the postnatal period.  Two experimental blocks were completed with postnatal tissue 
collection from pups and dams (Table 4.1).  Total combined sample numbers for T4 and 
hepatic microsomal assays were: 21, 12, 22, 22, 18 for 0, 10, 30, 100, and 300 mg/kg/day 
treatment groups.  Due to limited serum volume particulary for early neonatal time points, 
TSH was measured in samples from Block 1 only (n=10 for 0, 30, 100 mg/kg/day and n=8 
for 300 mg/kg/day), and T3 was measured in samples from Block 2 only (n=11 for vehicle 
control, n=12 for 10, 30, and 100 mg/kg/day, and n=10 for 300 mg/kg/day).  For qPCR 
120 
 
experiments, n=6/treatment group using liver tissue from experimental Block 2.  For 
analytical determination of TCS in sera and liver tissue samples, n=6/treatment group from 
experimental Block 2.  From experimental Blocks 1 and 2, two dams including one vehicle 
control and one in the 300 mg/kg/day treatment group, were never pregnant; one dam in the 
300 mg/kg/day group failed to deliver live pups; one other dam in the 300 mg/kg/day group 
died of unknown causes; and another was sacrificed early and excluded due to degenerative 
changes in one kidney and excessive urination. 
An additional experimental block, Block 3 (n=55, with 11 animals/treatment group), 
was performed to collect fetal and dam tissues at GD20.  Dams were dosed GD6 through 
GD19 only.  The GD20 sample size for all measurements is as follows: n=11 for 0, 10, 30, 
and 100 mg/kg/day treatment groups, and n=10 for the 300 mg/kg/day treatment group, 
except for analytical determinations of TCS in sera and liver tissue samples, which used 
n=6/treatment group (Table 4.1).  One dam in the 300 mg/kg/day group was hyperventilating 
and hyperactive, and the clinical veterinarian opinion was that the animal may have suffered 
abdominal torsion; this dam was sacrificed early on GD15. 
 
Chemicals and treatment.  Triclosan (5-chloro-2-(2,4-dichloro-phenoxy)phenol 
(CAS#3380-34-5; 98+ % pure) was obtained from Sigma-Aldrich Chemical Company (St 
Louis, MO, LOT#06415CD, Cat#524190-10G) and Ciba Grenzach GmbH (Germany, 
Lot#60023CL7).  Mass spectrometry analysis revealed that the triclosan used was greater 
than 98.2% pure; the sample also contained 0.05% iso-triclosan, 0.12% 2,8-
dichlorodibenzodioxin, and 0.1% 2,4,8-trichlorodibenzodioxin, but was free of biologically 
active dioxin compounds. The dosing solutions (0, 30, 100, and 300 mg/mL) were prepared 
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in corn oil (Sigma, Lot#117K0127), sonicated for 30 minutes, and stored in amber vials at 
room temperature.  Solutions were prepared every 5-7 days.  The 300 mg/kg/day dose 
partially precipitated within 24 hours and was therefore sonicated daily before use.  All doses 
were mixed on a stir plate during the dosing period each morning. Dams were semi-randomly 
assigned to treatment groups by counter-balancing body weights.  Administered volume was 
1.0 ml corn oil/kg body weight; daily body weights were recorded, and administered volumes 
were adjusted daily by weight. Prior to the sacrifice of dams and fetuses on GD20, pups on 
PND4 (only culled pups), 14 and 21 (one pup per sex per litter), animals were moved to a 
holding room, dams were weighed and dosed, pups were weighed, and all animals were 
acclimated for a minimum of 30 min.  Tissue collection was conducted between 0800 and 
1200 hrs in an adjacent room with a separate air supply.  The time of necropsy within the 4-
hr period was balanced among dose groups to control for time-of day effects on thyroxine 
levels (Dohler et al., 1979; Jordan et al., 1980). Trunk blood was collected from one male 
and one female pup per litter and pooled into one tube.  Blood from dams was collected after 
decapitation on PND22, 24 hr after the final dose.  Blood was collected into serum separator 
tubes (Beckton Dickinson, 36-6154).  Serum was obtained after clotting whole blood for 30 
min on ice, followed by centrifugation at 1278x g at 4°C for 30 min. Serum samples were 
stored at -80°C until analysis.  Liver was obtained from all offspring and dams, divided into 
sections, and immediately frozen in liquid nitrogen and stored at -80°C until analysis. 
Thyroid hormone assays.  Serum total T4 and total T3 was measured in duplicate by 
standard solid-phase Coat-A-Count radioimmunoassay (RIA) kits (Siemens Medical 
Solutions Diagnostics, Los Angeles, CA).  T3 was not measured for GD20 fetuses nor PND4 
neonates due to limited serum volumes and a lack of effect on any other time point.  Serum 
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TSH concentrations were analyzed in duplicates with a double antibody RIA method 
(Greenwood et al., 1963) with some modification (Zorrilla et al., 2009).  The TSH 
radioimmunoassays were performed using materials supplied by the National Hormone and 
Pituitary Agency: iodination preparation (I-9-TSH); reference preparation (RP-3); and 
antisera (S-6-TSH).  Iodination material was radiolabeled with 125I (Perkin Elmer, Shelton, 
CT).  Assay variation was assessed using the multivalent control module (Siemens Medical 
Solutions Diagnostics, Los Angeles, CA; Lot021) to measure low, medium, and high total 
T4, T3, and TSH values before and after measuring the experimental samples.  Intra-assay 
coefficients of variance for all assays ranged were below 15%, and the inter-assay 
coefficients of variance for T4, T3, and TSH were 5.8, 10.8, and 13.1% for assays conducted 
over a two year period.   Total serum T4 and TSH were calculated as ng T4/ml serum, and 
total serum T3 was calculated as ng T3/dL serum.   
Total serum T4 for GD20 fetuses was measured in duplicate by a different 
radioimmunoassay method as described elsewhere (Bansal et al., 2005; Gauger et al., 2004).  
Briefly, each assay contained: 5 µl of rat serum, 100 µl barbital buffer (0.11 M barbital pH 
8.6, 0.1% w/v 8-anilino-1-napthalene-sulfonic acid ammonium salt (ANS), 15% bovine γ-
globulin Cohn fraction II, 0.1% gelatin), 100 µl anti-T4 (rabbit, Sigma) diluted to provide a 
final concentration of 1:21,000, and 100 µl 125I-T4 (diluted to yield a total of 12,000–15,000 
cpm; Perkin Elmer/NEN).  Triplicate standards ranging from 4 ng/mL to 256 ng/mL were 
prepared from T4 (Sigma). Following a 30 min incubation at 37°C, the tubes were chilled on 
wet ice for 30 min. Antibody-bound radiolabeled T4 was precipitated by addition of 300 µl 
ice-cold polyethylene glycol 8000 (20% w/w; Sigma). Tubes were then centrifuged at 1800 × 
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g for 20 min at 4 °C, and the supernatant was aspirated and counted on a gamma counter 
(Packard CobraII).  The lower limit of detection for this method was 2.0 ng/mL. 
Microsome preparation and EROD and PROD assays. Liver microsomal fractions were 
prepared as described previously (DeVito et al., 1993) and standardized using total protein 
(Bio-Rad, Richmond, CA). Hepatic microsomal EROD and PROD activities were assayed 
using a fluorometric microplate reader (Spectramax Gemini XPS, Molecular Devices/MDS 
Analytical Technologies,Toronto, Canada).  Each well in polystyrene 96-well plates (Nunc 
ThermoFisherScientific, Rochester, NY) contained a total of 235 ul, including 50 ul of 
substrate (1.5 nM ethoxyresorufin or pentoxyresorufin), 50 µL of diluted microsomes, and 
110 µL of 0.05 mM Tris buffer (pH 8.0).  Microsomes were diluted 1:10 for samples and 
1:100 for the positive control in order to maintain data points within the linear region of the 
standard curve.  An aliquot (25 µL) of NADPH was added to initiate the reaction.  The 
fluorescence signal was measured every 33 seconds for five min at 37ºC after reaction 
initiation. The rate of resorufin formation was estimated by calculating Vmax/min, using a 
resorufin standard curve to extrapolate resorufin concentrations in the reaction.  A similar 
method was used to measure hepatic microsomal PROD activity, using pentoxyresorufin as a 
substrate. Both EROD and PROD values were calculated as picomoles (pmol) resorufin per 
milligram protein per minute.  Two positive controls were used to facilitate inter-assay and 
mechanistic comparison: pooled microsomes from rats acutely exposed to 10 µg/kg 2,3,7,8-
tetrachlorodibenzo-p-dioxin or 300 mg/kg Aroclor, and pooled microsomes from rats that 
received  4-day intraperitoneal exposure to phenobarbital (81 mg/kg/d) or PCN (50 mg/kg). 
UGT activity assay.  UGT activity for T4 was measured by the method of (Beetstra et al., 
1991) as modified by (Zhou et al., 2001).  Detergent such as Brijj 56 was not included due to 
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the potential for increased basal T4 glucuronidation (Craft et al., 2002).  Two positive 
controls were used to facilitate inter-assay and mechanistic comparison: pooled microsomes 
from rats acutely exposed to 10 µg/kg 2,3,7,8-tetrachlorodibenzo-p-dioxin or 300 mg/kg 
Aroclor, and pooled microsomes from rats that received  4-day intraperitoneal exposure to 
phenobarbital (81 mg/kg/d) or PCN (50 mg/kg). 
mRNA preparation and analysis.  For each of the six time points included in this study, the 
n=6/treatment group, with all treatment groups represented (0, 10, 30, 100, 300 mg/kg/day).  
Extraction of mRNA from frozen tissue was performed using Qiagen RNeasy Mini Kits 
(Qiagen, Valencia, CA).  Approximately 60 mg of frozen tissue was homogenized and split 
between two Qiagen QIAShredder columns to assure complete homogenization.  RNA 
extraction was processed in duplicate for each sample per the directions.  Contaminating 
DNA was removed on the Qiagen Mini-Kit columns using the Qiagen DNase kit.  RNA 
content and purity was assessed using a Nanodrop ND-1000  spectrophotometer (NanoDrop 
Technologies, Inc.; Wilmington, DE) at absorbances of 230, 260, and 280 nm for the 
duplicate RNA samples.  Samples used in experiments were selected from duplicates based 
on optimizing the 260/230 and 260/280 ratios to 2.0 (range was 1.80 – 2.14 for 260/230 and 
1.95 – 2.11 for 260/280).    The average 260/230 ratio for samples used was 2.02, and the 
average 260/280 ratio for samples used was 2.06. 
RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription 
Kit with RNase Inhibitor (Applied Biosystems, Foster City, CA), as per the manufacturer 
directions.  Two micrograms of RNA were added to each 20 µL reverse transcription 
reaction.   
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qPCR gene expression assays were performed using Custom Taqman ® Low Density 
Arrays (Applied Biosystems, Foster City, CA; Cat.#: 4309169), which are 384-well 
microfluidic cards preloaded with 23 unique gene targets, including several potential 
endogenous controls, each performed in duplicate for each sample.  Eight samples were 
loaded per card, in a semi-random order, where samples for each developmental time point 
were randomized and then run as separate cohorts by time point.  Following sample loading, 
plates were centrifuged at 1200 rpm, 24ºC, twice for 1 min before being run on a ABI Prizm 
7900HT (Applied Biosystems) .  
qPCR data sets were analyzed using a relative quantification method (2-∆∆CT) to 
describe the change in expression of the target experimental gene relative to an endogenous 
reference gene (Livak et al., 2001).  Choice of an endogenous reference gene was based on 
constant gene expression across all of the dosing groups for each developmental time point 
(Dunn et al., 1998; Livak et al., 2001). The candidate endogenous reference genes Actb, 
GAPDH, Rps18, and Rpl13a were run for each sample (Pohjanvirta et al., 2006).  Since there 
can be differential expression of common endogenous control genes at different 
developmental ages, choice of the endogenous control gene was performed by picking the 
gene for which the standard deviation from the mean of treatment group expression values 
was the smallest, as per the a priori criteria.  Rps18 was chosen for GD20 and PND22 dams, 
GD20 fetuses, and PND21 offspring.  Actb was selected for PND4 and PND14 offspring.  
However, using Rps18 for all time points did not significantly alter the results (data not 
shown).  Choice of the genes included on the low density array was contingent upon three 
criteria: involvement of the isoform in TH metabolism and transport in rats, regulation of the 
isoform by nuclear receptors AhR, CAR, PXR, and/or PPAR, and sensitivity to tissue levels 
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of thyroid hormones.  A list of the genes and Taqman identifiers for these is listed in Table 
4.2. 
Analytical measurement of TCS in sera and liver.  Serum was obtained from animals iver 
homogenate were made by homogenizing 0.5 g of tissue in 2 mL of diH2O.  TCS content in 
these tissues was analyzed by liquid chromatography-mass spectrometry (LC-MS) utilizing 
isotope dilution (Agilent 1200 high performance liquid chromatography [HPLC] with API 
4000 Triple Quadrapole MS), similar to the method previously reported for measuring parent 
TCS (Fort et al., 2010).  The mass spectrometry turbolon spray was utilized in negative mode 
for the negative TCS ion, with multiple reaction monitoring detection for parent ion (286.0 
amu) and product ion (35.1 amu).  The calibrated range for TCS determination was 1-1000 
ng/mL with 13C6-TCS as an internal standard in blank serum.  Serum and liver homogenate 
were analyzed undiluted unless preliminary data suggested out-of-range values for TCS.   
Parent TCS was measured in samples that contained 100 µL serum or liver 
homogenate and a  10 ng 13C6-TCS spike.  Acetonitrile (200 µL) was added to precipitate 
protein.  Samples were vortexed (1 min), briefly centrifuged, and then analyzed by LC/MS.  
The limit of detection for parent TCS was 1 ng/mL. Conjugated and parent TCS, or total 
TCS, were measured following an enzymatic hydrolysis step with combined glucuronidase 
and sulfatase and precipitation with acetonitrile.  Serum or liver homogenate (100 µL) was 
spiked with 10 ng 13C-TCS and a glucuronide/sulfate standard tracer.  After addition of 50 
µL of β-glucuronidase and sulfatase enzymes (0.2 mg of enzyme total per sample), a 4 hr 
incubation at 37ºC was performed.  Acetonitrile (400 µL) was added to stop the reaction and 
precipitate the protein.  Samples were vortexed (1 min) and centrifuged.  The supernatant 
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containing total TCS was then analyzed by LC/MS.    The limit of detection for total TCS 
was 5 ng/mL serum or liver homogenate. 
Data Analysis.   Dam bodyweight data for prenatal and postnatal stages were analyzed 
separately using repeated measures ANOVAs (SAS 9.1, SAS Institute, Cary, NC), followed 
by mean contrast testing with Duncan’s New Multiple Range Test (p<0.05), with dose and 
animal as independent variables.  All other data were analyzed by ANOVAs, with significant 
main effects followed by Duncan’s New Multiple Range Test. Gestation length was defined 
as the period from GD0 to the day of birth.  The viability index was calculated as the number 
of pups alive on PND0 divided by the number alive on PND4 per litter prior to culling.  Sex 
ratio was calculated as the number of female pups divided by the number of male pups. Eye 
opening was calculated as mean percent of pups with at least one eye open in a litter for each 
treatment.  
 Benchmark dose (BMD) and lower-bound confidence limit (BMDL) estimates were 
determined using USEPA Benchmark Dose Software (BMDS Version 2.0beta) as previously 
described (Crofton et al., 2007; Zhou et al., 2001; Zhou et al., 2002; Zorrilla et al., 2009). 
The benchmark response (BMR) (EPA, 2000) was set at a 20% decrease in thyroxine, 
reflecting previous use of this BMR in the literature Crofton and Zhou refs.  The BMD was 
calculated from a model fit to the data. The BMDL (lower-bound confidence limit) was 
calculated as the 95% lower confidence interval.  
4. Results 
 
Gestational maternal exposure to TCS did not affect the number of fetuses [F(4,48)=1.13, 
p<0.3549], and there were no effects of treatment on maintenance of pregnancy, as indicated 
by the lack of treatment-related difference in the number of implantation sites and fetuses on 
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GD20 [F(4,48)=1.41, p<0.2452].  Perinatal maternal triclosan exposure did not affect any 
reproductive parameters including: gestation length [F(3, 93)=0.05, p<0.8155],  litter size 
[F(3,93)=0.62, p<0.4314], viability index [F(3,92)=3.55, p=0.0627], or sex ratio 
[F(3,92)=2.93, p<0.0901]. Treatment did not elicit effects on the day of eye opening 
[F(1,90)=1.51, p<0.2216] (data not shown).  Further, no gross terrata were observed in any 
of the pups, and offspring viability was unaffected by treatment. 
 No treatment-related clinical signs of toxicity were observed in the dams or offspring 
during the either the 19 or 36 day course of TCS treatment.  There was no main effect of 
treatment on dam body weight during gestation [F(4,91)=1.65, p<0.1681]. However, dam 
body weights for the 300 mg/kg/day treatment group decreased by approximately 10% 
throughout the postnatal period (p<0.05).  This observation is supported by a main effect of 
treatment on the body weight of dams [F(4,83)=4.80, p<0.0016], though there was no 
postnatal-day and treatment interaction [F(80,1660)=1.76, p<0.7005].  There were no effects 
of treatment on pup body weight, male or female, at ages PND4, PND14, or PND21 (data not 
shown).  There were no effects of treatment on dam liver weight [F(4,89)=1.31, p<0.2740]  
or liver-body weight ratio [F(4,85)=1.52, p<0.2025]. 
A main effect of TCS treatment on serum total T4 was observed, with a significant 
decrease of 15% for PND22 dams with 100 mg/kg/day of TCS [F(4,85)=12.77, p<0.0001], 
and 30% for both the GD20 dams [F(4,48)=3.78, p<0.0095] and the PND22 dams with 300 
mg/kg/day of treatment (Figure 4.2).  The no-observed-effect level (NOEL) for TCS and T4 
was 100 mg/kg/day for GD20 dams and 30 mg/kg/day for PND22 dams.  The BMDs for 
serum T4 concentrations were 124 and 115 mg/kg/day with 95% lower confidence limits of 
25.2 and 62.1 mg/kg/day for GD20 and PND22 dams, respectively (Table 4.3).  For 
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offspring, there was a main effect of TCS treatment on serum total T4, except that this effect 
was limited to GD20 fetuses and PND4 neonates.  Serum total T4 was decreased by 25% and 
29% in fetuses from the 100 and 300 mg/kg/day treatment group [F(4,48)=2.91, p<0.0312] 
and by 26% in PND4 pups from the 300 mg/kg/day treatment group [F(4,85)=5.02, 
p<0.0011].  The computed BMDs for serum T4 were 95.4 and 150 mg/kg/day with 95% 
lower confidence limits of 33.0 and 61.8 mg/kg/day for GD20 fetuses and PND4 neonates, 
respectively (Table 4.3). There were no effects of treatment on serum T4 for PND14 
[F(4,89)=1.44, p<0.2261] or PND21 [F(4,89)=1.59, p<0.1831] neonates from any treatment 
group. 
There were no effects of treatment on serum T3 on any dam or offspring timepoint 
(data not shown; see Appendix 4).  Only sera from GD20 dams [F(4,49)=0.82, p<0.5215], 
PND22 dams [F(4,51)=2.23, p<0.0783], PND21 pups [F(4,51)=0.37, p<0.8296], and PND14 
pups [F(4,52)=0.52, p<0.7238] were analyzed.  Offspring from GD20 and PND4 were not 
tested due to limited serum volumes.  There were no effects on T3 for the GD20 or PND22 
dams, both of which demonstrated T4 reductions. 
There were no effects of treatment on serum TSH on any age tested, including GD20 
dams [F(4,49)=0.64, p<0.6382], PND22 dams[F(3,34)=0.27, p<0.8478], PND21 pups 
[F(3,34)=0.42, p<0.7406], PND14 pups [F(3,33)=0.52, p<0.6733], or PND4 pups 
[F(3,27)=2.01, p<0.1363] from any treatment group (Figure 4.3).  Serum obtained from 
GD20 fetuses was not tested due to limited serum volumes and a lack of effect on TSH for 
GD20 dams, PND22 dams, and PND4 neonates, which did demonstrate effects on T4. 
TCS increased PROD activity in an age-dependent manner that mostly reflected the 
ages associated with T4 decreases in this study.   Increased hepatic microsomal PROD 
130 
 
activity was observed for PND4 neonates and PND22 dams only (Figure 4.4).  PROD 
activity increased to 220 ± 38 percent of vehicle control for PND4 pups [F(4,51)=8.19, 
p<0.0001] and to 309 ± 44 percent of vehicle control for PND22 dams [F(4,85)=9.55, 
p<0.0001]. No significant effects were observed in GD20 dams [F(4,48)=1.89, p<0.1272] 
despite an effect of TCS on T4 for animals at this time point.  No effects of TCS were 
observed on PROD activity induction for PND14 [F(4,85)=2.34, p<0.0616) or PND21 
[F(4,85)=1.64, p<0.1705] neonates, and GD20 fetuses were not tested, as Cyp2b activity 
surges at parturition in rats  (Borlakoglu et al., 1993), and we were unable to measure any 
activity using our assay.  TCS decreased EROD activity for GD20 dams [F(4,48)=9.04, 
p<0.0001] , PND22 dams [F(4,85)=20.03, p<0.0001], and PND14 neonates [F(4,85)=11.82, 
p<0.0001] by approximately 40-50% for the 100 and 300 mg/kg/day treatment groups 
(Figure 4.4).  No effects of TCS were seen on EROD activity for PND4 [F(4,51)=0.44, 
p<0.7797] or PND21 [F(4,85)=1.34, p<0.2616] neonates, and GD20 fetuses were not tested. 
 
 Hepatic microsomal UGT-T4 activity was induced by TCS only for PND22 dams 
[F(4,84)=3.00, p<0.0228] to approximately 150% of vehicle control with no effect of block 
(Figure 4.5).  UGT-T4 activity for GD20 dams [F(4,48)=0.57, p<0.6849] and PND4 
neonates [F(4,49)=0.70, p<0.5954] was not affected by treatment, and UGT-T4 activity was 
not measured for ages which did not have a treatment-related effect on T4 (PND14, PND21 
neonates) or GD20 fetuses, due to limited tissue.  Positive controls representing prototypical 
microsomal enzyme inducers have been included for comparison.  Positive control 1 is a pool 
of microsomes obtained from animals treated once by gavage with either TCDD (10 µg/kg) 
or Aroclor 1254 (300 mg/kg); this pool induced UGT activity 202 ± 19 percent of control.  
Positive control 2 is a pool of microsomes obtained from animals treated for four days by 
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intraperitoneal injection with either phenobarbital (81 mg/kg/d) or PCN (50 mg/kg); this pool 
failed to induce UGT-T4 activity in this assay (113 ± 7.6 percent of control).   
TCS treatment had minor effects on CYP gene expression, producing few and only 
modest significant effects at any time point included in this study (Figure 4.6).  Cyp2b2 
expression was increased to 2.8141 ± 0.5223 and 2.4767 ± 0.4061 fold-control at 300 
mg/kg/d for GD20 dams [F(4,25)= 4.12, p<0.0107] and PND22 dams[F(4,25)=4.35, 
p<0.0083], respectively.   Cyp3a1 was induced 2.0390 ± 0.2745 fold-control for PND22 
dams only at 300 mg/kg/day [F(4,25)=3.55, p<0.0200], and there was also a strong 
increasing trend for Cyp3a2 in PND22 dams as well (2.6 fold-control at 300 mg/kg/day, 
p<0.0529) (data not shown). Cyp3a9 expression was induced to 1.8286 ± 0.1378 fold-control 
for GD20 dams [F(4,25)=4.17, p<0.0100], and values for Cyp3a9 expression in PND14 and 
PND21 pups could not be reported due to low expression.  Cyp4a2 was induced in GD20 
fetuses to 1.8398 ± 0.2044 fold-control [F(4,25)=4.46, p<0.0074].  Any TCS effects on 
hepatic CYP expression appear to be isoform- and age-dependent; no single CYP was 
uniformly changed by TCS treatment in all age groups.  With no effects of TCS on T4 
concentrations at PND14 and PND21, little to no effect on hepatic gene expression was 
anticipated.  Overall the data suggest that TCS up-regulated expression of Cyp2b in adult 
dams, with some increased Cyp3a expression, though for different isoforms in the pregnant 
versus the nursing dam. 
There were no statistically significant treatment related effects on hepatic gene 
expression of Ugt1a1 or Ugt1a6 for any of the developmental time points included in this 
study (Figure 4.7).  Although GD20 fetuses appear to demonstrate increased Ugt1a1 
expression (1.88 ± 0.56), variability in the data prevents a statistically significant effect at 
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300 mg/kg/day [F(4,25)=0.95, p<0.4537].  Hepatic sulfotransferase expression of Sult1b1 
was not affected by treatment for any of the time points included.  However, expression of 
Sult1c3 was induced for PND14 and PND21 neonates to 1.98 ± 0.23 fold-control 
[F(4,25)=2.86, p<0.0444] and 2.44 ± 0.32 fold-control [F(4,25=4.81, p<0.0051], 
respectively.  There were no significant changes in gene expression in GD20 dams, PND22 
dams, GD20 fetuses, or PND4 neonates, the groups which experienced decreased serum T4 
at 300 mg/kg/day. 
 There were no significant dose-dependent effects of TCS treatment on transporter 
gene expression for the isoforms chosen: Mct8, Mrp2, and Oatp1a4 (data not shown; refer to 
Figure 4.10).  Oatp1a4 basal expression was too low in GD20 fetuses to be included in our 
relative quantitative analysis, and so values for GD20 fetuses are were not calculated.  No 
effects on Mct8 expression were noted for any of the positive controls either .  All of the 
prototypical inducers appeared to increase Mrp2 expression (Figure 4.9); Mrp2 was induced 
to 1.90 ± 0.41, 2.54 ± 0.11, 3.57 ± 0.39, 2.06 ± 0.06, and 2.11 ± 0.21 fold-control by TCDD, 
Aroclor 1254, PCN, PB, and pooled TCDD and Aroclor 1254, indicating that the strongest 
induction was by the prototypical PXR agonist, PCN.  Only PCN capable of noticeable 
Oatp1a4 induction (4.82 ± 0.34 fold-control).   
TCS did not affect the gene expression of TH-responsive genes, which we defined as 
DioI, Me1, and Thsrp (also known as Spot14) at any time point included in this study (Figure 
4.8).   Though Thrsp expression appears increased for PND14 pups at 300 mg/kg/day (3.65 ± 
2.45 fold-control), there was extensive variability in the data set preventing a significant 
effect.   
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For comparison, the positive control set produced changes in gene expression for 
Me1: 11.94 ± 1.73, 14.80 ± 0.74, 5.47 ± 0.54, 6.59 ± 1.51, 12.73 ± 1.24 fold-control for 
TCDD, Aroclor 1254, PCN, PB, and a pool of TCDD and Aroclor 1254, respectively (Figure 
4.9).  Expression of Thrsp was also altered by treatment with these prototypical inducers, but 
the magnitudes of the changes were more modest; TCDD, Aroclor 1254, and pooled TCDD 
and Aroclor 1254 induced Thrsp expression to 1.90 ± 0.30, 1.66 ± 0.16, and 1.69 ± 0.22 fold-
control, whereas PCN and PB seemed to have no effect (0.68 ± 0.17 and 1.03 ± 0.17 fold-
control, respectively).  
Clearly there were few effects of TCS exposure on hepatic gene expression of the 
target genes chosen; the main effects were on dam expression of Cyp2b and Cyp3a isoforms.  
A visualization of all of the data for the target genes and animal ages is provided in Figure 
4.10.  
 Analytical measurement of total TCS in sera, defined here as the parent TCS and the 
glucuronide and sulfate conjugates,  demonstrated that GD20 dams had the most  total TCS 
in their serum, followed closely by GD20 fetuses and PND4 neonates (Figure 4.11).  Total 
TCS appeared in serum per the following relationship: GD20 dams > GD20 fetuses > PND4 
neonates > PND22 dams > PND14 neonates >> PND21 neonates.  The concentration of 
parent TCS in sera suggested that TCS is predominantly found as conjugate in the systemic 
circulation of rats, with the exception of PND4 neonates, which had markedly increased 
parent TCS in their sera.  This is further illustrated by examination of the percent parent 
(Figure 11C) in PND4 neonates, which is consistently measured as 30-40% of the total TCS 
found in their circulation.  In contrast all of the other time points included appear to have 
approximately 0-10% parent TCS in their sera. 
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 Measurement of total TCS in liver homogenate suggested a similar relationship to the 
sera data set; GD20 dams had the highest concentration of total TCS in their livers, followed 
closely by PND22 dams, GD20 fetuses, and PND4 neonates (Figure 4.11).  Total TCS 
appeared in liver per the following relationship: GD20 dams > PND22 dams > GD20 fetuses 
> PND4 neonates > PND14 neonates >> PND21 neonates, indicating that as expected, the 
animals that were directly gavaged with TCS, i.e. the dams, had the highest target tissue dose 
of total TCS.  The relative concentrations of total TCS in liver appear to have been consistent 
with the concentration of parent TCS in liver.  In contrast to the concentrations of parent TCS 
in sera, parent TCS appears to have comprised a larger fraction of the TCS present in the 
livers of these animals.  For PND21 neonates, which demonstrated the lowest target tissue 
doses, nearly all of the TCS was parent (80-100%), with the amount of conjugate present 
increasing with the amount of total TCS exposure.  For GD20 fetuses, which demonstrated 
greater concentrations of total TCS exposure, approximately half of the TCS present in their 
livers appears to have been parent, except for the vehicle control group, which appeared to 
have about 20% parent TCS.  However, the amounts of TCS present in the vehicle control 
group are close to zero.  For all of the other time points, including GD20 dams, PND22 
dams, PND4 neonates, and PND14 neonates, the amount of parent TCS in the liver was 
about 70-80%, except for the vehicle group, which again had trace amounts of TCS that were 
about 60% parent TCS. 
 Figure 4.12 illustrates the amount of total TCS in sera (A) and liver (B) at 300 
mg/kg/day, the dose that elicited T4 effects in GD20 dams and fetuses, PND4 neonates, and 
PND22 dams.  A decreasing internal exposure in offspring throughout lactation is evident, 
with an apparent relationship that is consistent for both sera and liver samples: GD20 fetuses 
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> PND4 neonates > PND14 neonates >> PND21 neonates.  For total TCS in sera and liver, it 
appears that for TCS to induce equivalent hypothyroxinemia in GD20 and PND22 dams, a 
30% reduction in T4, GD20 dams maintain a higher internal concentration of TCS.  
Similarly, GD20 fetuses and PND4 neonates also experienced an approximate 30% decrease 
in T4 in the 300 mg/kg/day treatment group, and their sera and liver concentrations appear to 
be nearly the same as the two groups of dams.   
5. Discussion 
 
This work confirms preliminary findings and provides the first report of several key 
results following developmental TCS exposure.  First, dams, fetuses, and young neonates are 
susceptible to TCS-induced hypothyroxinemia, confirming previous observations (Paul et al., 
2010a), with no effects on T3 or TSH concentrations at any time point.   Serum total T4 
concentrations were reduced in GD20 fetuses and PND4 neonates, but recovered to control 
values for PND14 and PND21 neonates, representing a unique pattern of T4 effects in 
offspring.   Second, we observed modest increases in markers of hepatic microsomal enzyme 
induction that were consistent with moderate decreases in serum T4 and our previously 
hypothesized MOA.  Finally, analysis of serum and liver TCS content revealed that PND14 
and PND21 neonates had lower internal concentrations of TCS, which suggested that 
toxicokinetics may account for the recovery of serum T4 to control values in these animals.  
As a whole the data indicate that TCS is a low-potency and low-efficacy thyroid hormone 
disruptor; developmental exposures of up to 300 mg/kg/day resulted in moderate decreases in 
T4 and a minor up-regulation of hepatic catabolism, which supports our hypothesis that TCS 
may increase catabolism and elimination of T4, potentially contributing to the observed 
systemic T4 decreases. 
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Gestational and perinatal maternal exposure to TCS resulted in mild hypothyroxinemia in 
GD20 dams and PND22 dams, as well as in GD20 fetuses and PND4 neonates.  The 
approximate 30% reductions in T4 observed for these four groups is consistent with previous 
studies in rats (Crofton et al., 2007; Paul et al., 2010a; Paul et al., 2010b).  However, this is in 
contrast to one recent report, which demonstrated 30-40% decreases in maternal T4 with 50 
mg/kg/d TCS administered via drinking water to Wistar rats from 8 days prior to mating 
through lactation (Rodriguez et al., 2010); this study also demonstrated serum T3 decreases 
of 15-20% at 50 mg/kg/d that were not observed in the present work with doses up to 300 
mg/kg/d. The current work also confirms previous findings of no reproductive toxicity, with 
no effects of treatment on gestation length, viability, eye opening, sex ratio, or pup body 
weights, with minor decreases in dam bodyweight observed during the postnatal period for 
the 300 mg/kg/d group (Paul et al., 2010a).   
The observed hypothyroxinemia in dams, fetuses, and young offspring demonstrate and 
confirm the previous findings of TCS-induced hypothyroxinemia following developmental 
and juvenile exposures (Crofton et al., 2007; Paul et al., 2010a; Paul et al., 2010b; Zorrilla et 
al., 2009).  These data also confirmed the recent report of a unique pattern of effects on 
offspring during the postnatal period: a decrease in T4 at an early age (PND4) followed by a 
return to control T4 concentrations at PND14 and PND21 (Paul et al., 2010a).  Oral exposure 
to the dams produced similar decreases of approximately 30% in the dams at GD20 and 
PND22, and GD20 fetuses and PND4.  This is consistent with our previous observations of 
30% decreases in serum total T4 following perinatal exposure (Paul et al., 2010a).  An 
additional study, though not a developmental exposure, of the effects of TCS on serum T4 in 
Long-Evans weanling females exposed for 4 days to TCS also demonstrated 30% decreases 
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with 300 mg/kg/day TCS (Crofton et al., 2007; Paul et al., 2010b).  However, different rat 
strains, gender, chemical source, and exposure duration may impact the relative potency and 
efficacy of TCS exposure and limit the ability to compare studies.  Another  non-
developmental exposure study that employed a 31-day exposure with juvenile male Wistar 
rats demonstrated 50% decreases in serum total T4 with 30-100 mg/kg/day TCS (Zorrilla et 
al., 2009), suggesting greater potency in their model.  Currently there is no evidence to 
inform a hypothesis about the differences in potency between the study in juvenile weanling 
male Wistar rats and studies in Long-Evans female rats, particularly pregnant rats, but a 
plausible theory might be that these animals demonstrate both toxicodynamic and 
toxicokinetic differences in response to TCS exposure. 
The unique pattern of  the T4 in offspring in response to maternal TCS exposure during 
the postnatal period was surprising and confirmed our previous preliminary findings (Paul et 
al., 2010a).  The lack of effect on T4 concentrations in PND14 and PND21 offspring during 
the lactation period incited further questions: (1) does TCS elicit a different toxicodynamic 
response in perinatally-exposed PND14 and PND21 neonates with no subsequent effects on 
T4 concentrations; or (2) what is the relative dose received by all of the offspring, and do 
PND14 and PND21 neonates receive as much TCS as GD20 fetuses and PND4 neonates?  
This work tested the hypothesis that PND14 and PND21 neonates were not receiving the 
same level of exposure to TCS as GD20 fetuses and PND4 neonates.  Previous studies on 
polybrominated diphenyl ethers, polychlorinated biphenyls, propylthiouracil, and 2,3,7,8-
tetrachlorodibenzodioxin (TCDD) have demonstrated that postnatal thyroid hormones are 
usually affected by perinatal (i.e., gestational and lactation) maternal xenobiotic exposure 
during the entirety of the postnatal lactation period (Crofton et al., 2000; Gilbert et al., 2006; 
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Goldey et al., 1995; Kodavanti et al., 2010; Morse et al., 1993; Royland et al., 2008; Sharlin 
et al., 2006; Zhou et al., 2001; Zhou et al., 2002).  Previous studies with rats exposed from 
27-29 days of age demonstrated effects on T4 and increases in markers of hepatic catabolism 
(Paul et al., 2010b), and microsomal enzymes, including CYPs and UGTs, are known to be 
inducible in PND14 and PND21 neonates (Zhou et al., 2002), so differences in the ontogeny 
of hepatic enzymes seemed an unlikely explanation.   Measured TCS content in the sera and 
liver of the dams demonstrate similar serum and liver concentrations of both the parent and 
total TCS at GD20 and PND22.  However, TCS concentrations in fetal and neonatal serum 
and liver depend on the age of the animal.  Parent and total TCS concentrations decreased in 
PND14 and PND21 offspring when compared to GD20 fetuses and PND4 pups (Figure 
4.12), and suggest that a lack of effect on T4 at PND14 and PND21 are due to the much 
lower exposures PND14 and PND21.  Internal serum and liver concentrations of TCS was 
measured as a surrogate for exposure in offspring, so the exact transplacental and oral 
lactation exposures are not described, and the impact of different absorption rates by 
developmental life stage is unknown.  The GD20 fetuses demonstrated the highest 
concentration of total TCS in offspring, which was close to the internal concentration for 
GD20 and PND22 dams.  The finding that nearly all of the TCS present in the GD20 fetus 
was TCS-conjugate is consistent with previous reports in sheep that demonstrated fetal 
capacity to glucuronidate and sulfate acetaminophen, but an inability to clear  the conjugates 
or hydrolyze the conjugates back to parent (Wang et al., 1986).  The total TCS dose received 
via transplacental exposure appeared to be the greatest, but the magnitude of the effect on T4 
concentrations in GD20 fetuses was still comparable to dams and PND4 neonates, indicating 
that GD20 fetuses may be less or similarly sensitive to T4 perturbation than other life stages 
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exposed in this study.  The lowest internal serum concentration of TCS that elicited a 
statistically significant effect on T4 was found in PND22 dams, which experienced a 15% 
decrease in serum T4 with approximately 5120 ng/mL total TCS measured in their sera.  
Comparing this with the highest known reported human plasma concentration of total TCS, 
303 ng/mL, reported by Allmyr et al. after conducting a 14-day exposure to TCS-containing 
toothpaste using a normal dental hygiene routin (Allmyr et al., 2009), yields a ~17-fold 
difference in exposures.  Importantly, the individual human exposure that produced a serum 
concentration of 303.4 ng/mL resulted in only a slight increase in a serum marker of 
CYP3A4 activity and no changes in serum free T4, with no statistically significant changes 
in CYP3A4 activity or THs for the study group as a whole (Allmyr et al., 2009).  Based on a 
comparison of the data presented in this work and the work of Allmyr et al., at a minimum it 
can be ascertained that humans are not 17-times more susceptible to TCS-induced 
hypothyroxinemia than rats.   
Indicators of Phase I metabolism were slightly increased in response to TCS exposures 
that produced mild hypothyroxinemia; PROD activity increases were observed in PND4 
offspring and GD20 and PND22 dams, and Cyp2b and Cyp3a isoform-specific expression 
increases were observed in dams, consistent with activation of the constitutive androstane 
receptor or pregnane X receptor.  Increased hepatic microsomal PROD activity was 
consistent with increased hepatic catabolism, though the observed effects were minor. TCS-
induced increases in PROD activity, indicative of Cyp2b activity in the rat, were fairly 
consistent with observed reductions in T4, and were concordant with previously reported 
PROD activity and/or Cyp2b1/2 protein increases following in vivo non-developmental TCS 
exposures in rats (Hanioka et al., 1997; Paul et al., 2010b; Zorrilla et al., 2009) and in vitro 
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TCS exposures in rat microsomes and hepatocytes (Hanioka et al., 1996; Jinno et al., 1997).  
PROD activity was increased 2-3-fold control for PND22 dams and PND4 neonates; GD20 
dams also demonstrated T4 deficits, but no significant effects on PROD activity were 
observed.  PROD activity was not measured in GD20 fetuses due to limited tissue and low 
CYP activity (de Zwart et al., 2008).  The lack of effect on PROD activity for GD20 dams 
may be due to their unique metabolic status during pregnancy; several CYPs including 
Cyp2b2 protein are known to be decreased in rat liver during pregnancy and return to pre-
pregnancy levels during lactation (He et al., 2005b; He et al., 2005a).  Further evidence 
suggests that Cyp2b1/2 may be less susceptible to protein induction or gene expression 
increases resulting from PB or PCN treatment during pregnancy, while other Phase I 
enzymes such as Cyp3a1 remain inducible (Ejiri et al., 2005a; Ejiri et al., 2005b).  No 
increases in PROD activity were observed for PND14 or PND21 pups.  However, these 
CYPs are functional at these ages, with assessment of the ontogeny of Cyp2b1/2 activity  
demonstrating high activity during the mid- to late-lactation period (de Zwart et al., 2008); 
further, PROD is inducible at these postnatal ages as demonstrated by perinatal exposure to 
DE-71 (Szabo et al., 2009; Zhou et al., 2002).  Based on analytical measurement of TCS in 
the sera and livers of these PND14 and PND21 offspring, we propose that the lack of effect 
on PROD activity is consistent with a reduced TCS exposure rather than a toxicodynamic 
difference between PND14 and PND21 offspring and PND4 offspring and dams.  Cyp2b2 
expression was increased approximately 2.5- to 3-fold control in GD20 and PND22 dams.   
Cyp3a1 was induced 2-fold for PND22 dams only, while Cyp3a9 expression was induced to 
approximately 2-fold for GD20 dams only.  These effects are consistent with our previous 
observations from a short-term exposure, which demonstrated that a 4-day TCS-exposure 
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resulted in up-regulated expression of both Cyp2b2 and Cyp3a1/23 (Paul et al., 2010b).  
Increased PROD activity in PND4 offspring and dams, and increased expression of Cyp2b 
and Cyp3a isoforms in dams, suggests that TCS may activate CAR and/or PXR, which also 
regulate the expression of key Phase II catabolic enzymes and hepatic transporters that 
maintain euthyroid status (Kretschmer et al., 2005).  Activation of these receptors could 
initate transcriptional up-regulation of UGTs and SULTs, thereby supporting our hypothesis 
that TCS-induced hypothyroxinemia in vivo may at least partially result from up-regulated 
hepatic catabolism of THs. 
However, the observed effects of TCS on markers of hepatic catabolism were minor. 
UGT-T4 activity was only increased in PND22 dams, and the gene expression for Ugt1a1, 
Ugt1a6, Sult1b1, and Sult1c3 were unchanged for all time points.  UGT-T4 activity increased 
nearly 50% for PND22 dams only, with no effects of TCS exposure on UGT-T4 activity for 
PND4 offspring or GD20 dams (UGT-T4 activity was not measured in GD20 fetuses).  This 
small increase in UGT-T4 activity was consistent with the moderate increases observed in 
UGT-T4 activity in rat hepatic microsomes following non-developmental 4-day (Paul et al., 
2010b) and 31-day exposures (Zorrilla et al., 2009).  Increased glucuronidation of T4 is 
thought to result in increased biliary excretion of conjugated hormone (Barter et al., 1994; 
Liu et al., 1995; Vansell et al., 2002; Vansell et al., 2001).  PND4 neonates did demonstrate 
decreased serum T4 concentrations, but no detectable changes in UGT-T4 activity, but basal 
hepatic UGT-T4 activity may not reach adult levels until mid-lactation or PND15 (de Zwart 
et al., 2008).  Previous work in our lab has demonstrated UGT-T4 activity was inducible with 
perinatal DE-71 exposure in PND4 offspring and GD20 dams (Zhou et al., 2002).  Failure to 
observe an increase in UGT-T4 activity in PND4 offspring and GD20 dams may just be the 
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result of a failure to greatly perturb UGT-T4 activity, as T4 changes were moderate.  Another 
confounding factor may be that UGT-T4 activity does not have a clear linear relationship 
with T4 concentrations (Craft et al., 2002; Hood et al., 2000; Richardson et al., 2010).  To 
demonstrate that our UGT-T4 assay was functional, we utilized two positive control 
microsome pools from rats treated with TCDD/Aroclor1254, and rats treated with PB/PCN.  
TCDD and Aroclor1254 are aryl hydrocarbon receptor (AhR) and AhR/CAR activators, 
while PB can activate CAR and PXR, and PCN is an agonist for PXR.  While regulation of 
Ugt1a1 is thought to depend on multiple receptors including CAR, PXR, and the 
glucocorticoid receptor (GR) (Sugatani et al., 2005), Ugt1a6 is transcriptionally regulated by 
AhR (Auyeung et al., 2003).  The UGT-T4 assay is non-specific and includes Ugt1a1, 1a6, 
and 1a7 activities; our control data suggest that AhR activators, namely TCDD and Aroclor 
1254, more successfully increase UGT-T4 activity in this assay, versus CAR/PXR activators, 
PB and PCN, which failed to increase UGT-T4 activity.  Based on CYP induction, and a 
report of TCS activation of the human PXR, we hypothesize that TCS is a CAR/PXR-type 
activator that may not produce significant UGT-T4 activity increases in this assay.  Failure of 
TCS to significantly increase the expression of Ugt1a1 and Sult1c3 is inconsistent with our 
previously published increases in these isoforms following non-developmental 4-day 
exposure to weanling rats (Paul et al., 2010b).  Thus it would seem probable that TCS is a 
weak activator of Phase II hepatic catabolism function, and that other MOAs may contribute 
to the moderate hypothyroxinemia observed.  Verification that the negative results for 
changes in gene expression for UGT and SULT isoforms were not due to inability to 
successfully run the low density arrays was accomplished using control mRNA from TCDD-, 
Aroclor1254-, PB-, and PCN-treated livers, derived from the same livers from which 
143 
 
microsomal pools were made, was also examined by low density qPCR array (Figure 10, B).   
Only PCN appeared to increase Ug1a1 expression, while AhR activator TCDD and mixed 
AhR/CAR activator Aroclor 1254 induced Ugt1a6 expression.  Sult1b1 was most highly 
increased by TCDD, Aroclor1254, and PCN, suggesting an AhR/PXR transcriptional 
regulation for this gene.  Sult1c3 expression was best increased by AhR activators TCDD and 
Aroclor1254.  Though no dose-response information is available due to the use of a single 
dose for each compound, these results clearly demonstrate the inducibility of gene expression 
using these low density arrays. 
Hepatic gene expression of markers of Phase III hepatic transport activity were also 
unchanged by TCS exposure for any time point, in accordance with our previous in vivo 
assessment of hepatic transporter expression following a 4-day exposure (Paul et al., 2010b).  
It was important to verify that that the low density arrays were executed correctly in the 
absence of any effect for any hepatic transporter.  Prototypical nuclear receptor activators are 
known to increase the mRNA expression and protein content of key hepatic transporters that 
function in the uptake and biliary elimination of THs, including uptake transporters Oatp1a1 
and Oatp1a4 and canalicular transporters Mdr1 and Mrp2 (Friesema et al., 1999).  The well-
known CAR activator, PB, has been shown to increase the expression and protein content of 
canalicular transporters Mdr1 and Mrp2 in rats and human hepatocytes (Jigorel et al., 2006; 
Johnson et al., 2002). Prototypical PXR agonist PCN has been shown to increase Oatp1a4 
mRNA in mouse liver (Cheng et al., 2005) and Mrp2 protein expression in rat liver (Johnson 
et al., 2002), and another PXR agonist, dexamethasone, is also known to increase hepatic 
transporter expression and function of Oatp1a4  and Mrp2 (Turncliff et al., 2004).  To 
demonstrate that increases in hepatic transporter mRNA expression were possible with 
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prototypical inducers, mRNA from TCDD-, Aroclor1254-, PB-, and PCN-treated livers, 
derived from the same livers from which microsomal pools were made, was also examined 
by low density qPCR array.  Though no dose-response relationships can be established since 
single treatment groups by chemical were employed, PCN, the PXR agonist, appeared to 
increase the expression Mrp2 by the largest margin, with moderate increases observed with 
all of the inducers.  PCN was the only control compound to induce Oatp1a4 expression.  
These results with positive control compounds suggest that activation of AhR, CAR, and in 
particular PXR, can up-regulated expression of these targets.  
Hepatic gene expression of markers of liver-specific TH-responsive genes demonstrated 
no effects of TCS treatment, suggesting that TCS did not change the T3 concentrations at the 
target tissue.  Genes defined as TH-responsive for this work are deiodinase I (DioI), malic 
enzyme I (MeI), and Spot14 (Thrsp). Hepatic expression of MeI has been shown to increase 
with TH-disrupting chemicals, including perfluorooctanesulfonate (PFOS) (Chang et al., 
2008) and polychlorinated biphenyls (PCBs) (Gauger et al., 2007) with concomitant serum 
T4 decreases.  Spot 14/Thrsp protein is thought to be regulated by CAR (Breuker et al 2010).  
Again the lack of effects with TCS exposure required verification that these assays were 
successful.  The expression of DioI and Thrsp seemed unaffected by any of the controls 
employed, but MeI expression was induced greatly by AhR activators TCDD and Aroclor 
1254, with good demonstrated increases with PB and PCN of a slightly decreased magnitude.  
Together these data indicate that TCS is capable of mildly decreasing serum T4 
concentrations in dams, fetuses, and young neonates, and that transplacental exposure 
provides more TCS to the progeny than lactation exposure.  Further, minor increases in 
markers of Phase I and Phase II catabolism suggest that TCS may activate hepatic nuclear 
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receptors, e.g. CAR and/or PXR, to transcriptionally up-regulate metabolism of THs to result 
in hypothyroxinemia. 
6. Conclusion 
 
This study confirmed previous observations of moderate hypothyroxinemia in dams and 
young neonates induced by TCS exposure.  This study provided the first report 
demonstrating the importance of transplacental exposure and effects on GD20 T4 in dams 
and offspring, and established that exposure conveyed from dams to offspring diminishes 
over the lactation period, such that PND14 and PND21 neonatal T4 concentrations return to 
control levels, likely due to a lack of TCS exposure.  Further, this study provides some 
evidence that TCS up-regulated hepatic catabolism in GD20 and PND22 dams and PND4 
offspring, though the effects were minor.  The minor effects on CYP and UGT activity and 
expression are consistent with previous findings in a short-term exposure model that suggest 
that TCS activates CAR and/or PXR resulting in downstream up-regulation of hepatic 
catabolism of thyroid hormones.  The relatively minor effects on Phase I and Phase II 
metabolism are in keeping with the mild hypothyroxinemia induced as a result of treatment.  
Further research should characterize the human relevance of this work; in particular, the 
proposed MOA should be evaluated in a human model because maternal hypothyroxinemia, 
however minor, indicates a potential hazard for human neurodevelopment.  Specifically, the 
putative initiating key event, interaction with CAR and/or PXR, is a highly species-
dependent event and should be evaluated with human receptors. 
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Figure 4.1.  Dosing and tissue collection schedule, from GD6 through PND22.  Dams 
received TCS by oral gavage daily; no TCS was administered directly to offspring.  Serum 
and liver were collected prenatally on GD20 from dams and fetuses and postnatally on 
PND4, PND14, and PND21 from pups and on PND22 from dams. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 4.2.  Percent of control T4.  A) GD20 and PND22 Dams, with vehicle control = 23.1 ± 1.3 and 51.8 ± 2.1, respectively. 
B) GD20 Fetuses and Pups aged PND4, PND14, and PND21, with vehicle control = 4.15 ± 0.22, 9.70 ± 0.43, 42.8 ± 1.9, 38.2 
± 1.3 ng/mL, respectively.  V=vehicle control; † = significantly different from control and all other treatment groups; * = 
significantly different from vehicle control. 
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Figure 4.3.  Percent of control serum TSH for dams and offspring.  A) GD20 and PND22 Dams, with vehicle control = 
3.51 ± 0.46 and 3.28 ± 0.68 ng/mL, respectively. B) Pups aged PND4, PND14, and PND21, with vehicle control = 2.10 ± 0.22, 
2.19 ± 0.27, 1.73 ± 0.20 ng/mL, respectively.  V=vehicle control.
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Figure 4.4. Percent of control EROD and PROD activity for dams and offspring compared to controls. A) PROD activity for 
control microsome pools.  The controls are presented as the percent of vehicle control for each age tested.    TCDD+ A1254 is 
a microsome pool from rats exposed to a single gavage dose of TCDD (10 µg/kg) or Aroclor 1254 (300 mg/kg); PB+PCN is a 
microsome pool from rats that received a 4-day intraperitoneal exposure to phenobarbital (81 mg/kg/d) or PCN (50 mg/kg). B) 
PROD activity for dams at GD20 and PND22.  C) PROD activity for pups aged PND4, PND14, and PND21.  D) EROD 
activity for controls.  E) EROD activity for dams at GD20 and PND22.  F) EROD activity for pups aged PND4, PND14, and 
PND21.V=vehicle control; * = significantly different from vehicle control.  
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Figure 4.5.  Hepatic microsomal UGT-T4 activity. A) Positive controls.  TCDD+ A1254 is a 
microsome pool from rats exposed to a single gavage dose of TCDD (10 µg/kg) or Aroclor 
1254 (300 mg/kg); PB+PCN is a microsome pool from rats that received a 4-day 
intraperitoneal exposure to phenobarbital (81 mg/kg/d) or PCN (50 mg/kg). B) PND4 
neonates, GD20 dams, and PND22 dams.  V=vehicle control; * = significantly different from 
vehicle control. 
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Figure 4.6. Hepatic CYP gene expression changes.  A,C,E,and G) Dams: GD20 and PND22 
dams for Cyp1a1, Cyp2b2, Cyp3a1/23, Cyp3a2, Cyp3a9, and Cyp4a2.  B, D, F, and I) 
Offspring: GD20 fetuses, PND4 , PND14, and PND21 pups for Cyp1a1, Cyp2b2, 
Cyp3a1/23, Cyp3a2, Cyp3a9, and Cyp4a2. V=vehicle control.* = significantly different from 
vehicle control. 
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Figure 4.7.  Hepatic Phase II gene expression.  A,C,E,and G) Dams: GD20 and PND22 dams 
for Ugt1a1, Ugt1a6, Sult1b1, Sult1c3.  B, D, F, and I) Offspring: GD20 fetuses, PND4 , 
PND14, and PND21 pups for Ugt1a1, Ugt1a6, Sult1b1, Sult1c3. V=vehicle control. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Hepatic TH-responsive gene expression.  A and C) Dams: GD20 and PND22 
dams for MeI and Thrsp.  B and D) Offspring: GD20 fetuses, PND4 , PND14, and PND21 
pups for MeI and Thrsp.  V=vehicle control. 
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Figure 4.9. Positive controls (Phase I, Phase II, Phase III, and TH-sensitive).  A) Phase I 
metabolic genes: Cyp1a1, Cyp2b2, Cyp3a1/23, Cyp3a2, Cyp3a9, and Cyp4a2.  B) Phase II 
metabolic genes; Ugt1a1, Ugt1a6, Sult1b1, and Sult1c3.  C) Hepatic transport genes: 
Oatp1a4, Mrp2, Mct8.  D) TH-responsive genes: DioI, MeI, and Thrsp.  V = vehicle control; 
TCDD = hepatic mRNA from rats exposed to a single gavage dose of TCDD (10 µg/kg); 
A1254 = hepatic mRNA from rats exposed to single 300 mg/kg dose of Aroclor 1254; PB = 
hepatic mRNA from rats that received a 4-day intraperitoneal exposure to PB (81 mg/kg/d); 
PCN = hepatic mRNA from rats that received a 4-day intraperitoneal exposure to PCN (50 
mg/kg). 
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Figure 4.10. Heatmap of hepatic gene expression by time point and TCS exposure group 
(mg/kg/day). For all time points, the vehicle control value was standardized as 1, and all of 
the other exposure groups are expressed as a ratio of the vehicle control.  Heatmap was 
generated without scaling by column or row, as data were already standardized to the vehicle 
control (generated with R 2.12.0).
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Figure 4.11. Mean total, parent, and percent parent TCS content in sera and liver (ng/mL, ± SE).  A)  Total TCS in sera, 
comprised of parent and glucuronide and sulfate conjugates (ng/mL); B) Parent TCS only in sera (ng/mL); C) Percent parent 
out of the total TCS in sera; D) Total TCS in liver, comprised of parent and glucuronide and sulfate conjugates (ng/g); E) 
Parent TCS only in liver (ng/g); F) Percent parent out of the total TCS in liver. 
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Figure 4.12. TCS content in sera and liver versus serum T4 concentrations at 300 mg/kg/day. 
A)  Total TCS in sera, comprised of parent and glucuronide and sulfate conjugates (ng/mL); 
B) Parent TCS only in sera (ng/mL); C) Percent parent out of the total TCS in sera; D) Total 
TCS in liver, comprised of parent and glucuronide and sulfate conjugates (ng/g); E) Parent 
TCS only in liver (ng/g); F) Percent parent out of the total TCS in liver. 
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Experimental 
Block 
Time 
Points 
T4 T3 TSH EROD/PROD   
UGT-T4 
qPCR Analytical 
measurement 
1 Offspring: 
PND4, 14, 
21; Dams: 
PND22 
n = 21, 12, 
22, 22, 18 
for 0, 10, 
30, 100, 
300 
mg/kg/d 
Not 
measured 
n = 10, 10, 
10, 8 for 0, 
30, 100, 
300 
mg/kg/d  
n = 21, 12, 22, 
22, 18 for 0, 
10, 30, 100, 
300 mg/kg/d 
Not 
measured 
Not measured 
2 n = 11, 12, 
12, 12, 10 
for 0, 10, 
30, 100, 
300 
mg/kg/d 
Not 
measured 
n = 6/ 
treatment 
group 
n = 6/ 
treatment 
group 
3 Fetuses 
and Dams: 
GD20 
n = 11, 11, 11, 11, 10 for 0, 10, 30, 100, 300 mg/kg/d n = 6/ 
treatment 
group 
n = 6/ 
treatment 
group 
 
Table 4.1. Experimental blocks and n for each parameter measured.  Experimental Blocks 1 
and 2 included postnatal time points and experimental Block 3 included a single prenatal 
time point. 
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Table 4.2. Taqman Gene Expression Assays included in the Taqman Custom Low Density 
Array.  Rps18 was used as the endogenous control to standardize the gene expression assay 
results for GD20 and PND22 dams, GD20 fetuses, and PND21 offspring.  PND4 and PND14 
offspring were standardized to Actb. 
 
Summary of Taqman Gene Expression Assays included in the Taqman Custom Low Density Array 
Function 
category 
Gene Gene abbreviation Taqman Gene Expression 
Assay ID 
Nuclear receptors aryl-hydrocarbon receptor AhR Rn00565750_m1 
peroxisome proliferator activated 
receptor alpha 
Pparα Rn00566193_m1 
Phase I 
metabolism 
cytochrome P450, family 1, 
subfamily a, polypeptide 1 
Cyp1a1  Rn00487218_m1 
cytochrome P450, family 2, 
subfamily b, polypeptide 2 
 
Cyp2b2 Rn02786833_m1 
cytochrome P450, family 3, 
subfamily a, polypeptide 
23/polypeptide 1 
Cyp3a1/3a23 Rn01640761_gH 
cytochrome P450, family 3, 
subfamily a, polypeptide 2 
 
Cyp3a2 Rn01412889_mH 
cytochrome P450, family 3, 
subfamily a, polypeptide 9 
 
Cyp3a9 Rn00595977_m1 
cytochrome P450, family 4, 
subfamily a, polypeptide 2 
Cyp4a2 Rn01417066_m1 
Phase II 
metabolism 
UDP glucuronosyltransferase 1 
family, polypeptide A1 
Ugt1a1 Rn00754947_m1 
UDP glucuronosyltransferase 1 
family, polypeptide A6 
Ugt1a6 Rn00756113_mH 
UDP glycosyltransferase 2 
family, polypeptide B 
Ugt2b Rn02349652_m1 
sulfotransferase family, cytosolic, 
1B, member 1 
Sult1b1 Rn00673872_m1 
sulfotransferase family, cytosolic, 
1C, member 3 
Sult1c3 Rn00581955_m1 
Hepatic transport ATP-binding cassette, sub-family 
C (CFTR/MRP), member 2 
Abcc2/Mrp2 Rn00563231_m1 
solute carrier organic anion 
transporter family, member 1a4 
Slco1a4/Oatp1a4 Rn00756233_m1 
solute carrier family 16 
(monocarboxylic acid 
transporters), member 2 
 
Slc16a2/Mct8 Mm00486202_m1 
Thyroid 
hormone-
responsive 
deiodinase, iodothyronine, type I Dio1 Rn00572183_m1 
malic enzyme 1 NADP(+)-
dependent, cytosolic 
Me1 Rn00561502_m1 
thyroid hormone responsive Thrsp Rn01511034_m1 
Candidate 
endogenous 
controls 
ribosomal protein L13A Rpl13a Rn00821946_g1 
ribosomal protein S18 Rps18 Rn01428915_g1 
glyceraldehyde-3-phosphate 
dehydrogenase 
Gapdh Rn99999916_s1 
actin, beta Actb Rn00667869_m1 
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No-observed-effect level and benchmark dose levels for T4 
decreases by age 
Age NOEL BMD BMDL 
GD20 Dams 100 124 25.2 
PND22 Dams 30 115 62.1 
GD20 Fetuses 100 95.4 33.0 
PND4 Pups 100 150 61.8 
 
 
Table 4.3. No-observed-effect level (NOEL) and benchmark dose levels for T4 decreases.  
NOELs are reported as the mg/kg/day exposure group.  BMD = benchmark dose US EPA 
Benchmark Dose Software (BMDS Version 2.0Beta) was used to determine the BMD and 
BMDL, with a 95% confidence limit, for the selected BMR = 20% reduction in serum T4. 
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1.  Abstract 
Triclosan (2,4,4’-trichloro-2’-hydroxyphenylether) (TCS) is a chlorinated biphenyl  
antibacterial found in numerous personal care products, and through use and disposal, in 
human sera, milk, and urine, and in surface waters.  Triclosan (TCS) decreases serum 
thyroxine (T4) in the rat.  Previous research has focused on the in vivo mode-of-action 
(MOA) of TCS-induced hypothyroxinemia observed in rats; results suggested that TCS up-
regulates hepatic catabolism of thyroid hormones, resulting in increased clearance of thyroid 
hormones.  Key biomarkers of Cyp2b2, Cyp3a1, Ugt1a1, Sult1c1, and glucuronidation of T4 
were up-regulated.  The expression of these Phase I and Phase II enzymes is regulated by 
nuclear receptors including the constitutive androstane receptor (CAR) and pregnane-X 
receptor (PXR), but evolutionary divergence of these receptors has made activation of these 
receptors a species-dependent event, indicating the possibility that downstream up-regulation 
of hepatic catabolism may also be a species-dependent event.  To test the hypothesis that 
TCS may activate xenobiotic nuclear receptors in both rats and humans, and that the 
increased biomarkers of hepatic catabolism and decreased thyroid hormones observed in rats 
may be possible in humans, cell-based nuclear receptor reporter assays were employed to 
indirectly measure the ability of TCS to activate human (hPXR) and rat PXR (rPXR), all 
three biologically-active splice variants of human CAR (hCAR), and rat CAR (rCAR).  
Additional data was also collected on mouse CAR (mCAR) and PXR (mPXR) for 
comparison.  TCS moderately activated human PXR in both full-length  and chimeric 
receptor-reporter assays  by approximately 2- to 3-fold vehicle control at about 10 µM ; 
strongly activated hCAR2 (19.8 ± 4.9-fold vehicle control 30 µM TCS); and, was a moderate 
agonist of hCAR3 (2.63 ± 0.75-fold vehicle control 30 µM TCS).  In addition,  TCS acted as 
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an inverse agonist of hCAR1(EC50 = 19.8 µM).  TCS failed to activate rPXR in both 
receptor-reporter models, and instead acted as a modest inverse agonist of rCAR (EC50 = 
3.50 µM TCS ).  TCS failed to activate mouse PXR and was an inverse agonist of mouse 
CAR, which reflected the data for the rat receptors.   These data suggest that TCS may be 
capable of interacting with rat CAR, activating human CAR and PXR in order to potentially 
up-regulate hepatic catabolism in both species.  Although TCs activated different nuclear 
receptors between species, activation of nuclear receptors in both species is likely to result in 
up-regulation of hepatic catabolism.  This is consistent with in vivo observations in the rat.  
Overall these data support the conclusion that TCS may have similar adverse effects in all 
three species assuming doses are high enough to activate hepatic xenobiotic receptors.    
2. Introduction 
Triclosan (2,4,4’-trichloro-2’-hydroxyphenylether) decreases thyroxine (T4) in 
juvenile rats (Crofton et al., 2007; Paul et al., 2010b; Zorrilla et al., 2009) as well as 
maternal, fetal, and early neonatal thyroxine following developmental exposures (Paul et al., 
2010a).  Decreased maternal T4 during gestation leads to irreversible decreases in 
neurodevelopment and motor function in humans (Haddow et al., 1999; Pop et al., 2003; Pop 
et al., 1999; Vermiglio et al., 2004), and neurological deficits and alterations in the cellular 
organization of the brain in rats (Auso et al., 2004; Gilbert et al., 2000; Gilbert et al., 2006; 
Goldey et al., 1998; Goldey et al., 1995; Lavado-Autric et al., 2003; Opazo et al., 2008).  
Although the general mechanisms for thyroid hormone maintenance and biology are 
conserved across species (Yen, 2001; Zoeller et al., 2007), interspecies-differences can 
present a major uncertainty when using solely in vivo animal data for human health risk 
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assessment. Determination of a proposed MOA in rats enables parallel hypotheses to be 
investigated for plausibility in humans using in vitro models (Boobis et al., 2008). 
Thyroid-disrupting chemicals may act via one or more of several proposed MOAs, 
including by inhibition of iodine uptake or enzymatic synthesis of thyroid hormones in the 
thyroid gland; by inhibition of peripheral deiodination of T4 to triiodothyronine (T3); by 
displacement of thyroid hormones from serum binding proteins in the systemic circulation; 
and by up-regulation of hepatic catabolism and transport of thyroid hormones, resulting in 
increased, disproportionate excretion of thyroid hormones (Boas et al., 2006; Capen, 1994; 
Crofton, 2008; Miller et al., 2009).  The hypothyroxinemia induced by TCS exposure in rats 
as been hypothesized to be the result of up-regulation of hepatic catabolism of thyroid 
hormones.  In vitro treatment of rat hepatocytes resulted in increased Cyp2b and Cyp3a1 
protein and enzymatic activity increases in markers of cytochrome P450 activity including 
pentoxyresorufin-O-depentylase (PROD), benzyloxyresorufin-O-debentylase (BROD), and 
ethoxyresorufin-O-deethylase (EROD) (Jinno et al., 1997).  In vivo triclosan treatment of rats 
also induced hepatic Cyp2b, Cyp3a, and Cyp4a protein and PROD and BROD activity 
(Hanioka et al., 1997).  Evidence of Phase I induction in vitro and in vivo, in addition to in 
vitro pregnane X receptor (PXR) activation by TCS (Jacobs et al., 2005), suggest that TCS 
activates nuclear receptors, in particular the constitutive androstane receptor (CAR) and/or 
PXR, as indicated by inductive effects on the cytochrome P450s primarily regulated by these 
receptors, Cyp2b and Cyp3a respectively (Goodwin et al., 2001; Maglich et al., 2002; Moore 
et al., 2002).  Our previous work with TCS in a four-day exposure to young adult rats 
demonstrated that TCS up-regulated cytochrome P450 mRNA expression and activity and 
Phase II hepatic catabolism; specifically, hepatic mRNA expression levels of Cyp2b2, 
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Cyp3a1/23, Ugt1a1, and Sult1c1, as well as hepatic microsomal uridine diphosphate 
glucuronyltransferase (UGT) activity and pentoxyresorufin-O-deethylase (PROD) activity, 
were induced by triclosan treatment (Paul et al., 2010b).  These effects are consistent with 
other microsomal enzyme inducers that are thought to decrease thyroid hormones at least 
partially via up-regulation of hepatic catabolism (Barter et al., 1994; Chen et al., 2003; Hood 
et al., 2003; Vansell et al., 2002; Vansell et al., 2001).  In aggregate the data suggest that 
TCS may activate CAR and/or PXR in the rat, and PXR in humans. 
CAR and PXR function at the nexus of exogenous and endogenous biology, 
regulating expression of cytochrome P450s, UDP-glucuronyltransferases (UGTs), 
sulfotransferases (SULTs), and drug transporters to mount metabolic responses to 
xenobiotics (Goodwin et al., 2001; Guo et al., 2003; Lehmann et al., 1998; Maglich et al., 
2002; Moore et al., 2002; Wei et al., 2002; Zhou et al., 2005), but also to regulate hepatic 
energy metabolism (Konno et al., 2008; Maglich et al., 2009; Maglich et al., 2003; Maglich 
et al., 2004), detoxify and excrete bilirubin, and prevent cholestatic injury by increasing 
elimination of bile acids (Guo et al., 2003; Staudinger et al., 2001; Zhang et al., 2004).  Upon 
activation by xenobiotics, CAR and PXR heterodimerize with the retinoid-X receptor 
(RXRα), recruit co-activators and/or release co-repressors, and bind to promoter response 
elements to transcriptionally regulate an overlapping set of genes necessary for maintenance 
of euthyroid status (Kretschmer et al., 2005), as well as elimination of xenobiotics and 
endogenous energy and lipid metabolism. Generally PXR and CAR are the primary 
regulators of Cyp3a and Cyp2b domains (Wang et al., 2003c), respectively, though the 
precise isoform is species-dependent and there is considerable cross-talk between receptors 
due to competition for an overlapping set of promoter response elements (Faucette et al., 
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2006; Goodwin et al., 2001; Istrate et al., 2010; Smirlis et al., 2001; Wei et al., 2002).  
Activation of human PXR (hPXR) results in transcriptional induction of CYP3A4 (Jones et 
al., 2000), as well as other Phase I and II hepatic biotransformation enzymes, i.e. 
glucuronyltransferases and sulfotransferases that catabolize thyroid hormones as part of 
thyroid hormone homeostasis (Capen, 1994; DeVito et al., 1999; Schuur et al., 1997; Wang 
et al., 2006), and Phase III transporters, including organic anion transporting peptides and 
multidrug resistance proteins (Burk et al., 2005; Geick et al., 2001; Kretschmer et al., 2005), 
which are known to mediate hepatic uptake and secretion of thyroid hormones (Jansen et al., 
2005).  Similarly, activation of human CAR results in transcriptional up-regulation of 
CYP2B6 (Maglich et al., 2002; Sueyoshi et al., 1999; Wang et al., 2004; Wang et al., 
2003a), as well as UGT1A1, SULT2A1, and hepatic transporters including multi-drug 
resistance associated proteins MRP2 and MRP3 and the multi-drug resistance protein MDR1 
(Urquhart et al., 2007).  Murine knockout models have demonstrated that CAR and PXR are 
necessary for the downstream effects of compounds including phenobarbital (Qatani et al 
2005) and PCN (Chen et al., 2003; Cheng et al., 2006), respectively, on glucuronidation and 
thyroid hormone elimination.  Increased expression and activity of the Ugt1a family of 
glucuronyltransferases that conjugate thyroid hormones (Barter et al., 1994; Liu et al., 1995) 
is well established for microsomal enzyme inducers that activate CAR and PXR (Buckley et 
al., 2009).  Activation of CAR and/or PXR is the putative initiating key event that may result 
in up-regulation of metabolic enzymes that catabolize and transport T4, potentially 
decreasing serum concentrations of T4 via metabolic turnover. 
 Activation of CAR and PXR by xenobiotics is exceedingly species-dependent.  Two 
contributing factors, among myriad potential biological differences in the activation of these 
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receptors, to this species-dependent activation are: (1) the divergence of the ligand-binding 
domains of the receptors across species; and, (2) differential expression of splice variants of 
these receptors by species.  PXR ligand-binding domains (LBDs) have diverged considerably 
through evolution, such that the LBD of rat and mouse PXR 75-77% homologous to the LBD 
of human CAR (Jones et al., 2000; Moore et al., 2002).  The DNA-binding domains (DBDs) 
remain highly conserved with over 95% homology between murine and human PXRs (Iyer et 
al., 2006; Jones et al., 2000; Timsit et al., 2007).  The variation in the LBD across species 
poses a major uncertainty for extrapolating from murine models to humans.  A significant 
difference between murine CAR and human CAR is the variation in the transcriptome: rat 
CAR and mouse CAR have only one known functional splice variant each, and hCAR has 
three active splice variants. These three splice variants of human CAR include hCAR1 or 
wildtype, hCAR2, and hCAR3 (Auerbach et al., 2003; Jinno et al., 2004; Savkur et al., 2003) 
comprising the transcriptome for hCAR.  The hCAR1 variant compromises the majority of 
hCAR expression in the liver.  Recent reports suggest that hCAR2 may comprise up to 30% 
of the transcriptome, and further that hCAR2 and hCAR3 together may comprise up to 50% 
of the transcriptome and possess the majority of the ligand-binding activity demonstrated by 
the transcriptome (DeKeyser et al., 2009; Ross et al., 2010; Savkur et al., 2003).  All three 
hCAR SVs bind response elements from promoters of CYP2B6 and CYP3A4 (Auerbach et 
al., 2007; Auerbach et al., 2005).  The reference form hCAR1 constitutively activates the 
PBREM and XREM response elements in the CYP2B6 and CYP3A4 promoter regions, 
unlike hCAR2 and hCAR3, which appear to be highly ligand-dependent for nuclear 
translocation (DeKeyser et al., 2009). In contrast, hCAR2 is ligand-dependent and hCAR3 is 
somewhat ligand-dependent for activation due to amino acid insertions in the ligand-binding 
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domain (Auerbach et al., 2007; Auerbach et al., 2003). Thus, there is certainly the potential 
for different hCAR splice variants to bind agonists with varying affinity, or different 
agonists/activators altogether.  The result of the interplay of these three SVs in response to an 
agonist or activator remains unclear from nuclear receptor-reporter assays, and requires 
analysis of the downstream metabolic responses of primary hepatocytes or whole animals 
that contain the entire hCAR transcriptome.  Due to the clearly different roles for the three 
human CAR SVs, it is difficult to compare rat and mouse CAR to human CAR.  Together the 
differences between murine CAR and PXR and human CAR and PXR necessitate assessment 
of receptors across species to determine if a chemical such as TCS can activate receptors in 
both murine and human models. 
There are numerous examples of species-dependent activation of CAR and PXR by 
xenobiotics that are also known to perturb thyroid hormones.  The compounds 6-(4-
chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime 
(CITCO), carbamazepine, efavirenz, and nevirapine are known to preferentially activate 
human CAR and not mouse nor rat CAR (Chang et al., 2006; Faucette et al., 2007; Moore et 
al., 2000).  Conversely,1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) is a known 
murine CAR activator (Buckley et al., 2009; Maglich et al., 2009; Tzameli et al., 2000).  
Rifampicin, perhaps the most recognized for its species-selectivity, and hyperforin of St. 
John’s Wort, selectively activate human PXR (Jones et al., 2000; LeCluyse, 2001; Lehmann 
et al., 1998; Sinz et al., 2007; Watkins et al., 2003), and pregnenolone-16α-carbonitrile 
(PCN) is generally recognized as a selective murine agonist of PXR (Cheng et al., 2006; 
Cheng et al., 2005; Guo et al., 2002a; Guo et al., 2002b; Sinz et al., 2007).  However, there 
are also chemicals that can activate both human and murine receptors, including TO-901317 
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for PXR (Mitro et al., 2007) and DEHP (DeKeyser et al., 2009; Ren et al., 2010) 
aphenobarbital for CAR (Mutoh et al., 2009; Qatanani et al., 2005a; Sueyoshi et al., 2001; 
Yueh et al., 2005).  It is important to underscore that inducers of hCAR transcriptional 
activity may be divided into two categories: direct agonists and indirect activators of CAR.  
Treatment with phenobarbital, an indirect activator of CAR, results in protein kinase C-
mediated dephosphorylation of threonine 38 of hCAR, with subsequent translocation and 
transcriptional activity (Mutoh et al., 2009), and the ligand-independent reference form 
hCAR1 has been reported to be responsive to phenobarbital (Jinno et al., 2004).  
Phenobarbital presents a prime example of the difficulty in comparing human and rodent 
receptors: if mouse and rat only have one CAR splice variant each, how does this splice 
variant potentially function through the ligand-dependent and ligand-independent 
mechanisms suggested by the activity of human CAR splice variants?  There is a 
demonstrable need to examine a chemical like TCS across species to determine if the 
receptor-regulated downstream biology observed in the rat is plausible for humans. 
The present work tested the hypothesis that the in vivo effects of TCS in rats on 
hepatic catabolism and thyroid hormones were mediated by interaction with rat PXR and/or 
rat CAR, and, further, that TCS could also activate human PXR and/or CAR in order to 
mediate a similar cascade of hepatic catabolic events in humans.  Two distinct types of 
receptor-reporter assays were employed to test this hypothesis.  First, cell-based full-length 
receptor reporter assays (Puracyp, Inc.) were used to determine if TCS is an agonist for 
hPXR and rPXR and to measure induction of CYP3A activity in vitro.  Second, chimeric 
receptor constructs, with the native DNA-binding domain replaced by the yeast transcription 
factor Gal4 (INDIGO BioSciences), were used to determine if TCS could interact with the 
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three splice variants of human CAR (hCAR1, hCAR2, hCAR3) and rCAR, and to confirm 
our original findings with  the full-length hPXR and rPXR cell lines.  Additionally, these 
chimeric receptor reporter assays were used to analyze the potential interaction for TCS with 
mCAR and mPXR.  Collectively these data address a major uncertainty regarding the 
potential interspecies response to TCS at the molecular level of interaction with species-
divergent nuclear receptors, and the capacity for TCS to initiate a proposed MOA for TCS-
induced hypothyroxinemia in humans. 
3. Methods 
a. Chemicals and treatment.  Rifampicin (≥97%) and dexamethasone (≥97%) were 
obtained from Sigma (St. Louis, MO) and triclosan (≥99%) was a gift from BASF/Ciba 
Specialty Chemicals.  Dimethyl sulfoxide (DMSO) (Sigma, ≥99.7%) was the vehicle solvent 
for all chemicals used.  Chemicals were administered to 96-well plates of cells using a 
BioMek 2000 (Beckman Coulter; Brea, CA), which robotically transferred 327 nanoliters of 
chemical solution to each treated well.   
b.  Full-length receptor reporter assays (Puracyp, Inc.).  A HepG2 cell line (DPX2)  
with a stable transfection of the full length human PXR and PXR response elements within 
the CYP3A4 promoter was obtained from Puracyp, Inc. (Carlsbad, CA).   A FAO cell line 
(RPXR) containing the full length rat PXR and PXR response elements within the CYP3A4 
promoter was also obtained from Puracyp, Inc. (Carlsbad, CA). Construction and subsequent 
validation of these stably-transfected cell lines has been reported previously (Raucy et al 
2002, 2003, Yueh et al 2007). The cells were maintained per the company’s directions for a 
maximum of 30 days in culture (10-12 passages) to ensure optimal activity in luciferase 
induction assays.  For experimental analysis of luciferase induction, cells were harvested 
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from 10 cm dishes at 50-70% confluency, and re-seeded in 96-well plates (2 x 104 cells/well 
and 1 x 104 cells/well in 165 µL of media for the DPX2 and RPXR cells, respectively), and 
allowed to recover overnight.  Each chemical concentration was tested in technical triplicates 
on three separate occasions for n=3; each of the three separate experiments was performed 
using cells from the same lot, but a consecutive cell passage.  Identical plates of treated cells 
were performed in parallel for separate assessment of luciferase induction and cytotoxicity.  
TCS exposure concentrations ranged from 0.387 to 99.1 µM; rifampicin exposure 
concentrations ranged from 0.0968 to 24.8 µM; and, dexamethasone exposure concentrations 
ranged from 0.387 to 99.1 µM.  Using the molecular weight of TCS (289.54 g/mol), the in 
vitro TCS concentration range can be expressed as 0.112 to 28.7 mg/L.  The in vivo doses 
used in Chapters 2, 3, and 4 of this dissertation work, 10 to 1000 mg/kg/day, can similarly be 
converted to 34 to 3400 µmol/kg/day. Following chemical treatment, cells were exposed for 
24 hr prior to measurement of luciferase induction (for PXR or CYP3A activity) and 
cytotoxicity.  For the time-course experiments, cells were incubated for 6, 12, 24 or 48 hr 
before analysis of luciferase induction and cytotoxicity.  Luciferase induction was measured 
using BrightGlo luciferase detection reagent (Promega; Madison, WI) and cytotoxicity was 
measured using CellTiterGlo (Promega; Madison, WI).  Signal detection of luciferase for 
both the induction and cytotoxicity assays was performed with a FLUOstar Optima BMG 
plate reader (BMG LabTech, Offenburg, Germany).  
c.  CYP3A activity assays in Puracyp receptor-reporter cell lines.  CYP3A 
activity was measured in RPXR and DPX2 cells following a 24 hr incubation with the test 
chemicals.  The P450-GloTM CYP3A4 assay with luciferin-IPA (Promega; Madison, WI) was 
conducted per the manufacturer’s directions.  Briefly, media from well of a 96-well plate was 
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aspirated and replaced with 30 uL of diluted (1:1000) luciferin-IPA reagent.  The plate was 
then incubated at 37°C for 30 min before addition of 30 uL of the reconstituted luciferase 
detection reagent.  The plate was allowed to equilibrate to room termperature for 20 min 
before signal detection of luciferase activity with a FLUOstar Optima BMG plate reader 
(BMG LabTech, Offenburg, Germany).  
d.  Chimeric receptor-reporter assays (INDIGO Biosciences).  HEK293T 
fibroblasts were   
transiently transfected with a chimeric receptor construct where the DNA-binding domain for 
the receptors has been replaced with a GAL4 element under regulatory control of the SV40 
promoter.  Cells were co-transfected with a reporter plasmid containing the fusion of the 
UAS GAL4 DNA response element to the firefly luciferase gene along with a transfection 
efficiency control vector containing a renilla luciferase reporter element (pRL-luciferase; 
Promega; Madison, WI) used to determine viable, transfected cell fraction.  Use and 
validation of these cell lines has been previously reported (Tien et al., 2006; Vanden Heuvel 
et al., 2006).  The luciferase-based reporter assays were conducted using the Luciferase dual 
reporter assay kit (Promega; Madison, WI) and a Tecan GeniosPro luminescent plate reader 
(Research Triangle Park, NC).   
e.  Data analysis.  
i.  Puracyp cell lines.  All results obtained for PXR activation and CYP3A4 
induction were in relative luminescence units (RLU).  To correct for differences in cell 
viability following chemical exposure, the RLU was divided by the corresponding RLU for 
cell viability, as measured in a parallel plate.  This ratio was then converted to a percent of 
DMSO vehicle control for the time-course data and CYP3A4 activation data, and to a percent 
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of maximal positive control response for PXR activation at 24 hr. These computations were 
performed with SAS 9.2 (SAS Institute; Cary, NC).  Four parameter logistic models were 
used to determine EC50s for positive control data using 6 to 10 concentrations of each 
chemical (SigmaPlot 11.0, GmbH, Germany).   
ii.  INDIGO cell lines.  All results obtained for receptor activation were also in RLU, 
which were corrected by Renilla luciferase units that represented cell viability.  The 
RLU/renilla luciferase ratio was converted to a percent of DMSO vehicle control (SAS 9.2, 
SAS Institute; Cary, NC).  Due to the limited number of data points for many of the 
chemicals tested, data were analyzed by ANOVAs to determine effects significantly different 
from the DMSO vehicle control, with significant main effects of treatment followed by 
Duncan’s new multiple range test.  For those chemicals where a full dose-response curve 
could be achieved, with a minimum and maximum, a four parameter logistic model was used 
to determine EC50s (SigmaPlot 11.0, GmbH, Germany).   
4. Results 
a.  Full-length hPXR and rPXR reporter assays 
Rifampicin (RIF) activated the full-length hPXR with maximal efficacy at 24.8 µM at all 
time points tested; activation was best detected at 24 and 48 hr of chemical exposure, and 
produced 1671 ± 91.4 and 3722 ± 597 percent of vehicle control RLU, respectively (Figure 
5.1A).  The EC50s for RIF at 24 and 48 hr were 1.07 ± 0.060 and 1.20 ± 0.086 µM, 
respectively (Figure 5.1A).  TCS activated the full-length hPXR with maximal efficacy at 
24.8 µM with the best detection at 24 and 48 hr, which produced 1165 ± 158 and 2199 ± 352 
percent of vehicle control RLU, respectively (Figure 5.1B).  The dose-response curve for 
TCS activation of hPXR is truncated at 24.8 µM due to overwhelming cytotoxicity in DPX-2 
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cells at 49.5 µM and above.  Therefore, an EC50 using a Hill model cannot be computed 
because a maximal efficacy cannot be achieved without considerable cytotoxicity, and 
subsequent analysis of TCS-induced activation of the full-length hPXR is reported as a 
percent of maximal RIF response.  Following a 24 hr treatment period, TCS activated the 
full-length hPXR by 12.3% ± 1.2, 25.3% ± 1.3, and 64.4% ± 7.8 of the maximal RIF 
response at 6.2, 12.4, and 24.8 µM TCS, where the maximal efficacy of RIF was 100% ± 
2.48 at 12.4 µM in DPX-2 cells (Figure 5.3A).    Since a maximum efficacy could not be 
obtained with TCS exposure due to cytotoxicity, a rough comparison of the estimated TCS 
concentration (20 µM)  that corresponds to the RIF EC50 concentration (1 µM) demonstrates 
an approximate 20-fold difference in potency in the full-length hPXR assay between TCS 
and RIF. 
Dexamethasone (DEX) activated full-length rPXR with maximal efficacy at 49.5 µM at 
all time points tested, and again detection was optimal at 24 and 48 hr of chemical exposure 
(Figure 5.2A).  The EC50s for DEX at 24 and 48 hr were 3.21 ± 0.22 and 3.93 ± 0.42 µM, 
respectively (Figure 5.2A).  TCS failed to activate the full-length rPXR at any dose in the 
RPXR cells.  The TCS dose-response curve was truncated at 12.4 µM as fewer than 50% of 
RPXR cells were viable at higher concentrations (Figure 2B).  Following a 24 hr incubation, 
DEX achieved maximal efficacy at 49.5 µM (100.6% ± 4.7) in RPXR cells (Figure 5.3B).  
No relative TCS potency can be reported due to a lack of TCS activity in this full-length 
rPXR reporter assay. 
CYP3A4 induction by RIF and TCS in DPX-2 cells mirrored the PXR activation 
response observed with the full-length hPXR model (Figure 5.4A).  Maximal efficacy was 
obtained once again with 12.4 µM RIF to produce an effect that was 866 ± 44 percent of 
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DMSO vehicle control (Figure 5.4A).  Exposure to 12.4 and 24.8 µM TCS produced a 
response of 178 ± 5.4 and 288 ± 16 percent of DMSO vehicle control, respectively (Figure 
5.4A).  A relative potency estimate between the approximate RIF EC30 (0.9 µM) and the 
corresponding TCS concentration that induced the same CYP3A4 activity (24.8 µM) 
illustrates about a 30-fold potency difference between RIF and TCS for CYP3A4 activity 
induction. Maximal CYP3A4 induction in RPXR cells was obtained with 49.5 µM DEX, 
which produced a response that 2023 ± 296 percent of DMSO vehicle control (Figure 5.4B).  
TCS did not induce CYP3A4 in the RPXR cell model at any concentration (Figure 5.4B). 
Increasing the length of TCS exposure duration did not appear to affect the resultant 
cytotoxicity response of DPX-2 and RPXR cells (data not shown; see Appendix 5 for 
cytotoxicity data over time).  With 12.4 µM TCS, there was a decrease of 10-20% in DPX-2 
cell viability at all of the time-points tested.  With 24.8 µM TCS, there was a decrease of 
approximately 50% in DPX-2 cell viability at all of the time-points tested.  At 49.5 µM TCS, 
approximately 10% of cells were still viable; thus, all TCS dose-response curves in DPX-2 
are truncated at 24.8 µM.  In comparison, RPXR cell viability was decreased by 
approximately 10%, 15-25%, 30-45%, 70-75%, and 100% at 3.10. 6.20, 12.4, 24.8, and 49.5 
µM, respectively. TCS initiates cytotoxicity at 6.20 µM in the RPXR cells, a dose tolerated 
well by DPX-2 cells, and which elicited an approximate 200% of control PXR activation 
response.  This comparison highlights a narrow window between loss of cell viability and 
activation of hPXR in DPX-2 cells.  The concentration that produced the maximal hPXR 
activation in DPX-2 cells, 24.8 µM, results in 70-75% cell death in RPXR cells. 
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b.  Chimeric receptor reporter assays 
There was modest cytotoxicity demonstrated by a 30-40% loss in cell viability with TCS 
at the maximum concentration of 30 µM TCS in the HEK293T fibroblast cell lines with the 
chimeric receptor reporters.  As the same cell line was used for all of the chimeric receptor 
reporters, the moderate cytotoxic effects were consistent assay to assay. 
TCS significantly activated the chimeric hPXR reporter by 2.41 ± 0.28, 2.84 ± 0.30, and 
5.67 ± 0.035-fold vehicle control at 10, 20, and 30 µM TCS [F(5,11)=39.00, p<0.0001] 
(Figure 5.5A).  The positive control for the chimeric hPXR reporter assay was the known 
hPXR agonist TO-901317, which activated hPXR up to 7.21 ± 0.13-fold vehicle control at 
0.4 µM TO-901317 [F(5,15)=139.09, p<0.0001] (Figure 5.5A).  A comparison of the 
potency between TO-901317 and TCS, i.e. the TCS concentration that corresponds to the 
visually estimated EC50 for TO-901317, demonstrates a  
TCS failed to activate the chimeric mPXR reporter at any concentration [F(6,17)=1.45, 
p<0.2549] (Figure 5.5B).  TO-901317 activated the chimeric mPXR reporter 1.67 ± 0.13-fold 
vehicle control at 2 µM TO-901317 [F(5,15)=3.48, p<0.0274] (Figure 5.5B). 
TCS demonstrated splice-variant dependent activities for the chimeric hCAR reporter 
assays (Figure 5.6).  TCS decreased the activation of hCAR1 to a minimum of 0.28 ± 0.092-
fold vehicle control at 30 µM TCS, with an EC50 of 19.8 µM (Figure 5.6A).  The positive 
controls clotrimazole (CTZ) and di-(2-ethylhexyl)phthalate (DEHP) decreased activation of 
hCAR1, with EC50s of 6.33 and 8.48 µM for CTZ and DEHP, respectively (Figure 5.6A).  
The control CITCO did not have activity at hCAR1 (Figure 5.6B). 
 For hCAR2, a ligand-dependent splice variant, TCS acted as a strong agonist of the 
chimeric receptor (Figure 5.6C) [F(6, 14)=13.40, p<0.0001].  TCS activated hCAR2 by 4.12 
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± 0.53, 5.19 ± 0.95, and 19.8 ± 4.9-fold vehicle control at 10, 20, and 30 µM TCS.  
Previously, DEHP activated hCAR2 greater than 5-fold vehicle control in receptor-reporter 
assays in HepG2 cells (DeKeyser et al., 2009).  CTZ appeared to increase activation of 
hCAR2, but these results were not dose-dependent and represented a two to three-fold 
vehicle increase for all concentrations.  No effects of CITCO or PB exposure were observed 
on hCAR2 activation. 
 For hCAR3, TCS, CITCO, DEHP, and phenobarbital (PB) all demonstrated 
activation of the chimeric receptor (Figure 6D-E).  TCS activated hCAR3 by 3.28 ± 0.41 and 
4.14 ± 1.2-fold vehicle control at 20 and 30 µM TCS [F(6,13)=3.83, p<0.0202] (Figure 6D).  
DEHP activated hCAR3 up to 3.20 ± 0.61-fold vehicle control [F(3,8)=5.74, p<0.0215] at 10 
µM DEHP and PB activated hCAR3 up to 3.38 ± 0.31-fold control [F(3,8)=5.66, p<0.0223].  
CITCO, the most potent and efficacious agonist, activated hCAR3 by 22.6 ± 0.67 and 66.2 ± 
6.4-fold vehicle control at 0.5 and 5 µM CITCO, respectively [F(3,8)=87.84, p<0.0001] 
(Figure 6E).   
 TCS decreased the activation the chimeric rCAR and mCAR.  For rCAR, TCS 
decreased the activation 40-50% of vehicle control at 10-30 µM TCS concentrations, with an 
EC50 of 3.50 µM TCS [F(6,14)=20.81, p<0.0001] (Figure 5.7A).  The controls TCPOBOP 
and CTZ also decreased the activation of the chimeric rCAR (Figure 5.7A); TCPOBOP 
decreased rCAR activation to 0.70 ± 0.033-fold vehicle control at 10 µM TCPOBOP 
[F(4,10)=20.37, p<0.0001] with an EC50 of 8.56 µM TCPOBOP, and CTZ decreased rCAR 
activation to 0.40 ± 0.036-fold control at 12.5 µM CTZ [F(5,12)=117.09, p<0.0001] with an 
EC50 of 4.80 µM CTZ.  For mCAR, TCS decreased the activation of the chimeric receptor 
0.16 to 0.44-fold control for 10-30 µM TCS [F(6,14)=7.41, p<0.0010] (EC50 computation 
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failed).  PB also decreased the activation of the chimeric mCAR, by 0.43 to 0.76-fold vehicle 
control for all PB concentrations (0.1 – 100 µM) [F(4,10)=8.37, p<0.0031] (EC50 
computation failed).  Conversely, TCPOBOP and CTZ were agonists of the chimeric mCAR, 
and activated the receptor up to 6.39 ± 0.20 and 8.20 ± 0.33-fold vehicle control for 10  µM 
TCPOBOP [F(4,10)=186.50, p<0.0001]  and 12.5 µM CTZ [F(5,12)=201.80, p<0.0001], 
respectively.  
5. Discussion 
The current work tested the hypothesis that TCS activates rodent and human CAR and/or 
PXR, to potentially initiate an up-regulation of hepatic catabolism across multiple species.  
Consistent with this hypothesis, TCS activated human PXR and had activity at multiple 
human CAR splice variants.  TCS was an agonist for hPXR in both full-length and chimeric 
receptor reporter assays; and agonist for hCAR2; an agonist of hCAR3; and, an inverse 
agonist for the constitutively activated hCAR1.  TCS failed to activate full-length rPXR and 
chimeric mPXR; rather, TCS decreased the activation of both rCAR and mCAR suggesting 
that TCS is an inverse agonist of the murine CAR receptors, similar to the activity of TCS at 
hCAR1.  The data obtained suggest that TCS is capable, given a high enough concentration, 
of up-regulating hepatic catabolism in humans, including cytochrome P450, glucuronidation 
and sulfation activity.  Intriguingly, these data indicate that TCS may be able to activate CAR 
in rats and both CAR and PXR in humans, and initiate an up-regulation of hepatic 
catabolism, though perhaps by an initial nuclear receptor interaction that is species-
dependent. 
The positive controls RIF and DEX activated hPXR and rPXR in full-length receptor 
model cell lines, respectively, with EC50 values that are consistent with previous reports 
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utilizing these commercially-available cell lines (Sinz et al., 2007; Yueh et al., 2005).  TO-
901317, the positive control for human and mPXR used in the chimeric receptor reporter 
assays, also obtained similar activation of these receptors to previously reported findings 
(Mitro et al., 2007).  CITCO, CTZ, DEHP, PB, and TCPOBOP activities for the human, rat, 
and mouse chimeric CARs were also consistent with previous literature reports (Buckley et 
al., 2009; Chang et al., 2006; Dekeyser et al., 2011; DeKeyser et al., 2009; Faucette et al., 
2007; Maglich et al., 2009; Moore et al., 2000; Mutoh et al., 2009; Qatanani et al., 2005b; 
Sueyoshi et al., 2001; Yueh et al., 2005). 
TCS activated hPXR in both the full-length and chimeric receptor reporter assays, 
indicating that TCS may interact with hPXR to mediate downstream transcriptional up-
regulation of Phase I-Phase III metabolic enzymes in humans.  TCS was a moderate agonist 
in both models of hPXR and also increased CYP3A4 activity in the full-length receptor 
reporter cell lines at 10 to 30 µM TCS.  These results confirm a previous report using a 
luciferase-based human PXR reporter assay in human hepatoma cells that demonstrated 
moderate in vitro activation of PXR by triclosan, as 10 µM triclosan produced 46% of the 
response of 10 µM of the prototypical inducer rifampicin (Jacobs et al., 2005).  This lent 
support to the hypothesis that the up-regulation of Phase I-II biology observed in vivo in the 
rat is mediated via PXR in a human model.  In contrast, we were unable to demonstrate 
activation of rPXR in either the full-length receptor reporter model of the chimeric receptor 
reporter model, in direct opposition to our hypothesis, previously published in vivo data that 
demonstrated increased Cyp3a1 expression (Paul et al., 2010b), and increased Cyp3a1 
protein content (Hanioka et al., 1997).  However, it is possible that the effects observed on 
Cyp3a in in vivo rodent studies could be the result of CAR activation in the rat.   
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TCS demonstrated an interesting pattern of effects on hCAR that were splice variant-
dependent, and suggest that TCS may also interact with hCAR to potentially up-regulate 
hepatic catabolism downstream in humans.  TCS decreased activation of hCAR1, was a 
potent agonist of hCAR2, and was a moderate agonist of hCAR3 in the chimeric receptor 
reporter assays.  The effect of TCS on hCAR1 activation is consistent with activity as an 
inverse agonist of CAR (Baldwin et al., 2008; Chen et al., 2010).  Despite seemingly 
opposed receptor activities, inverse agonism of hCAR1 and agonism of hCAR3 is consistent 
with other compounds including CITCO and PB (Chen et al., 2010). The unique properties 
of the three known active splice variants of hCAR create a hypothetical scenario: TCS 
decreases the high, ligand-independent constitutive activity of hCAR1 and increases the 
ligand-dependent activity of hCAR2 and hCAR3, which have much lower constitutive 
activation (Auerbach et al., 2007; Chen et al., 2010).  This could result in an increased 
translocation of activated CAR complex to the nucleus of the cell and transcriptional up-
regulation of hCAR target genes such as CYP2B6.  Most striking was the observation that 
TCS is a potent agonist for hCAR2, a highly selective ligand-dependent splice variant of 
hCAR (Auerbach et al., 2007), with only one other known agonist, DEHP (DeKeyser et al., 
2009).  These data suggest that both hPXR and hCAR may both be involved in mediating 
transcriptional responses to TCS exposure.   
The results of the  rCAR and mCAR assays were similar to the activity displayed by TCS 
toward hCAR1, with TCS appearing to act as an inverse agonist.  Though initially appearing 
counter to our hypothesis, this activity is mirrored by PB in this model: phenobarbital is an 
inverse agonist of rCAR, despite well-defined effects on Cyp2b expression that are known to 
be dependent upon CAR function (Qatanani et al., 2005b; Smirlis et al., 2001; Sueyoshi et 
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al., 1999).  This conundrum may also stem from the complex biology of the rodent CAR; if 
rCAR and mCAR act like hCAR1 and express high constitutive activation, then it may be 
difficult to detect and identify ligands/activators for the receptor in vitro (Baldwin et al., 
2008).  Although we were unable to demonstrate activation of rat PXR by TCS in either the 
chimeric or full-length receptor reporter models, TCS appeared to follow the pattern of PB 
action, displaying inverse agonism in the rat and mouse CAR assays.  The finding that TCS 
activated hPXR and not rPXR was consistent with previous reports that demonstrate that PB 
moderately activated hPXR (Fery et al., 2010; Luo et al., 2002) but not rPXR in receptor 
reporter assays (Fery et al., 2010; Sinz et al., 2007).  Based on the similar response of TCS to 
known microsomal enzyme inducers PB, TCPOBOP, and CTZ in the rCAR assay, we 
propose that TCS initiates an up-regulation of hepatic catabolism via indirect activation of 
rCAR in rats.   
The data herein suggest several alternative hypotheses due to the unexpected lack of 
activation of rPXR.  First, that only rCAR is responsible for transcriptional up-regulation of 
the downstream effects observed in rats in vivo; second, that the methodology employed is 
inadequate to model the potential interaction of TCS with rat nuclear receptors in vivo; or, 
third, that other nuclear receptors or factors, in addition to or instead of rCAR and rPXR, 
contribute to the downstream biology observed in vivo in the rat.  While rCAR may be the 
primary driver of the downstream biology observed in vivo in the rat, it is not clear if TCS-
induced activation of human PXR and CAR has a greater role in producing downstream up-
regulation of hepatic catabolism.  Further, these in vitro receptor reporter models do not 
necessarily take into account potential interactions with other receptors and/or 
coactivators/corepressors that may be important for mediating the total biological response to 
193 
 
TCS; these interactions are presently an unknown variable in this model.  Potential 
involvement of the glucocorticoid receptor (GR) has been ignored in the current approach; 
the GR is known to regulate the expression and availability of CAR, PXR, and RXR in 
human hepatocytes (Pascussi et al., 2003; Pascussi et al., 2001; Wang et al., 2003b). Hepatic 
nuclear factor 4a (HNFa), another orphan nuclear receptor, may be a critical co-regulator of 
Cyp3a activation via binding to a cis promoter element in conjunction with PXR or CAR 
binding (Jover et al., 2009; Tirona et al., 2003) in human hepatocyte models. This hypothesis 
introduces the possibility that the importance of co-regulatory transcription factors vary in 
importance by species.  TCS may also affect co-activator recruitment; an interesting example 
in the literature is guggulsterone, which when co-administered to PXR-null mice with 
TCPOBOP, a potent mouse CAR agonist, produced decreased expression of Cyp2b10;  a 
current hypothesis for this action if that guggulsterone preferentially recruits the co-activator 
SRC-1 to PXR and displaces SRC-1 from mouse CAR (Ding et al., 2005; Pascussi et al., 
2008).  The complexity of nuclear receptor and transcription factor interactions clearly 
emphasizes that a lack of agonism in the rPXR assay does not eliminate the possibility of 
rPXR involvement in mediating the in vivo response to TCS.  Determination of the 
cumulative result of potential activation of multiple human receptors, e.g. up-regulation of 
markers of Phase I and Phase II metabolism, necessitates use of a primary hepatocyte model. 
6. Conclusions 
The human nuclear receptor data presented in the current work demonstrate that TCS is 
capable of activating hPXR, hCAR2, and hCAR3.  These receptors are known to be involved 
in the transcriptional regulation of Phase I, II, and III xenobiotic metabolizing enzymes and 
hepatic transporters that help maintain thyroid hormone homeostasis.  TCS acts as an inverse 
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agonist in the rCAR and mCAR reporter assays, suggesting that the in vivo effects of TCS 
may be due to CAR activation in the rat in a manner similar to PB.  Based on these nuclear 
receptor actions, the hazard of TCS-induced hypothyroxinemia, as observed in vivo in the rat, 
seems plausible in a human model.  These results indicate that up-regulation of important 
Phase I markers and Phase II metabolizing enzymes may occur in both humans and rats, but 
perhaps with species-dependent bias toward the nuclear receptor most involved: both CAR 
and PXR may be important for mediating downstream responses in humans, and CAR may 
be more important for the rat.   
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Figure 5.1. hPXR activation in DPX2 cells at 6, 12, 24, and 48 hr of chemical exposure.  
A. RIF induction over a 48 hr period with concentrations spanning 0.0968 to 24.8 µM.  
B.  TCS induction over a 48 hr period with concentrations spanning 0.387 to 24.8 µM. 
Using the molecular weight of TCS (289.54 g/mol), the in vitro TCS concentration range 
(0.387 to 24.8 µM) can be expressed as 0.112 to 7.18 mg/L.  The in vivo doses used in 
Chapters 2, 3, and 4 of this dissertation work, 10 to 1000 mg/kg/day, can similarly be 
converted to 34 to 3400 µmol/kg/day. 
 
 
 
 
 
 
B A 
196 
 
Rifampicin (RIF) concentration (µM)
0.1 1 10 100 1000Pe
rc
e
n
t o
f D
M
SO
 
ve
hi
cl
e 
co
n
tro
l P
XR
 
a
ct
iva
tio
n
,
 
co
rr
ec
te
d 
fo
r 
ce
ll v
ia
bi
lity
 
(m
e
an
 
±
 
SE
)
0
200
400
600
800
1000
1200
1400
6 hr
12 hr
24 hr
48 hr
Triclosan (TCS) concentration (µM)
0.1 1 10 100
0
200
400
600
800
1000
1200
1400
6 hr
12 hr
24 hr
48 hr
 
Figure 5.2.  rPXR activation in RPXR cells at 6, 12, 24, and 48 hr of chemical exposure.  
A. DEX induction over a 48 hr period with concentrations spanning 0.387 to 99.1 µM.  
B.  TCS induction over a 48 hr period with concentrations spanning 0.387 to 12.4 µM.  
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Figure 5.3.  Comparative activation of full-length PXR for human and rat.  A.  RIF and TCS 
activated hPXR.  B.  DEX activated rPXR, while TCS failed to activate at any dose. 
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Figure 5.4.  Comparative CYP3A4 activation for human and rat in the full-length 
receptor reporter cell lines.  A.  RIF and TCS induced CYP3A4 activity in DPX-2 cells.  B.  
DEX induced CYP3A4, and TCS did not produce any effect. 
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Figure 5.5.  Activation of chimeric human and mouse PXR.  A.  TO-901317 and TCS both activated hPXR.  B.  TO-901317 
activated mPXR significantly at 2 µM, but TCS failed to significantly activate mPXR.  Using the molecular weight of TCS 
(289.54 g/mol), the in vitro TCS concentration range (0.3 to 30 µM) can be expressed as 0.087 to 8.7 mg/L.  The in vivo doses 
used in Chapters 2, 3, and 4 of this dissertation work, 10 to 1000 mg/kg/day, can similarly be converted to 34 to 3400 
µmol/kg/day.
197
 
199 
 
 
 
 
200 
 
Figure 5.6.  Activation of the chimeric hCAR by splice variant.  A and B.  TCS, CTZ, and DEHP 
were inverse agonists of hCAR1, while CITCO and PB appeared to have no activity at the receptor.  
C.  TCS demonstrated significant and strong agonism of hCAR2; CTZ demonstrated moderately 
increased activation of hCAR2 that was not dose-dependent; DEHP, CITCO, and PB failed to 
activate hCAR2.  D and E.  TCS, DEHP, and PB were moderate agonists of hCAR3, while CITCO 
demonstrated potent and efficacious agonism. 
 
 
 
 
Figure 5.7.  Activation of chimeric rat and mouse CAR.  A.  TCS, CTZ, and TCPOBOP 
demonstrated inverse agonism toward rCAR, while PB demonstrated no activity.  B and C. CTZ 
and TCPOBOP were agonists of mCAR, whereas TCS and PB demonstrated inverse agonism of 
mCAR. 
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 The current work characterized a mode-of-action (MOA) for triclosan- (TCS) induced 
decreases in thyroid hormones (THs) in rats, and investigated the human relevance of this 
MOA.  TCS is an active anti-bacterial agent found in a variety of personal care products and 
medical topical disinfectants.  In the last decade, analytical chemistry advances identified a 
set of emerging contaminants of concern, which includes TCS (reference on emerging 
contaminants).  Detection of TCS by a USGS team in surface waters across the United States 
demonstrated that TCS was one of the most ubiquitously detected contaminants, found at 
over 50% of the sites above the limit of detection, though at low concentrations in the parts 
per trillion range on average (50 ng/L) (Kolpin et al., 2002).  Though systemically toxic to 
algae, macroinvertebrates, and fish, an understanding of how the combined environmental 
and hygienic exposure to TCS could impact the human thyroid hormone (TH) homeostasis 
had not been evaluated.  Limited evidence from the literature suggested that TCS might be a 
candidate thyroid hormone disruptor: TCS increased the rate of triiodothyronine- (T3) 
mediated anuran metamorphosis (Veldhoen et al., 2006), moderately activated the human 
pregnane X receptor (PXR) in an in vitro receptor reporter assay (Jacobs et al., 2005), 
increased protein expression and activity in primary rat hepatocytes (Jinno et al., 1997) as 
well as rat hepatic microsomes prepared following in vivo exposures (Hanioka et al., 1997), 
and inhibited sulfotransferases in vitro (Wang et al., 2004; Wang et al., 2006).  A clear data 
gap and subsequent hypothesis was identified based on these published results: TCS alters 
TH regulation, and in mammals does so via interaction with nuclear receptors, resulting in 
increased hepatic Phase II metabolism and transport.  This research tested the hypothesis that 
TCS decreases thyroid hormones in vivo via activation of nuclear receptors that regulate key 
hepatic enzymatic regulators of TH homeostasis. Extension of this work to a developmental 
exposure model addressed the capacity for TH disruption by TCS during neurodevelopment.  
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Finally, using the hypothesized MOA, the initiating key event and biomarkers of hepatic 
catabolism were assessed for plausibility using comparative in vitro models for rats and 
humans.   
 Chapter 2 of this work demonstrated that short-term TCS exposure decreased 
thyroxine (T4) and T3 in a dose-dependent manner.  The no observable adverse effect level 
(NOAEL) for T4 was 30 mg/kg/day, and the greatest effect observed as an approximate 55% 
decrease in T4 with 1000 mg/kg/day TCS.  Effects on T3 were minimal, with 12% and 25% 
decreases at 100 and 300 mg/kg/day, respectively; most likely these were only significant 
changes due to the large N used in this study.  The magnitude of these changes versus the 
dose administered indicates that TCS is a low potency thyroid hormone disruptor when 
compared to other xenobiotics.  Similar 4-day exposures with other compounds have yielded 
greater depletion of thyroid hormones.  Commercial mixtures of polybrominated diphenyl 
ethers (PBDEs) DE-71 and DE-79 decreased T4 by 80 and 70% respectively, and T3 by 25-
30%, with no effects on TSH, following 4-day exposures of 300 mg/kg/day (Zhou et al., 
2001).  The NOAEL for these PBDE-mediated effects was 3 mg/kg/day, as T4 was decreased 
20-30% even with 10 mg/kg/day (Zhou et al., 2001), indicating that PBDEs disrupt TH 
homeostasis with higher potency than TCS.  Similarly, polychlorinated biphenyls (PCBs) are 
more potent and more efficacious than TCS; dioxin-like PCBs, e.g. PCB126 which interacts 
with the aryl hydrocarbon receptor (AhR) to mediate downstream extrathyroidal effects, 
decreased T4 by 50% in a rat at 30-100 µg/kg/day, and phenobarbital-like PCBs, e.g. 
PCB153 thought to interact with the constitutive androstane receptor (CAR), decreased T4 
by 70-80% with 90-300 mg/kg/day in a rat when exposed for four consecutive days.  Thus 
the consistent finding that TCS decreased T4 by approximately 30% at doses as high as 300 
mg/kg/day demonstrates that TCS appears to be relatively less efficacious and less potent 
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than many environmental thyroid disruptors such as PBDEs and PCBs.  Minor decreases in 
T3 and a lack of consistent, dose-dependent effects on TSH are consistent with other thyroid 
disrupting chemicals, including  3MC, Aroclor 1254, and phenobarbital (PB) (Hood et al., 
1999; Liu et al., 1995; Vansell et al., 2001).  One area of uncertainty in the study of thyroid 
disruption is the correlation, or lack of correlation, between T4 disruption, T3 disruption, and 
TSH increases; for instance, though Aroclor 1254 is capable of potent disruption of T4, it 
does not increase TSH (Hood et al., 1999; Liu et al., 1995; Vansell et al., 2001).  A 
predominant theory is that activation of negative feedback to produce TSH increases in 
response to T4 decreases requires concomitant increases in T3 glucuronidation, and that 
variability among hepatic microsomal enzyme inducers in their ability to increase 
glucuronidation of T4 as well as T3 underlies the variability in TSH response (Hood et al., 
2000; Richardson et al., 2010a).   
Similar to many other environmental chemicals and drugs (Brucker-Davis, 1998), the 
current body of in vivo work presented in Chapters 2 and 4 suggests that TCS exposure 
decreases T4 in vivo via up-regulation of hepatic catabolism.  This hypothesized MOA 
begins with activation of nuclear receptors, including the constitutive androstane receptor 
and/or pregnane-X receptor (CAR and/or PXR), and followed by a transcriptional up-
regulation of hepatic microsomal enzymes responsible for decreasing the serum half-life of 
T4 (e.g. glucuronyltransferases, sulfotransferases, and hepatic transport proteins).  Chapter 2 
provides data to suggest that it is plausible that this MOA at least partially accounts for the 
systemic T4 decreases observed in rats following a 4-day TCS exposure.  Both hepatic 
microsomal activity and quantitative RT-PCR demonstrated isoform-specific increases in 
Phase I metabolic markers of upstream nuclear receptor activation; pentoxy-o-resorufin 
deethylase activity, a marker for Cyp2b activity in the rat, and Cyp2b1/2 and Cyp3a1/23 
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expression, were increased, suggesting that CAR and/or PXR were activated by TCS 
exposure.  Hepatic microsomal T4-glucuronidation activity was increased nearly two-fold at 
1000 mg/kg/day only, and qRT-PCR demonstrated two-fold increased expression of Ugt1a1 
at 100-300 mg/kg/day and nearly three-fold increased expression of Sult1c1, suggesting that 
sulfotransferase activity may also have contributed to increased catabolism of thyroid 
hormones in vivo.  The potential contribution of nuclear receptor-mediated changes in 
hepatic transport expression was also evaluated, but qRT-PCR revealed no significant 
changes despite known regulation of key transporters by CAR and PXR.  Follow-up studies 
of in vitro functional activity of hepatic transport in sandwich-cultured rat hepatocytes, 
presented in Appendix 6, confirmed a lack of significant effect on hepatic transporter protein 
function and expression following TCS exposure.  Collectively, the data suggest that 
increased T4 glucuronidation and subsequent excretion following short-term TCS exposure, 
initiated by activation of hepatic nuclear receptors, is plausible in the rat.  This follows the 
MOA pattern for several known and well-characterized thyroid disrupting chemicals, such as 
PB, PCN, Aroclor 1254 and single PCB congeners, 3MC, and PBDEs.  In particular it is 
important to examine these prototypical inducers with respect to their known receptor targets.  
In the rat, PB is known to activate CAR; PCN activates PXR; Aroclor 1254 is a mixed 
inducer containing PCB congeners that activate AhR and/or CAR; 3MC is an AhR agonist; 
and PBDEs activate CAR and/or PXR.  The data presented in Chapter 2 does not delineate 
the specific nuclear receptor interaction because considerable cross-talk between CAR and 
PXR could enable either receptor to increase the expression of Cyp2b and Cyp3a activity and 
expression.  However, TCS appears to act upon thyroid hormones in a manner more 
consistent with CAR activator PB, i.e. moderate effects on T4, minimal effects on T3, and no 
significant effects on TSH with increases in Cyp2b/Cyp3a markers and T4 glucuronidation 
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activity following short-term administration.  Though the data and comparison to known 
thyroid-disrupting chemicals illustrates the plausibility of this MOA following short-term 
exposure in a rat model, a necessary caveat is that T4 glucuronidation may not completely 
account for the T4 decreases observed.  In fact, previous reports of the correlation between 
T4 glucuronidation activity and T4 decreases for PB and PCN indicated that other events 
may contribute to the observed TH deceases (Kato et al., 2005; Liu et al., 1995; Richardson 
et al., 2010b).   
Evaluation of this plausible MOA, derived from a short-term exposure model, in a 
developmental model was a critical component of this work because subclinical maternal 
hypothyroxinemia results in critically delay neurological and behavioral functions and 
manifests permanently as decreased cognitive function in both rat (Axelstad et al., 2008; 
Goldey et al., 1998; Lavado-Autric et al., 2003; Opazo et al., 2008), and human offspring 
(Berbel et al., 2009; Haddow et al., 1999; Henrichs et al., 2010; Kooistra et al., 2006; Li et 
al., 2010; Pop et al., 2003; Pop et al., 1999).  Thus the developing fetus and neonate 
represent a susceptible population of concern for TH disruption.  For the work detailed in 
Chapters 3 and 4, perinatal exposure of dams from early gestation through the end of 
lactation modeled the potential transplacental and lactational exposures to offspring; these 
routes of exposure likely occur in humans, as TCS has been measured in human plasma 
(Adolfsson-Erici et al., 2002; Allmyr et al., 2008; Allmyr et al., 2006b) and breast milk 
(Adolfsson-Erici et al., 2002; Allmyr et al., 2006a; Dayan, 2007).   This work tested the 
hypothesis that TCS decreases thyroid hormones, and that this disruption proceeds through 
increased hepatic catabolism of thyroid hormones, as with the short-term exposure model.  
The results presented in Chapters 3 and 4 reveal three key findings: (1) TCS moderately 
decreased T4 in dams, fetuses, and early neonates, with no effects on thyroid hormones in 
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pups during mid- to late-lactation (Paul et al., 2010b); (2) Transplacental exposure occurs, 
and lactation exposure alone produced more limited internal exposures to neonates as they 
approached weaning; and, (3) markers of up-regulated hepatic catabolism were increased in 
dams, suggesting that TCS-induced hypothyroxinemia during the fetal and early neonatal 
period was at least partially due to the previously hypothesized MOA.   
The observation that T4 was moderately decreased in vivo for dams at gestational day 
20 (GD20) and postnatal day 22 (PND22), GD20 fetuses, and PND4 neonates was consistent 
with the decreases observed in T4 following a 4-day exposure (Paul et al., 2010a).  There 
were no perinatal effects on T3 or TSH for dams or PND14 and PND21 offspring.  Serum T4 
for dams, fetuses, and PND4 neonates was decreased by approximately 30% for the 300 
mg/kg/day exposure group; this finding is particularly interesting because on GD20, dams 
had received TCS for 14 days, and on PND22, dams had received TCS for 36 days, yet the 
magnitude of the effect at 300 mg/kg/day was concordant with the effect for 300 mg/kg/day 
following a 4-day exposure.  This could be due to the short half-life for TCS, estimated to be 
9-18 hr for oral administration in the rat (personal communication, James Plautz, Ciba 
Specialty Chemicals) (Black et al., 1975; Siddiqui et al., 1979).  This is similar to the 10-24 
hr oral half-life reported in humans (Rodricks et al., 2010; Sandborgh-Englund et al., 2006).  
Thus, following a 4-day exposure, animals may have achieved steady-state kinetics for TCS, 
such that a 15-day or 36-day exposure would reflect the same internal concentrations of TCS.   
The data from Chapters 3 and 4 demonstrated a unique pattern of perinatal TCS 
exposure on the serum T4 concentrations of pups during the lactation period, i.e. the serum 
T4 concentrations of pups recovered to control levels by the end of weaning. This pattern 
suggests that toxicokinetic factors may have affected maternal disposition of triclosan into 
milk and thereby limited lactation exposure to pups, or that the triclosan may not have 
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triggered the same toxicodynamic effects in offspring during the lactation period as in 
exposed weanlings or dams.  The work in Chapter 4 tested the hypothesis that the recovery of 
serum T4 to control levels at PND14 and PND21 in offspring was due to decreased exposure 
of these pups.  As the fetuses and offspring only received TCS via maternal compartments, 
the similar magnitude of decrease in T4 warranted follow-up analysis of internal TCS 
exposures to these animals.  A lack of TCS-induced hypothyroxinemia on PND14 and 
PND21 in the offspring makes the effects of perinatal TCS exposure distinct from other 
known developmental TH disruptors, including polybrominated diphenyl ethers (PBDEs), 
polychlorinated biphenyls (PCBs), propylthiouracil (PTU), and 2,3,7,8-
tetrachlorodibenzodioxin (TCDD), which when administered to dams are known to decrease 
offspring T4 during the entire postnatal lactation period, typically with the most pronounced 
effects on offspring T4 on PND14 (Crofton et al., 2000; Gilbert et al., 2006; Goldey et al., 
1995; Kodavanti et al., 2010; Morse et al., 1993; Royland et al., 2008; Sharlin et al., 2006; 
Zhou et al., 2001; Zhou et al., 2002).  Markers of hepatic Phase I and Phase II catabolic 
activity are known to be inducible at PND4, 14, and 21 (Zhou et al., 2001; Zhou et al., 2002), 
suggesting that a differential toxicodynamic response by postnatal age was likely not 
responsible for the variable T4 response.  Based on the lack of effect during these later 
postnatal offspring ages, a toxicokinetic hypothesis was proposed: PND14 and PND21 
neonates recover to vehicle control concentrations of serum T4 because their exposure via 
lactation is limited.   
 To evaluate the hypothesis that PND14 and PND21 serum T4 concentrations were 
unaffected due to limited lactation exposure, parent TCS and parent plus glucuronidated and 
sulfated TCS were measured in sera and liver homogenates from all of six of the 
developmental time points by high performance liquid chromatography coupled with tandem 
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mass spectrometry.  The results illustrate that dams experienced the highest internal total 
TCS concentrations in both sera and liver, with the concentrations slightly higher for GD20 
dams, followed closely by GD20 fetuses and then PND4 neonates.  A pronounced decrease 
in total TCS was observed for PND14 and even more so for PND21, indicating that exposure 
to neonates was decreasing over the lactation period.  This supported our hypothesis that the 
recovery of T4 to control concentrations in PND14 and PND21 neonates corresponded to 
decreased exposure through lactation.  Further, these data suggest that GD20 fetuses and 
PND4 neonates are not disproportionately susceptible to TCS-induced hypothyroxinemia; 
similar internal concentrations of TCS produced equivalent T4 reductions in dams, fetuses, 
and early offspring, such that fetuses and offspring do not appear to be more sensitive to 
exposure.  A potential follow-up to this work would be to test TCS concentrations in the milk 
of dams, to understand the oral dose being administered to pups, since this was not 
characterized.  TCS has previously been measured in human breast milk (Adolfsson-Erici et 
al., 2002; Allmyr et al., 2006a; Dayan, 2007).  Following oral ingestion of TCS, a 
predominant exposure route (Sandborgh-Englund et al., 2006), the concentration of TCS in 
plasma was greater than that of breast milk by a factor of four, possibly due to the relative 
chemical acidity of the matrices versus the protonation state of TCS (TCS has a pKa of 7.9, 
serum pH = 7.5, and breast milk pH = 6.5) (Allmyr et al., 2006a).  The contribution of other 
factors that would affect the diffusion of TCS across the mammary membrane, including 
active transport of TCS into the milk or binding of TCS to serum proteins, is unknown for 
humans and for rats.  Potential interspecies differences in transport of TCS or TCS 
conjugates into the milk compartment are still an uncertainty in the extrapolation of the rat 
data to potential human risk; e.g., if rats partition TCS into milk at a greater rate than 
humans, the risk of human neonatal exposure is further diminished. 
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 Following investigation of the pattern of serum T4 effects versus internal exposures, 
the hypothesized MOA for TCS-induced hypothyroxinemia was evaluated for plausibility 
following development exposure.  Analysis of the MOA in the developmental model 
importantly informs whether or not TCS-induced hypothyroxinemia could proceed through 
this MOA during the critical brain development window, and gives a series of events to 
evaluate in later in a human model for plausibility.  Hepatic microsomal activity assays were 
used to test up-regulation of markers of Phase I and Phase II activity.  Quantitative PCR 
arrays were employed to evaluate Phase I expression as a marker of upstream nuclear 
receptor activation, expression of Phase II glucuronsyltransferase and sulfotransferase 
isoforms, expression of Phase III hepatic transporters, expression of deiodinase I, and 
markers of tissue changes in T3 (malic enzyme I and Spot14).  TCS exposure increased 
PROD activity for PND22 dams and PND4 neonates only, and T4 glucuronidation activity 
for PND22 dams, at 300 mg/kg/day.  The qPCR arrays demonstrated that expression of 
Cyp2b2 and Cyp3a1/23 was increased by TCS exposure in both sets of dams.  However, 
there were no statistically significant effects for any other expression endpoints.  The limited 
findings are still consistent with activation of CAR and/or PXR, and potential up-regulation 
of hepatic catabolism, indicating that it is plausible that TCS activates nuclear receptors to 
result in increased hepatic catabolism of thyroid hormones with subsequent decreases in 
serum T4 concentrations.  The data further confirm that the doses of TCS used in this study, 
while high (maximum of 300 mg/kg/day), do not significantly perturb tissue concentrations 
of T3 that would be necessary to elicit more deleterious results during animal development, 
likely due to the low potency and efficacy of TCS. 
 Although TCS appears to decrease serum T4 with low potency and efficacy, and 
perhaps without changing tissue levels of T3, the determination of human relevance of the 
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proposed MOA is still critical because (1) TCS is only one of the potential thyroid disrupting 
chemicals that individuals are exposed to; (2) the relative sensitivity of humans and rats to 
this specific MOA is unknown; and, (3) initiation of the hypothesized MOA is highly 
species-dependent, as activation of nuclear receptors relies upon interaction of a chemical 
with species-divergent ligand-binding domains (Jones et al., 2000; Kretschmer et al., 2005; 
LeCluyse, 2001; Timsit et al., 2007).  The proposed initiating key event in the hypothesized 
rat MOA presented an easily measured target across multiple species.  The hypothesis tested 
in Chapter 5 was that TCS activates human and rat PXR and CAR resulting in potential up-
regulation of hepatic catabolism of thyroid hormones and decreased serum T4 
concentrations.  Species-specific in vitro receptor reporter assays were employed to make an 
interspecies comparison.  First, a full-length receptor reporter assays was used to demonstrate 
activation of human and rat PXR (Puracyp, Inc.).  Second, a set of chimeric receptor-reporter 
assays was utilized to test ligand-binding only for rat CAR and PXR, all three human CAR 
splice variants and human PXR, and mouse CAR and PXR (INDIGO Biosciences).  The 
results demonstrated an interesting pattern that challenged preconceived notions of the 
involvement of rat PXR.  A previous report of activation of human PXR by TCS (Jacobs et 
al., 2005), and agreement with our findings of up-regulated markers of Cyp3a in the rat (Paul 
et al., 2010a), motivated the theory that rat PXR was involved in mediating the downstream 
effects of TCS in vivo.  Both the full-length and chimeric receptor reporter assays confirmed 
that TCS is a moderate activator of human PXR.  However, TCS was not a rat PXR agonist 
in either receptor-reporter assay.  Intriguingly, TCS appeared to be an inverse agonist for rat 
CAR, similar to the response of PB and CITCO against rat CAR.  The similarities for the 
pattern of effects between TCS and PB was important for hCAR as well, and the results for 
the hCAR splice variants were extremely surprising. The present work demonstrated that 
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TCS was (1) an inverse agonist for hCAR1, the constitutively-active, ligand-independent 
splice variant (Auerbach et al., 2005; Chen et al., 2010; Savkur et al., 2003); (2) a potent 
agonist for hCAR2, the ligand-dependent splice variant with only one other known agonist 
(Auerbach et al., 2007; DeKeyser et al., 2009); and, (3) an agonist for hCAR3, a largely 
ligand-dependent splice variant (Auerbach et al., 2005; Chen et al., 2010).  Finally, our 
finding that TCS activated hPXR and not rPXR was consistent with previous reports that 
demonstrate that PB is known to moderately activate human PXR in receptor reporter assays 
(Fery et al., 2010; Luo et al., 2002) with no activating effect on rat PXR in receptor reporter 
assays (Fery et al., 2010; Sinz et al., 2007). 
First, it is important to underscore that this pattern of effects for TCS and the three 
human CAR splice variants is the same as the pattern for PB, suggesting that TCS may be 
PB-like in its activation of CAR for both the human and the rat.  Second, the activation of 
hCAR2 by TCS was indeed striking and unexpected.  To date, only DEHP has been 
identified as an agonist of hCAR2 (DeKeyser et al., 2009); the previously reporter maximal 
activation of hCAR2 in a receptor-reporter assay was 6-fold vehicle control at 10 µM 
(DeKeyser et al., 2009), whereas in the chimeric receptor reporter assays employed here, 
TCS activated hCAR2 4-, 5-, and 20-fold DMSO vehicle control at 10, 20, and 30 µM, 
respectively.  What is truly novel about the aggregate receptor activation findings is the 
potential for different receptors to mediate the same downstream effects in two different 
species.  Thus, Chapter 5 is the first report of TCS interaction with rCAR and hCAR splice 
variants and a lack of activation of rat PXR, and confirms a previous report of hPXR 
activation by TCS. 
 The collection of studies included here demonstrates that TCS induced a PB-like 
response in vivo for thyroid hormones and markers of hepatic catabolism, and in vitro at the 
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nuclear receptor level.  But what is a PB-like response?  In vivo PB exposure is known to up-
regulate Cyp2b activity and expression (Honkakoski et al., 1998a; Honkakoski et al., 1998b; 
Sueyoshi et al., 2001) as well as Cyp3a1 (Lecureux et al., 2009); increase hepatic 
microsomal glucuronidation activity in rats toward T4 and T4 elimination (Hood et al., 2003; 
Hood et al., 2000; Lecureux et al., 2009; Liu et al., 1995; Qatanani et al., 2005); and decrease 
T4 consistently with minor decreases on T3 (Barter et al., 1994; Capen, 1994; Lecureux et 
al., 2009).  PB effects on TSH are not as consistent, with reports of little to no effect on TSH 
concentrations (Lecureux et al., 2009; Vansell et al., 2001), though some small increases (50-
100%) have been observed (Liu et al., 1995) (Note: PTU-induced increases in TSH range 
from 4- to 5-fold control (O'Connor et al., 2002)).  In vitro rat hepatocyte models have 
confirmed these actions, and provided further support for PB activation of CAR; recently, in 
vitro human models have demonstrated that PB activation of CAR proceeds via an indirect 
mechanism that does not involve ligand binding, but rather results in protein kinase C-
mediated dephosphorylation of threonine 38 of hCAR1 with subsequent translocation to the 
nucleus and transcriptional regulatory activity (Mutoh et al., 2009).  In vitro PB exposures in 
human hepatocytes and cell lines have further demonstrated activation of CYP2B6 by CAR 
in response to PB (Maglich et al., 2003; Sueyoshi et al., 1999; Wang et al., 2003) and 
potential cross-talk between promoter elements enabling CAR-mediated induction of CYP3A 
(Faucette et al., 2006; Faucette et al., 2007).  As PB is prescribed as an anti-epileptic, PB is 
one of the few thyroid disrupting chemicals that has been studied in humans and has 
demonstrated that the hypothesized MOA is plausible.  PB decreased thyroid hormones in 
humans in vivo (Curran et al., 1991) and increased expression and activity of UGT1A1 in 
human hepatocytes (Ritter et al., 1999).  The PB-like response exhibited by TCS implies that 
if the correct dose were achieved, TCS could initiate a similar cascade of events in humans. 
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 Overall the data presented herein suggest that activation of nuclear receptors leading 
to increased hepatic catabolism of thyroid hormones and systemic decreases in T4 is 
plausible for the rat, following short-term and developmental exposures.  The initiating key 
event, perhaps with a species-dependent bias for the nuclear receptor involved, occurs in an 
in vitro human model.   Further, the pattern of effects observed for TCS and rat and human 
nuclear receptors suggested a PB-like response, and PB is one of the only chemicals for 
which the hypothesized MOA has actually been observed in humans.  An obvious remaining 
question is: based on the dose-response observed in the rat, is it possible that TCS-induced 
hypothyroxinemia would occur in humans?  While the MOA for TCS-induced 
hypothyroxinemia is plausible in humans, few data describing human exposure are available 
to compare to rats. 
In a 14-day study of 12 adults, the participants were asked to brush their teeth for 3 
min with 2 cm of Colgate Total ® toothpaste each day containing 0.3% TCS (Allmyr et al., 
2009). Measurement of TCS in the sera of these volunteers demonstrated that the median 
serum concentration was 54 ng/g (assuming a human plasma density of 1.025 ng/mL, this 
would be 55 ng/mL), with the maximum measured serum concentration of 303 ng/mL.  
Importantly, the volunteers in the human study experienced no effects on a marker of 
CYP3A4 activity and no change in serum free T4 concentrations (Allmyr et al., 2009).  The 
minimum serum concentration that elicited a significant effect on T4 in rats was 5120 ng/mL 
in PND22 dams, which corresponded to a statistically significant 15% decrease in serum T4.  
Comparison of this value with the highest measured human serum concentration yields a 17-
fold margin of exposure.  The lowest average serum concentration in rats that elicited a 30% 
decrease in T4, 19,000 ng/mL in PND22 dams, would yield a 60-fold margin of exposure.    
Comparisons of serum TCS concentrations and lowest observable effect levels for T4 
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decreases in rats to a human study that described no effects of TCS exposure on a marker of 
CYP3A4 activity of serum free T4 concentrations make conclusions difficult.  The only 
conclusion that can therefore be derived from this comparison is that humans are not 17-fold 
or 60-fold more sensitive than rats to TCS exposure.  Based on a comparison of serum 
concentrations of TCS across species, it appears unlikely that TCS exposure alone would 
cause hypothyroxinemia in humans. 
 Several uncertainties remain for the thyroid-disrupting activity of TCS specifically, 
nuclear receptor-mediated thyroid hormone homeostasis, and the function of TCS in the 
milieu of thyroid-disrupting chemicals to which the population is exposed.  This dissertation 
research has only addressed one potential MOA for TCS-induced hypothyroxinemia.  The 
contribution of other potential MOAs has not been assessed, and a poor correlation between 
UGT activity increases and T4 decreases in vivo may suggest the involvement of other 
MOAs or perhaps just other catabolic activities not fully considered here such as 
sulfotransferase activity.  Future work would be required to understand the relative 
contribution of TCS activation of hCAR splice variants and hPXR; i.e., in a primary human 
hepatocyte, what is the overall resulting outcome of the potential interactions of TCS with 
multiple receptor types?  Since hCAR2 is only 30% of the transcriptome (Auerbach et al., 
2007), with hCAR1 comprising the majority of CAR transcripts in hepatocytes, does TCS 
activation of hCAR2 result in strong downstream up-regulation of CAR transcriptional 
targets?  If TCS is a non-specific activator of both hPXR and hCAR, then to which receptor 
does TCS have the greatest affinity?   
Further in vivo work with animals or in vitro work with nuclear receptor targets might 
help address the question of how TCS might contribute to the thyroid-disrupting activity of a 
mixture of chemicals.  Since TCS is a low potency thyroid hormone disruptor, and exposure 
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concentrations in humans are low, is TCS a relevant component of the mixture to which 
humans are exposed? Clearly the most salient future experiment is exposure of human 
hepatocytes to demonstrate the impact of TCS exposure on markers of Phase I and Phase II 
metabolism in a more relevant human model. 
A further consideration for extension of this work is the use of nuclear receptor 
reporters assays to screen for other toxicants like TCS that disrupt TH homeostasis via 
interaction with nuclear receptors and subsequent up-regulation in hepatic catabolism and 
elimination of THs.  The use of PXR reporter assays is found commonly in the literature, 
generally as a means for identifying compounds that may lead to adverse drug interactions 
centered on CYP3A4-mediated metabolism (Fery et al., 2010; Luo et al., 2002; Shukla et al., 
2009; Shukla et al., 2011; Yueh et al., 2005), but the use of these assays as screening for 
potential thyrotoxicants is growing (Creusot et al., 2010; Lemaire et al., 2004; Rotroff et al., 
2010).  To this end, following characterization of TCS alone in full-length PXR receptor-
reporter assays, the method was extended to consider environmental water samples 
containing a complex and uncharacterized mixture of compounds (Appendix 7).  This 
extended work underscores that comparative in vitro nuclear receptor reporter models may be 
used to evaluate the MOA for one compound, or to evaluate an environmental mixture for its 
potential thyroid-disupting activity via an MOA similar to the one proposed for TCS.  
Increasing use of nuclear receptor reporter assays for screening for thyroid-disrupting 
chemicals necessitates a greater understanding of the molecular events involved in nuclear 
receptor activation and nuclear receptor transcriptional regulation of downstream 
metabolism, e.g. co-activator/co-repressor recruitment, the involvement of multiple receptors 
and/or response elements, the contributions of multiple splice variants to downstream 
transcriptional changes, etc.  Further research in this area using prototypical TH disruptors 
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may provide additional insight into molecular events that may uniquely distinguish 
subclasses of compounds that interact with nuclear receptors to increase hepatic catabolism 
and elimination of THs. 
 In summary, this research provides important findings for understanding the mode-of-
action (MOA) for TCS-induced hypothyroxinemia in rats and provides initial support for the 
plausibility of this mode-of-action in a human model.  Disruption of thyroid hormones by 
TCS and characterization of a MOA for these thyroid hormone changes following short-term 
and developmental exposures were previously unreported.  The data presented within provide 
a critical metric for comparing exposures in rat studies to human exposures.  Importantly, the 
initiating molecular key event of the proposed MOA for TCS-induced hypothyroxinemia was 
evaluated to demonstrate that nuclear receptor interactions with TCS occur in both rat and 
human models.
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 1.  Abstract 
 
Triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol) is a chlorinated phenolic 
antibacterial compound found as an active ingredient in many personal care and household 
products. The structural similarity of triclosan to thyroid hormones and recent studies 
demonstrating activation of the human pregnane X receptor (PXR) and inhibition of 
diiodothyronine (T2) sulfotransferases, have raised concerns about adverse effects on thyroid 
homeostasis. The current research tested the hypothesis that triclosan alters circulating 
concentrations of thyroxine. The hypothesis was tested using a four-day oral triclosan 
exposure (0–1000 mg/kg/day) in weanling female Long Evans rats, followed by 
measurement of circulating levels of serum total thyroxine (T4).  Dose-dependent decreases 
in total T4 were observed. The benchmark-dose (BMD) and lower bound on the BMD 
(BMDL) for the effects on T4 were 69.7 and 35.6 mg/kg/day, respectively. These data 
demonstrate that triclosan disrupts thyroid hormone homeostasis in rats.  
2. Introduction 
Triclosan is a chlorinated phenolic antibacterial compound used as an active 
ingredient in many personal care and household products (Bhargava et al., 1996; Dayan, 
2007). The bactericidal activity of triclosan results from inhibition of the enoyl-acyl carrier 
protein reductase (ENR) of gram-negative and gram-positive bacteria, thereby preventing 
bacterial lipid biosynthesis(Heath et al., 2000; Levy et al., 1999; McMurry et al., 1998).  The 
ubiquitous usage in consumer products has led to widespread environmental contamination 
evidenced by detection of triclosan in wastewater effluent in the US, UK, Japan, and other 
countries (Kanda et al., 2003; Loraine et al., 2006; Nakada et al., 2006).  Triclosan has been 
found in fish exposed to wastewater treatment plant effluents (Adolfsson-Erici et al., 2002), 
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in human breast milk samples (Adolfsson-Erici et al., 2002; Dayan, 2007), and in urine 
samples from young girls (Wolff et al., 2007).  
The structural similarity to thyroid hormones (THs, Figure 1) and evidence for human 
exposures have increased concern about possible endocrine disrupting effects of triclosan 
(Veldhoen et al., 2006).  Foran et al. (2000) studied the potential estrogenic effects of 
triclosan in Oryzias latipes (medaka) and concluded that it is not estrogenic, but may be a 
weak androgen. Vitellogenin induction, a biomarker for endocrine activity, has been found in 
medaka and Xenpous laevis (clawed frog) and was attributed to weak estrogenic activity of a 
triclosan metabolite (Ishibashi et al., 2004). There is also evidence that triclosan may disrupt 
thyroid mediated development. Exposure of Rana catesbeiana (North American bullfrog) to 
triclosan resulted in accelerated thyroid hormone dependent metamorphosis and decreased 
expression of thyroid receptor beta mRNA (Veldhoen et al., 2006).  Triclosan also affects a 
number of biochemical processes important for thyroid hormone homeostasis.  Triclosan 
induces hepatic EROD and PROD activity, and cytochromes P450 2B1/2 (Hanioka et al., 
1996; Jinno et al., 1997).  Inhibition of iodothyronine sulfotransferase activity was 
demonstrated in both rat and human hepatic microsomes (Schuur et al., 1998; Wang et al., 
2004). Furthermore, triclosan activates pregnane-X receptor(PXR)-mediated transcription in 
transient transfection studies with human PXR in a human hepatoma cell line (Jacobs et al., 
2005).  PXR activation leads to increases in Phase I and II hepatic biotransformation 
enzymes, including glucuronidases that catabolize thyroid hormones (THs) (You, 2004).  
These enzymes are important in maintaining euthyroid hormone concentrations (Capen, 
1994; DeVito et al., 1999; Hill et al., 1998).  Developmental disruption of circulating THs 
concentrations leads to adverse outcomes including altered neurodevelopment (Koibuchi et 
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al., 2006; Mitchell et al., 2004; Morreale de Escobar et al., 2004; Zoeller et al., 2000).   
Currently it is unknown whether triclosan affects circulating concentrations of thyroid 
hormones.  
The present work tested the hypothesis that in vivo triclosan exposure alters 
circulating levels of thyroxine (T4).  T4 has been shown to be a sensitive biomarker for 
disruption of thyroid homeostasis in rats (DeVito et al., 1999).  A four-day exposure to rats 
was employed as this protocol has been previously used to detect thyroid disrupting 
chemicals (Craft et al., 2002; Crofton, 2004; Zhou et al., 2001). In addition, triclosan up-
regulated rat hepatic microsomal enzymes after a four-day exposure (Hanioka et al., 1996). 
3. Materials and Methods 
Animals.  Long-Evans female rats at 21-23 days of age were obtained from Charles River 
Laboratories Inc. (Raleigh, NC).  These 80 rats were allowed 2-4 days of acclimation in an 
American Association for Accreditation of Laboratory Animal Care (AALAC)-approved 
animal facility prior to treatment.  Animals were housed two per standard plastic hanging 
cage (45 cm x 24 cm x 20 cm), with heat sterilized pine shavings bedding (Northeastern 
Products Corp., Warrenburg, NY).  Colony rooms were maintained at 21±2 oC with 50±10% 
humidity on a photo-period of 12L:12D (0600 – 1800 hr).  Food (Purina Rodent Chow 
#5001, Barnes Supply Co., Durham, NC) and tap water were provided ad libitum.  All animal 
procedures were approved in advance by the Institutional Animal Care and Use Committee 
of the National Health and Environmental Effects Research Laboratory of the US EPA. 
Chemicals.  Triclosan (5-Chloro-2-(2,4-dichloro-phenoxy)phenol, 99.6%, CAS#3380-34-5, 
Lot#06415CD) was obtained from Aldrich Chemical Company (St Louis, Mo., Cat#524190-
10G).  The dosing solutions at concentrations of 0, 10, 30, 100, 300 and 1000mg/kg/day were 
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prepared by mixing triclosan with corn oil and sonicating for 30 min at room temperature.  
The 1000 mg/kg/day dose precipitated within 12 hrs, therefore, it was sonicated daily before 
use. Dosing volume was 1.0 ml corn oil/kg body weight.  Rats at 27-29 days of age were 
exposed via oral gavage for four consecutive days (n=16 for all groups except 10 and 1000 
mg/kg/day where n=8/group).  All dosing was conducted between 0900 and 1000 hrs. Young 
female rats were chosen to be consistent with previous work in our lab using the short-term 
dosing model (Craft et al., 2002; Crofton, 2004; Zhou et al., 2001).  Rats were randomly 
assigned to treatment groups by counter-balancing body weights.  Body weights were 
recorded and dosing volumes adjusted daily.  Approximately 24 hours after the final 
treatment rats (0900 – 1100 hrs) were moved into a holding room.  Prior to termination, rats 
were weighed, acclimated for 30 min, and then taken to a separate room with a separate air 
supply and killed by decapitation.  Trunk blood was collected, after decapitation, into serum 
separator tubes (Becton Dickinson, 36-6154).  Serum was obtained after clotting whole blood 
for 30 min on ice, followed by centrifugation at 1278x g at 4o C for 30 min and stored at        
-80o C until analysis.  Livers were weighed,  quick frozen in liquid nitrogen and stored at        
-80o C for future analyses.   
Thyroxine assay.  Serum total T4 was measured in duplicate by standard solid-phase Coat-A 
Count radioimmunoassay (RIA) kits (Siemens Medical Solutions Diagnostics, formerly 
Diagnostic Products Corporation, Los Angeles, CA).  Intra-assay coefficient of variation for 
the triclosan data was 6.51%.  The inter-assay coefficient-of-variance for six separate assays 
over a one year period of time was 7.68%. 
Data analysis.  All data were analyzed as ng T4/ml serum.  The mean (±SE) for the control 
group is listed in the figure legend.  Statistical significance was tested with a one-way 
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ANOVA followed by Duncan’s Multiple Range Test, with acceptable significance level set 
at p> 0.05.  All data are represented as mean ± SE (n=16 for 0, 30, 100, and 300 mg/kg/day 
doses and n=8 for 10 mg/kg/day and 1000mg/kg/day doses).  No-observed-effects-levels 
(NOELs) were defined as the lowest dose without a significant effect. 
 Benchmark dose (BMD) and lower-bound confidence limit (BMDL) estimates were 
determined for alterations in serum thyroxine concentrations using USEPA Benchmark Dose 
Software (BMDS Version 1.40d).  The Hill model was chosen to fit these continuous data 
according to the following equations: 
                             
 
 
where y is the response; x is the dose; e0 is the estimated background response level; emax is 
the maximal increase or decrease from background; b is the ED50; n is the shape parameter.  
The benchmark response was set at a 20% decrease in T4 concentration (Zhou et al., 2001).  
The BMDs were calculated from the Hill model fits to the data. The BMDL (lower-bound 
confidence limit) was calculated as the 95% lower confidence interval.  
4. Results and Discussion 
No clinical signs of toxicity were observed in any animals following the 4-day oral 
triclosan exposure.  No treatment-related effects on body weight gain were found [F(5, 74) 
=0.40, p >0.8443], Body weight gains were between 26 and 28 g for all treatments.  There 
was a significant increase in liver weight [F(5,74)=4.23, p>0.002] of 15% in the 1000 mg/kg 
group (Table 1).  No other treatments were different than control.  
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Serum thyroxine concentrations were reduced in a dose dependent manner (Figure 2).  
Serum T4 was decreased 28, 34 and 53% following treatment with 100, 300, and 1000 
mg/kg/day triclosan, respectively.  This shows a significant main effect of treatment [F(5, 
74)=18.32, p>0.0001].  The NOEL for triclosan was 30 mg/kg/day.  The goodness-of-fit p-
value for the Hill model was 0.2232.  The BMD was 69.7 mg/kg/day and the BMDL was 
35.6 mg/kg/day.  
  These data clearly demonstrate for the first time that triclosan decreases circulating 
concentrations of T4 in rats.  The mechanisms by which triclosan reduces serum T4 are 
presently unknown, however, previous research suggests more than one possible mechanism.  
Evidence that PXR is activated by triclosan (Jacobs et al., 2005) suggests that decreases in T4 
may result from increases in the sulfonation or glucuronidation activity (Visser, 1996) via 
PXR-linked genes (Kretschmer et al., 2005).  This hypothesis is consistent with triclosan-
induced up-regulation of P450 2B isozymes (Hanioka et al., 1996; Jinno et al., 1997).  
Activation of PXR is known to result in induction of cytochrome P450s and uridine 
diphosphoglucuronyl transferases (UGTs).  UGTs are a family of isozymes, some of which 
glucuronidate THs, with subsequent excretion of the TH-glucuronide into the bile (Chen et 
al., 2003; Mackenzie et al., 2005; Zhou et al., 2005).  This is not consistent with a report that 
triclosan is a weak inhibitor of acetaminophen and bisphenol A glucuronidation (Wang et al., 
2004). However, morphine glucuronidation was not affected, suggesting an isoform-specific 
inhibition (Wang et al., 2004).  PXR activation has also been shown to regulate hepatic 
transporters (Klaassen et al., 2005).  These transporters can increase influx of T4 into the 
liver, and efflux of free and glucuronidated T4 into the bile (Friesema et al., 2005 ).  A 
combination of mechanisms may explain changes in TH levels, specifically the dose-
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dependent decrease in T4 observed in this study.  Future research on triclosan should 
characterize its effects on thyroid homeostasis and the relevance of these findings to humans. 
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Figure A1.1.  The structures of triclosan and thyroxine.  Both chemicals are halogenated 
biphenyl ethers.
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Figure A1.2.  Short-term oral exposure to triclosan decreased serum total T4  
concentrations.  Data are expressed as group mean values (±SE), V = corn oil vehicle  
only control.  Absolute T4 group mean value for the control group (0 mg/kg/day  
triclosan) is 41.8± 2.2 ng total T4/ml serum. [*Significantly different from the respective  
control (p < 0.05); n=16 for all groups except 10 and 1000 mg/kg/day where n=8/group] 
 
 
 
 
 
 
 
 
 
 
Dose (mg/kg/day)
V 10 30 100 300 1000
Se
ru
m
 
To
ta
l T
4,
 
n
g/
m
l (m
ea
n
±
SE
)
0
10
20
30
40
50
*
*
*
246 
 
Triclosan Dose 
(mg/kg) N 
Body Weight Gaina, 
g  (mean±SE) 
Liver Weight, g 
(mean±SE) 
Liver-Body 
Weight Ratiob 
(mean±SE) 
0 (vehicle) 16 26.6  ± 0.73 4.85 ± 0.18 0.050 ± 0.0006 
10 8 26.1 ± 1.05 4.46 ± 0.26 0.053 ±0.0007 
30 16 28.5 ± 0.99 4.97 ±0.23 0.051 ±0.0005 
100 16 26.7 ± 1.18 4.75 ± 0.25 0.050 ± 0.0004 
300 16 27.2 ± 2.01 5.04 ± 0.26 0.052 ± 0.0006 
1000 8 28.0 ± 1.31 6.26 ± 0.14* 0.056 ± 0.0008* 
Notes: a Weight gain between Day 1 and Day 5. 
b   Absolute liver weight divided by absolute body weight. 
* Significantly different from vehicle control group, p<0.05 
 
Table A-1.  Doses, group sizes, body weights, and liver weights. 
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Appendix 2:  Supplemental Data Table for Chapter 2 
Serum assays: Thyroxine (T4) data 
Endpoint 
Dose 
(mg/kg/d) N per dose 
 Mean (ng 
T4/mL serum) 
Standard deviation 
(SD) for ng T4/mL 
serum 
T4 0 24 44.97 9.31 
T4 10 8 41.41 9.46 
T4 30 24 40.99 7.32 
T4 100 24 33.24 7.35 
T4 300 24 29.06 5.35 
T4 1000 16 19.33 5.39 
Serum assays: Triiodothyronine (T3) data 
Endpoint 
Dose 
(mg/kg/d) N per dose 
 Mean (ng T3/dL 
serum) 
Standard deviation 
(SD) for ng T3/dL 
serum 
T3 0 8 107.45 11.73 
T3 30 8 108.84 8.93 
T3 100 8 98.61 5.96 
T3 300 8 95.31 9.46 
T3 1000 8 81.14 6.84 
Serum assays: Thyroid-stimulating hormone (TSH) data 
Endpoint 
Dose 
(mg/kg/d) N per dose 
 Mean (ng 
TSH/mL serum) 
Standard deviation 
(SD) for ng TSH/mL 
serum 
TSH 0 8 2.48 0.78 
TSH 30 8 1.94 0.64 
TSH 100 8 3.08 0.80 
TSH 300 8 2.70 1.48 
TSH 1000 8 3.12 1.87 
 
  
 
Appendix 3: Supplemental Data for Chapter 3 
Thyroxine (T4) n and mean ± SE for each age and dose. 
 
Dose 
(mg/kg/day) 
Offspring Dams 
PND4 PND14 PND21 PND22 
n Mean SE n Mean SE n Mean SE n Mean SE 
V 9 9.63 0.49 10 48.4 2.2 10 38.9 2.0 10 49.6 2.2 
30 9 9.12 0.66 10 47.1 2.5 10 38.9 1.3 10 45.4 3.7 
100 8 7.87 0.63 8 42.0 2.0 8 38.8 2.4 8 45.8 2.4 
300 8 7.08 0.64 8 40.6 2.3 8 36.0 1.8 8 34.1 3.7 
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Appendix 4: Supplemental Data for Chapter 4 
 
Triiodothyronine (T3) Concentrations in Dams and Offspring Following Perinatal TCS 
Exposure 
 
Percent of control serum T3 for dams and PND14 and PND21 Offspring.  GD20 and PND22 
Dams had vehicle control values = 85.3 ± 3.1 and 70.4 ± 2.8 ng/dL, respectively. PND14 and 
PND21 pups had vehicle control values = 80.7 ±2.1 and 95.1 ± 3.5 ng/dL, respectively.  
V=vehicle control. 
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Appendix 5: Supplementary Data for Chapter 5 
 
Time-course of Triclosan-Induced Cytotoxicity in DPX-2 and RPXR Receptor 
Reporter Cell Lines 
 
Cytotoxicity of chemical treatments at 6, 12, 24, and 48 hr of chemical exposure.  A.  Effects of 
DEX on RPXR cell viability.  B.  Effects of TCS on RPXR cell viability.  C.  Effects of RIF on DPX-
2 cell viability.  D.  Effects of TCS on DPX-2 cell viability. 
 
Appendix 6: 
Functional Hepatic Transport May Not Contribute Significantly to Triclosan-Induced 
Hypothyroxinemia in Rats: Description of Experiments and Results 
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1.  Abstract 
 
Triclosan [5-chloro-2-(2,4-dichlorophenoxy)phenol;(TCS)] decreased serum thyroxine 
(T4) in rats and upregulated Phase I and II hepatic metabolism in rats in our previous work. 
The role of hepatic transporters in the mode of action for TCS-induced hypothyroxinemia has 
not been evaluated. This work tested the hypothesis that TCS decreases T4 via activation of 
the pregnane X and constitutive androstane receptors (PXR and CAR) resulting in up-
regulation of thyroid hormone transport.  Rat sandwich-cultured hepatocytes (SCH) were 
treated with TCS (0-30µM; non-cytotoxic as determined by lactate dehydrogenase activity) 
for 10 min or 48 hr prior to measuring uptake and biliary clearance (Clb) of estradiol-17β-
glucuronide (E217G; Oatp/Mrp2 probe) and digoxin (Oatp1a4/Mdr1 probe) using B-
CLEAR® technology.  Minor (<20%) effects on E217G cell accumulation, but no significant 
differences in E217G Clb, were observed. TCS did not alter digoxin cell accumulation, but 
decreased digoxin Clb in a dose-dependent manner (48% at 30 µM TCS). Thus, TCS may 
modestly inhibit Mdr1-mediated biliary excretion. Protein content for Cyp3a1, Oatp1a1, 
Oatp1a4, Mdr1, Mrp2, Mrp3, and Mrp4 in SCH was assessed by immunoblotting. TCS 
increased Cyp3a1 at all doses; Oatp1a4 and Mrp2 protein were slightly increased. These data 
suggest that while TCS may interact with CAR and PXR to up-regulate hepatic catabolism 
and decrease circulating T4 concentrations in vivo, TCS has minimal effects on the 
expression and function of hepatic transporters associated with transport of thyroid hormone 
an an in vitro model. 
 2.  Introduction 
 
Triclosan (2,4,4’-trichloro-2’-hydroxyphenylether) (TCS) is a chlorinated phenolic 
bacteriostat found as an active ingredient in many personal care products, and as a surface 
water contaminant (ng/L) (Kolpin et al., 2002). Initial work addressed the data gap: is TCS a 
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mammalian thyroid hormone disruptor?  TCS treatment in a 4-day short-term assay produced 
dose-dependent decreases in thyroxine (T4) in weanling female Long Evans rats (Crofton et 
al., 2007).  In order to assess the potential hazard posed to human health by TCS, a mode-of-
action hypothesis was developed using in vivo rat models.  To test the hypothesized mode-of-
action that TCS decreases T4 via activation of the pregnane X and constitutive androstane 
receptors (PXR, CAR) via subsequent up-regulation of hepatic catabolism and transport of 
thyroid hormone, weanling female Long-Evans rats received TCS po (0-1000 mg/kg/day) for 
4 days. Pentoxyresorufin-O-deethylase (PROD) and uridine diphosphate 
glucuronyltransferase (UGT) enzyme activities were measured in liver microsomes.  qRT-
PCR was used to measure mRNA expression of cytochrome P450s 1a1, 2b2, and 3a, UGTs 
1a1, 1a6, and 2b5, sulfotransferases 1c1 and 1b1, and hepatic transporters Oatp1a1 and 1a4, 
Mrp2, and Mdr1b. PROD activity increased ~800 percent and T4-glucuronidation increased 
2-fold at 1000 mg/kg/day. Cyp2b2, Cyp3a, Ugt1a1, and Sult1c1 mRNA expression levels 
were induced 2-fold, 4-fold, 2.2-fold, and 2.6-fold at 300 mg/kg/day, respectively.  No 
changes were observed in mRNA levels for any hepatic transporters.  The current data only 
support the hypothesis that TCS up-regulates Phase II hepatic catabolism of thyroid hormone 
to produce hypothyroxinemia in vivo. Though the mRNA expression results do not suggest 
that changes in transporter expression contribute to the observed T4 decreases, these results 
do not exclude the possibility that hepatic transporter protein expression and activity may be 
altered by TCS treatment via receptor mediated post-translational modifications (Johnson et 
al., 2002b).   
Increased Cyp3a1/23 expression and in vitro receptor reporter assays (Jacobs et al., 2005) 
suggest that TCS activates PXR, perhaps altering expression and/or activity of PXR-
regulated Oatp1a4 (Kretschmer et al., 2005). It is important to measure protein activity of 
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transporters, as PXR ligands that induce Cyp3a may increase Mrp2 protein without 
increasing Mrp2 expression (Johnson & Klaassen 2002).  Due to the functional overlap 
between PXR and CAR (Faucette et al., 2006), it is also possible that TCS activates CAR to 
increase expression of Cyp3a1/23. CAR modulates expression and function of Mrp2, Mrp3, 
and Mrp4 canalicular transporters (Cherrington et al., 2002; Johnson et al., 2002a; Johnson et 
al., 2002b; Klaassen et al., 2005).  TCS may interact with CAR and/or PXR, and up-
regulated markers of hepatic catabolism in vivo, thus defining a major area of uncertainty in 
the proposed MOA for TCS-induced hypothyroxinemia: the potential contribution of up-
regulated hepatic transport.  
The objective of the current work was to determine the contribution of functional 
Phase III hepatic transport to TCS-induced hypothyroxinemia in rat hepatocytes to uncover 
potential effects of TCS on hepatic transporters that could not be evaluated with qRT-PCR 
alone.  Sandwich-cultured rat hepatocytes (SCRH) were used to examine hepatic uptake 
activity of organic anion transporting polypeptides (Oatps) and efflux activity of multidrug 
resistance/resistance-associated proteins (Mdr1, Mrp2) following TCS exposure.  Two 
hypotheses were tested: the protein expression and activity of the uptake transporters 
Oatp1a1 and 1a4 are increased by TCS treatment; and, protein expression and cannalicular 
transport function of the efflux transporters Mdr1 and Mrp2 are increased by TCS treatment.  
Uptake and biliary clearance were assessed in sandwich-cultured rat hepatocytes (SCRH) by 
assessing the accumulation of two substrates, estradiol-17β-glucuronide and digoxin, to 
probe the functional activity of Oatp1a1/1a4 and Mrp2, and Oatp1a4 and Mdr1, respectively  
(Liu et al., 1999; Marion et al., 2011; Swift et al., 2010; Turncliff et al., 2006; Wolf et al., 
2008).   
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3.  Methods 
 
A.  Materials 
 
Collagenase (Type 1, class 1) was obtained from Worthington Biochemicals (Lakewood, 
NJ). Dulbecco’s modified Eagle’s medium (DMEM, no phenol red), insulin, MEM non-
essential amino acids solution (100x), L-glutamine, penicillin G-streptomycin solution were 
purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum, sodium taurocholate, 
digoxin, Triton X-100, dexamethasone, methanol, Hanks’ balanced salts solution (HBSS) 
modified with (H-1387) or without (H-4891) calcium chloride, bovine serum albumin (BSA) 
were obtained from Sigma-Aldrich (St. Louis, MO). BioCoat™ collagen I plates, Matrigel™ 
basement membrane matrix, and ITS+™ (insulin/transferrin/selenium) culture supplement 
were purchased from BD Biosciences Discovery Labware (Bedford, MA). [3H]- estradiol-
17β-glucuronide (40 Ci/mmol, >97% purity) and [3H]-digoxin (40 Ci/mmol, >97% purity) 
were obtained from PerkinElmer Life and Analytical Sciences (Boston, MA). Bio-Safe II™ 
liquid scintillation cocktail was obtained from Research Products International (Mt. Prospect, 
IL). Bicinchoninic acid (BCA) protein assay reagents and BSA for the protein assay standard 
were purchased from Pierce Chemical Co. (Thermo Scientific, Rockford, IL).  
B. Source of rat hepatocytes 
Hepatocytes were obtained from male Wistar rats (200–325 g) from Charles River 
Laboratories, Inc. (Raleigh, NC).  Animals colony rooms were maintained at 21 ± 2°C with 
50  ± 10 % humidity on a photo-period of 12L:12D.  Food and water were provided ad 
libitum prior to surgical extraction of cells.  All animal procedures were compliant with the 
guidelines of the University of North Carolina at Chapel Hill Institutional Animal Care and 
Use Committee. 
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C.  Isolation and In Vitro Culture of Primary Rat Hepatocytes 
Hepatocytes were isolated from male Wistar rats (215.8 – 287.4 g) by collagenase 
perfusion (LeCluyse et al., 1996). Cell viability was determined by trypan blue exclusion to 
be ≥ 91.5%.  Hepatocytes were seeded at a density of 1.75 × 106 cells per well in 6-well 
BioCoat™ plates in DMEM supplemented with 2 mM L-glutamine, 1% (v/v) MEM non-
essential amino acids, 100 units penicillin G sodium/mL, 100 µg streptomycin sulfate/mL, 1 
µM dexamethasone, 5% (v/v) fetal bovine serum, and 10 µM insulin (Day 0 in culture), and 
cultured in a humidified incubator (95% O2, 5% CO2) at 37°C.  Hepatocytes were allowed a 
2 hr incubation time for attachment before media was aspirated to remove unattached and 
nonviable cells and replaced with fresh media.  Twenty-four hours after seeding (Day 1), 
hepatocytes were overlaid with Matrigel™ basement membrane matrix (0.25 mg/mL) in 2 
mL/well cold, serum-free DMEM containing 2 mM L-glutamine, 1% (v/v) MEM non-
essential amino acids, 100 units penicillin G sodium/mL, 100 µg streptomycin sulfate/mL, 
0.1 µM dexamethasone, and 1% (v/v) ITS+™
 
(note the absence of fetal bovine serum). The 
culture medium was changed every 24 hr until uptake experiments or protein collection were 
performed on Day 4 in culture. 
D. Chemical Treatment 
 
Most of the experiments utilized a 48 hr pretreatment period to allow enough time for a 
nuclear receptor-mediated up-regulation of hepatic transporter function.  For dexamethasone 
(DEX) only, treatment began on Day 1 in culture and concluded on Day 3 in culture to allow 
for a 24 hr wash-out period prior to uptake experiments.  Triclosan (TCS) and phenobarbital 
(PB) treatments were from Day 2 to Day 4.  Starting on Day 2 in culture, SCRH were 
pretreated with TCS or PB via addition of these compounds to the media applied to replenish 
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the SCRH.  TCS and DEX were dissolved in DMSO at stock concentrations of: 100 mM.  
Phenobarbital is a sodium salt and was prepared at a stock concentration of 100 mM in 
media.  The chemical stock solutions were then used to generate volumes of warmed media 
at concentrations of 10-100 µM that were applied to the SCRH. 
E.  Cytotoxicity Experiments 
To determine the cytotoxicity of TCS for different exposure durations, a time-course 
experiment was completed with TCS at 1, 10, and 30 µM.  For the 72 hr timecourse, SCRH 
were treated with TCS in the media starting on Day 1 in culture, 4 hrs after being overlaid 
with Matrigel.  At each subsequent 24 interval, i.e. Day 2, Day 3, and Day4, cytotoxicity was 
assessed by lactate dehydrogenase (LDH) activity assay (Roche Applied Science, Mannheim, 
Germany).  A 2% Triton-X stock, diluted with media, was used as the cytotoxicity control 
(100% cell death), while media from untreated wells of SCRH was used as the negative 
control.  For the 48 hr, 24 hr, and 2 hr timecourses, TCS treatment began on Day 2, Day 3, 
and Day 4.  The LDH assay was run according to the directions of the manufacturer; briefly, 
2 µL aliquots of media from treated SCRH wells were added to 100 µL of mixed LDH 
reagents in a 96 well plate.  The plate was incubated for 25 min at room temperature in the 
dark before being read on a warmed spectrophotometric plate reader at 492 nm.  Data were 
standardized to the Triton-X control per the following equation: 
 	
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F. Uptake Experiments 
 
 The method for determining the uptake and substrate accumulation of substrates in 
SCRH was performed as previously described   (Liu et al., 1999; Marion et al., 2011; 
Turncliff et al., 2004; Wolf et al., 2008).  All treatments were performed in technical 
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duplicates in three separate experiments.  In summary, hepatocytes were washed twice with 2 
mL warm Hanks’ balanced salts solution (HBSS) that contained Ca2+ or Ca2+-free HBSS, and 
subsequently incubated with 2 mL of the same buffer for 10 min at 37°C.  Incubation of the 
SCRH with Ca2+-free HBSS results in a loss of the tight junctions necessary to maintain bile 
canalicular networks enabling examination of the accumulation of substrate in cells alone.  
Conversely incubation with the Ca2+-containing HBSS maintained tight junctions and biliary 
networks, allowing for assessment of substrate accumulation in cells and bile. The buffer was 
removed, and the cells were incubated for 10 min at 37°C with 1.5 mL of [3H]-Estradiol-17β-
glucuronide (E217G) (1 µM) or [3H]-digoxin (10 µM) Ca2+-containing HBSS.  The SCRH 
were rinsed vigorously three times with 2 mL ice-cold Ca2+-containing HBSS after 
incubation with the tritiated substrate. For rinsing of [3H]-digoxin-treated SCRH, 10 µM non-
radiolabeled digoxin was added to the rinsing buffer to reduce nonspecific binding as 
described previously (Annaert et al., 2001).  E217G- and digoxin-treated hepatocytes were 
lysed with 1 mL 0.5% (v/v) Triton X-100 in phosphate-buffered saline by placing plates on 
an orbital shaker for a minimum of 20 min at room temperature. The samples were analyzed 
by liquid scintillation spectroscopy in a Packard Tri-Carb scintillation counter (PerkinElmer 
Life and Analytical Sciences). A sample was also reserved and kept at -20ºC for protein 
determination. 
G.  Total Protein Measurements 
 
The uptake experiment data were normalized to the protein concentration in each well 
(lysed with Triton X-100) and determined in duplicate aliquots using BCA protein assay 
reagents as instructed by the manufacturer (Pierce Chemical). BSA was used as a standard 
(0.2 – 1 mg/mL).  
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H.  Imunoblotting for protein content 
 
Parallel experiments were run to collect total protein from SCRH treated with TCS, DEX, 
and PB.  Instead of performing uptake experiments on Day 4, SCRH were incubated with 
400 µL lysis buffer (Complete Protease InhibitorTM (Roche Diagnostics), 1 mM EDTA, 1% 
SDS) and scraped off of the plates.  These samples were then briefly sonicated and 
centrifuged at 900 rpm for 5 min at room temperature.  Total protein measurements were 
performed on these lysates.  Samples were prepared for gel electrophoresis such that a 30 µL 
sample applied to each well contained 50 µg of protein, 10% 0.5 M DTT, 7.5 uL of Laemmli 
Sample Buffer, and Lysis Buffer.  Samples were stored at -20ºC until use.   
Target proteins were resolved by electrophoresis with NuPAGE 4-12% Bis-Tris Gels 
(Invitrogen; Carlsbad, CA), followed by transfer to PVDF membrane prior to 
immunoblotting.  The following antibodies were used for immunoblotting: Oatp1a1 and 
Oatp1a4 (Chemicon/Millipore); Mdr1 (Santa Cruz Biotechnology, Inc.); Mrp3 was a 
generous gift to the Brouwer laboratory from Dr. Yuichi Sugiyama; Mrp4 and Mrp2 (Alexis 
Biochemicals); Cyp3a1 (Xenotech, Inc.); Beta-actin for use as a loading control (Sigma-
Aldrich).  Immunoblot detection was performed with chemiluminescence reagents 
(SuperSignal/West Dura; Pierce Chemical, Rockford, IL). 
 
I. Data Analysis 
 
The BEI (%) and unbound intrinsic biliary clearance (intrinsic Clbiliary, mL/min/kg) were 
calculated using B-CLEAR® technology (Qualyst, Inc., Raleigh, NC; (Liu et al., 1999):  
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where substrate accumulation in the cell plus bile compartments was determined in 
hepatocytes preincubated in buffer containing Ca2+, and the accumulation of substrate in cells 
alone was determined in hepatocytes preincubated with Ca2+-free buffer.  Biliary clearance 
was given by: 
 
1.*.234  &'&()**+,-.*)  &'&()**+56)7.2  
 
where AUCmedia represents the area under the substrate concentration-time curve, determined 
by multiplying the incubation time (10 min) by the concentration of substrate used (1 µM). 
Intrinsic Clbiliary values were converted to mL/min/kg based on 200 mg protein/g of liver and 
40 g liver/kg of rat body weight (Seglen, 1976).  
 For uptake experiments, main effects of chemical treatment were determined by one-
way ANOVAs (SAS 9.1, SAS Institute, Cary, NC), followed by a mean contrast testing with 
Duncan’s New Multiple Range Test with a significance level of p<0.05 with chemical 
concentration as the independent variable.   
4.  Results and Discussion 
 
A.  LDH assay and TCS cytotoxicity 
 
LDH activity assays were conducted to determine the cytotoxicity of TCS and the non-
cytotoxic concentrations that could be used for uptake studies in the SCRH.  The greatest 
cytotoxicity was observed with 100 µM TCS, especially when SCRH were exposed starting 
on Day 1 of culture (Figure A6.1).  The exposure paradigm employed in uptake experiments, 
i.e. exposure for 48 hours beginning on Day 2 in culture, demonstrated that 100 µM TCS 
would have resulted in about 40% cell death.  Only 0-30 µM TCS were used in subsequent 
experiments. 
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B.  Immunoblotting for protein content 
Preliminary results from two sets of Western blots suggest that TCS did not greatly affect 
the protein expression of hepatic transporters.  A representative set of blots is shown in 
Figure A6.2, with densitometry average values presented in Table A6.1.  Densitometry 
identified small (20%) increases in Mrp2 expression and 10-50% increases in Oatp1a4 
expression, though these changes did not appear to be dose-dependent.  Treatment with DEX 
produced the most striking, dose-dependent changes; for 10 and 100 µM, DEX increased 
Mrp2 to 158 and 223 percent of control, Mdr1 to 127 and 141 percent of control, and for 100 
µM only DEX increased Mdr1 to 124 percent of control.  Like TCS, PB at the doses used 
had only limited, if any, effects on the expression of hepatic transporters.  For PB at 30 and 
100 µM, PB increased Mrp2 expression by about 20 percent.  It seems likely that changes of 
20% or less in protein content, detected by densitometry, may not be reflective of significant 
changes. 
Cyp3a1 protein content was also assessed to demonstrate that TCS entered the cells and 
behaved similarly to our ex vivo observations, and to demonstrate that DEX and PB 
functioned correctly in the SCRH.  DEX induced a dose-dependent increase in protein 
content; at 10 and 100 µM, DEX increased Cyp3a1 content to 252 and 300 percent of 
control.  PB also increased Cyp3a1, though less dramatically, to 154 and 168 percent of 
control.  TCS also had a moderate effect on Cyp3a1 protein expression; though not dose-
dependent, TCS increased Cyp3a1 content by about 50-60% for all of the doses tested.  This 
was a key finding because it demonstrated that TCS entered the cells, induced Cyp3a1 
indicative of PXR and/or CAR activation, and behaved similarly in vitro and in vivo, as 
Cyp3a1 mRNA expression was increased in vivo. 
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C.  Uptake experiments with E217G 
 
Substrate accumulation for E217G was evaluated due to the specificity of E217G for 
Oatp uptake transporters and Mrp2, a canalicular transporter.  This tested the hypothesis that 
pretreatment with TCS increased the functional activity of the Oatps and/or Mrp2, resulting 
in an increase in uptake and/or biliary excretion as measured by E217G disposition.  The 
Oatp uptake transporters and Mrp2 are known to be involved in thyroid hormone uptake 
(Friesema et al., 2005; Jansen et al., 2005) and thyroid hormone conjugate excretion 
(Lecureux et al., 2009; Wong et al., 2005), respectively.   
The cellular disposition of E217G was observed following 10 min of TCS pretreatment 
and 48 hr min of TCS pretreatment (Figure A6.3).  Although significant effects of treatment 
were observed for both pretreatment paradigms, these effects were minimal and most likely 
not biologically significant.  After 10 min of 1 µM TCS pretreatment, E217G accumulation 
in cells increased approximately 20%, associated with a decrease in BEI and Clb.  However, 
this effect did not appear to be dose-dependent, as accumulation in either the cells or 
cells+bile compartment was not increased 30 µM TCS.  At 30 µM TCS, there was actually a 
decrease in the accumulation in cells+bile.  The consistent trend with increasing TCS 
concentration was a decrease in BEI and Clb, suggesting that TCS treatment modestly 
decreased biliary elimination of E217G.  A similar pattern was observed following 48 hr of 
TCS pretreatment, suggesting that incubation time did not impact the results.  In fact, 
analysis using a two-way ANOVA with pretreatment time and dose as the independent 
variables demonstrated no effect of time on the results.  The observation that TCS slightly 
decreased E217G disposition in this model is counter to the original hypothesis that TCS 
would interact with nuclear receptors to transcriptionally and/or post-translationally up-
regulate transport function; but, the observed effects are extremely mild.  Further, the 
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observation of decreased elimination of E217G may be obfuscated by competition with TCS-
glucuronide.  TCS is efficiently glucuronidated in vivo by rats, so TCS-G may compete with 
the labeled E217G substrate for disposition by Mrp2.  Another confounding variable may be 
the off-target affinity of E217G for Mrp3, which would result in disposition of E217G into 
the media compartment, which was not tested. 
Due to the minor effects observed with TCS, both that the effects were minor and that the 
effects suggested an impairment of clearance rather than an increase, prototypical receptor 
activators known to increase hepatic transporter expression were tested in the same 
paradigm.  DEX and PB 48 hr pretreatments were employed to observe the potential effects 
on E217G disposition. Previously, DEX has been shown to up-regulate the protein content 
for Oatp1a4 and Mrp2 in sandwich-cultured hepatocytes (Turncliff et al., 2004), and PB has 
been shown to up-regulate Mrp3 and competitively inhibit Mrp2 function by its glucuronide 
metabolites (Chandra et al., 2005).  For PB at 30 and 100 µM, E217G accumulation was 
decreased in both cells + bile and cells compartments.  Similarly for DEX at 10 and 100 µM, 
accumulation of E217G was decreased in both compartments in a dose-dependent manner.  
However, there were no apparent effects on BEI or Clb (data not shown).  Though 
perplexing, this data suggests that increased Mrp3 function may be reflected in an apparent 
decrease in uptake, as substrate was likely excreted into the media.  TCS did not appear to 
function like DEX and PB in culture.  A mechanistic explanation is largely speculative.  
DEX is a model agonist for rat PXR, and PB is a model activator for rat CAR.  Previous 
work suggests that TCS interacts with one or more of these receptors to up-regulate Phase I 
and II metabolism.  However, TCS may not be as potent or efficacious of an activator of 
CAR and/or PXR.   
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D. Uptake experiments with digoxin 
Substrate accumulation of digoxin was evaluated because it is a probe substrate for 
Oatp1a4 and Mdr1.  As with the uptake experiments for E217G, digoxin disposition was 
assessed following pretreatment with TCS for 48 hr (Figure A6.5) to allow for potential 
nuclear receptor-mediated transcriptional and/or post-translational up-regulation of hepatic 
transport proteins.  Again, the effects were not striking.  There was a significant decrease of 
about 50% in the accumulation in the bile compartment for 30 µM TCS (computed as the 
difference between the cells + bile and cells compartments and not measured directly).  A 
significant 48% decrease in Clb was noted for 30 µM TCS, suggesting that TCS slightly 
inhibited Mdr1-mediated biliary excretion.  A decrease in biliary excretion activity would not 
support the hypothesis that increased hepatic transport activity led to increased rates of 
thyroid hormone elimination in vivo. 
5.  Conclusions 
 
The data presented suggest that changes in hepatic transport do not significantly 
contribute to the observed TCS-induced hypothyroxinemia observed in vivo.  Though 
exceedingly small increases in the cellular accumulation of E217G appeared statistically 
significant, it seems unlikely that these correspond to important biological changes in the 
context of chemicals that have inhibited hepatobiliary transport, such as bosentan and 
troglitazone, by much greater magnitudes (Lee et al., 2010a; Lee et al., 2010b; Marion et al., 
2007; Wolf et al., 2010).  The 50% decreased observed in Clb for digoxin following TCS 
exposure is discordant with the hypothesis that TCS could increase biliary elimination of 
substrates like thyroid hormones.  However, there were several limitations to interpreting 
these observations.  First, this assay is typically successfully employed to detect inhibitors of 
hepatic transport that might cause cholestatic injury in vivo (Swift et al., 2010).  For TCS, we 
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were trying to observe the opposite effect: an induction of hepatic transport and biliary 
elimination that would suggest increased biliary elimination of thyroid hormones and thyroid 
hormone conjugates in vivo.  Thus, we had limited experience to draw upon in trying to 
optimize the assay for our reverse purpose.  The data from positive controls known to be 
prototypical CAR and PXR agonists that increase hepatic catabolism and hepatic transport 
was difficult to interpret.  DEX and PB both seemed to significantly decrease the uptake and 
elimination of the E217G substrate.  DEX is known to upregulate Oatp1a4 and Mrp2 protein 
expression (Turncliff et al., 2004), so this result was counter to our expectation that both 
uptake and elimination would increase.  A potential hypothesis may be that both DEX and 
PB also increased the expression of Mrp3, which has some affinity for the E217G substrate, 
and these inducers may have been causing increased rates of substrate displacement back into 
the buffer, which was not tested for substrate concentrations.  Perhaps collection and analysis 
of the buffer from uptake experiments would provide important information about how these 
prototypical receptor activators control hepatic transport.  A final limitation may have been 
the choice of substrates.  It may have been more instructive to have used 125I-labeled 
thyroxine, as this is the compound of interest in the in vivo system. Then the relative 
displacement of labeled thyroxine could have been traced through the system following TCS 
pretreatment.  If greater effects had been observed in protein content with Western blots, this 
may have been an interesting follow-up study with TCS.  A more potent receptor agonist and 
known thyroid hormone disruptor, such as PCN, might produce a more pronounced result.  
Further investigation of how nuclear receptor agonists function in this model might be an 
interesting future experiment to understand how compounds that activate nuclear receptors 
might change the functional activity of hepatic transporters. 
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This work demonstrates a lack of effect of TCS on hepatic transport protein content and 
function.  The only statistically significant effects suggest that TCS decreased biliary 
clearance of probe substrates, which is the opposite direction of activity expected if TCS 
were to up-regulated hepatic transport function in vivo to increase biliary elimination of 
thyroid hormones. Therefore, there is no evidence to suggest that modulation of hepatic 
transport function significantly contributes to the proposed mode-of-action for TCS-induced 
hypothyroxinemia in vivo.  The key findings of this work were two-fold: TCS did not appear 
to affect hepatic transport, and TCS increased Cyp3a1 protein content in an in vitro model of 
rat liver.  Despite a lack of effects on hepatic transport, TCS increased a biomarker 
associated with nuclear receptor activation in this in vitro model and also in vivo, 
demonstrating concordance across models. 
6.  Acknowledgements 
This work was largely funded by a generous award from the Society of Toxicology 
Colgate-Palmolive Award for Student Research Training in Alternative Methods to K.B. 
Paul.  Dr. Brouwer was a kind and patient laboratory host and mentor, who not only provided 
ideas and education about her methods, but also supported this work in her laboratory (NIH 
GM41935).  Invaluable instruction and support from Drs. Kristina Wolf and Tracy Marion 
on sandwich-culture and experimentation made this work possible.  Dr. Yiwei Rong 
performed the collagenase perfusions to obtain the hepatocytes used.  K.B. Paul was 
supported by NIEHS T32-ES07126 and EPA CR833237 during completion of this work. 
 
270 
 
 
Figure A6.1. LDH activity assay data for TCS at 72, 48, 24, and 2 hr exposures. 
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Figure A6.2. Results of immunoblotting for hepatic transporters and Cyp3a1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure A6.3.  Disposition of E217G following A) 10 min pretreatment with TCS and B) 48 hr pretreatment with TCS.  † = 
different from control value for cells only compartment; * = different from control value for cells + bile compartment (p<0.05).   
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Figure A6.4.  Disposition of E217G following 48 hr pretreatments with TCS (1, 10, and 30 
µM), DEX (10 and 100 µM), and PB (30 and 100 µM).  a = Significantly decreased from 
control value for cells + bile compartment; b = greater significant decrease from control 
value for cells + bile compartment; c = significantly increased from control value for cells + 
bile compartment. 
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Figure A6.5.  Disposition of digoxin following 48 hr of TCS pretreatment. * = significantly 
different from control value for bile compartment (p<0.05). 
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Relative Western Blot Densitometry 
(percent of untreated control)  
 
Chemical µM Mrp2 Mrp3 Mrp4 Mdr1 Oatp1 Oatp2 Cyp3a1 
DEX  10 158 77 83 101 92 127 252 
DEX  100 223 73 97 124 81 141 300 
PB  30 117 86 105 81 89 102 154 
PB  100 123 81 109 84 108 103 168 
Control 1 0 90 82 100 92 117 119 119 
TCS 1 97 90 92 91 134 109 164 
TCS 10 107 85 87 101 98 154 147 
TCS 30 119 86 92 84 89 119 150 
Control 2 0 110 118 100 108 83 81 81 
Average Control 0 100 100 100 100 100 100 100 
 
Table A6.1. Relative densitometry for immunoblots (shown in Figure A6.1). 
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Appendix 7: 
Reconstituted Freeze-Dried Wastewater Effluents Activate the Human Pregnane-X Receptor 
in Receptor Reporter Assays in DPX-2 cells 
 
 
 Initial consideration of three different freeze-dried effluent samples (Marc Mills, 
Shoji Nakayama, U.S. EPA) demonstrated remarkable hPXR activation activity.  Freeze-
dried effluents were collected at wastewater treatment plant outflow at two different 
wastewater treatment plants (Cincinnati, OH), prior to dilution of the effluent into surface 
water.  The samples were then freeze-dried, and this sample was solubilized in media for use 
in receptor-reporter assays. The original constitution of this effluent is denoted as “1X,” with 
all other concentrations based on this benchmark.  Examination of these three effluents was 
performed in duplicate on three separate occasions (n=3).  The hPXR activation in the 
receptor-reporter assay by 1X effluent is 3- to 5-fold the vehicle control.  This represents a 
significant avenue for continued research, including further characterization of environmental 
samples with in vitro receptor reporter assays, but also in characterization of what 
environmental contaminants might be contributing PXR activity, like TCS and other known 
pharmacological agents that are hPXR agonists.   
  
 
 
Figure A7.1.  Three freeze-dried wastewater treatment plant effluent samples activated hPXR.   
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